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Executive Summary 
Problem  
Provider Opinion about Guidance Provided by a Prostate Cancer Screening Educational 
Pamphlet, a quality improvement initiative, addresses the non evidence-based practice of 
uninformed prostate cancer screening at the Denver Veteran Affairs Medical Center (VAMC).  
The population of interest is primary care providers (PCPs) in two Denver VAMC primary care 
clinics, Firm A Clinic and Saturday Intake Clinic. The intervention is the detailed prostate cancer 
screening educational pamphlet and corresponding discussions. The comparison is the frequency 
of prostate cancer screening informed decision making in Firm B, another Denver VAMC 
primary care clinic, without the guidance of the pamphlet. The outcome of interest is PCPs 
opinion about the pamphlet offering guidance with prostate cancer informed decision making. 
 Purpose  
Patients will continue to request prostate specific antigen (PSA) tests until providers educate 
them about the pros and cons of screening. The mission of this project is to ensure that Denver 
VAMC PCP’s are fully aware of the latest research and guidelines regarding prostate cancer 
screening in order to provide accurate information to male veterans in deciding about PSA 
testing by having them review the educational pamphlet that reflects current evidence- based 
practice.    
 Goals 
Denver VAMC PCPs must meet the following goals in order for the mission to occur: (a) to be 
knowledgeable about the latest prostate cancer screening research and guidelines; (b) to explain 
the risk of prostate cancer to male veterans;(c) to explain the risks, benefit, alternatives, and 
uncertainties of PSA screening to veterans; (d) to consider the male veteran’s values in deciding 
about PSA screening; and (e) to engage the male veteran in decision making at the desired level.     
 Objectives  
The outcome objectives are the means by which Denver VAMC PCPs will engage in the type of 
shared decision making that practice guidelines recommend.  The measurable project objectives 
include (a) design and print a prostate cancer screening educational pamphlet using the latest 
evidence based practice, (b) educate providers in Firm A Clinic and Saturday Clinic about the 
practice issue, and (c) measure perceptions of PCPs regarding use of the detailed prostate cancer 
screening pamphlet via a survey.  A comparison group, PCPs in Firm B Clinic, provides a link to 
current practices.  
 Plan, Outcomes and Results 
Outlook email messages were sent to all PCPS. The detailed pamphlet was tested by three PCPs 
in Firm A Clinic and five PCPs in Saturday Clinic. The eight completed surveys indicated that 
the brochure did offer Denver PCPs guidance in informing patients about prostate cancer 
screening. All eight PCPs found the detailed pamphlet informative, with appropriate graphics, 
and a user friendly format. Some physicians in Firm B do not routinely order PSAs because it is 
no longer a clinical reminder, but other PCPs order PSAs because of fear of liability.        
 
 
iii 
 
Table of Contents 
 
Copyright Statement ................................................................................................................. i 
Executive Summary ................................................................................................................. ii 
Table of Contents .................................................................................................................... iii 
List of Figures............................................................................................................................v 
List of Appendices ................................................................................................................... vi 
Problem Recognition and Definition ........................................................................................2 
Statement of Purpose .............................................................................................................2 
Problem Statement ................................................................................................................3 
PICO ......................................................................................................................................5 
Project Significance, Scope, and Rationale ...........................................................................6 
Theoretical Foundation for Project and Change ..................................................................7 
Literature Selection/ Systematic Process Supports Problem ............................................. 10 
Market/Risk Analysis .............................................................................................................. 17 
Project Strengths, Weaknesses, Opportunities, Threats .................................................... 17 
Driving /Restraining Forces ................................................................................................ 18 
Need, Resources, and Sustainability ................................................................................... 19 
Stakeholders and Project Team .......................................................................................... 21 
Cost Benefit Analysis ........................................................................................................... 22 
Project Objectives ................................................................................................................... 23 
Process/Outcomes Objectives .............................................................................................. 24 
Evaluation Plan ....................................................................................................................... 25 
Population/Sampling Parameters/Setting ........................................................................... 26 
Evidence-Based Practice Methodology and Measurement ................................................ 27 
Protection of Human Rights Procedure Complete ............................................................. 28 
Instrumentation Reliability/Validity and Intended Stats ................................................... 31 
Timeframe, Budget, and Resources .................................................................................... 32 
 
 
iv 
 
Project Findings and Results .................................................................................................. 33 
Statistical Data  .................................................................................................................... 37 
Reliability of Findings  ........................................................................................................ 38 
Results Discussed According to Evidence-Based Practice ................................................. 41 
Limitations, Recommendations, Implications for Change .................................................... 43 
   Limitations ……………………………………………………………………………………44 
Recommendations and Implications for Change................................................................ 44 
Conclusion ............................................................................................................................... 48 
 
 
 
v 
 
List of Figures 
Figure 1: Survey Results ........................................................................................................... 38 
 
 
vi 
 
List of Appendices 
Appendix A Systematic Literature Review Table ………………………………………………59 
Appendix B  Basic Prostate Cancer Screening Educational Pamphlet ....................................... 129  
Appendix C  Detailed Prostate Cancer Screening Educational Pamphlet .............................. 13434 
Appendix D Conceptual Model for Informed Prostate Cancer Decision Making .................. 13838 
Appendix E Conceptual Model for Informed Decision Making with the Guidance of Two 
Prostate Cancer Screening Educational Pamphlets............................................................... 13939 
Appendix F Conceptual Model for Informed Decision Making with the Guidance of a Prostate 
Cancer Screening Educational Pamphlet ............................................................................... 1400 
Appendix G  Logic Model for Prostate Cancer Screening Informed Decision Making (Initial 
Capstone) .............................................................................................................................. 1411 
Appendix H  Logic Model for Informed Decision Making with the Guidance of Two Prostate 
Cancer Screening Educational Pamphlets (Revised Capstone) ............................................. 14343 
Appendix I Logic Model for Provider Opinion about Guidance Provided by a Prostate Cancer 
Screening Educational Pamphlet (Final Capstone)................................................................. 1455 
Appendix J Measurement Tool ............................................................................................ 14747 
Appendix K Time Table Chart ............................................................................................. 14848 
Appendix L  Detailed Time Table of Accomplishments ....................................................... 14949 
Appendix M  Budget and Resources .................................................................................... 15454 
Appendix N CITI Collaborative Institutional Training Initiative .......................................... 15656 
Appendix O Human Research CITI Training ....................................................................... 15757 
Appendix P VA Clearance Letter ......................................................................................... 16060 
Appendix Q Regis IRB Approval Letter .............................................................................. 16262 
Appendix R COMIRB Modification Letter .......................................................................... 16363 
Appendix S COMIRB Approval Letter ................................................................................ 16464 
Appendix T VA Eastern Colorado Health Care System Authorization Letter ....................... 16565 
Appendix U COMIRB Completion... …………………………………………………………..166  
1 
 
 
 
 
Provider Opinion about Guidance Provided by a Prostate Cancer Screening 
Educational Pamphlet 
 The following proposal is a quality improvement initiative, or small scale intervention, 
linked to Denver Veteran Affairs Medical Center (VAMC) primary care providers’ (PCPs)  
assessment of a prostate cancer screening educational pamphlet  (Cassarett, Karlawish, & 
Sugarman, 2000).   Prostate Cancer Informed Decision Making, the original Capstone Project, 
was changed to Informed Decision Making with the Guidance of Two Prostate Cancer Screening 
Educational Pamphlets, and changed again, to Provider Opinion about Guidance Provided by a 
Prostate Cancer Screening Educational Pamphlet.  Each revision resulted in simplification, with 
less data needing to be collected and analyzed, including excluding the need for private 
information.  In other words, measuring the two patient categorical outcomes of informed versus 
not informed, and prostate specific antigen (PSA) drawn versus PSA not drawn, was replaced by 
measuring the two provider categorical outcomes of basic or detailed pamphlet preference (see 
Appendices B and C),  and guidance offered versus guidance not offered, by the two prostate 
cancer screening educational pamphlets. The final revision resulted in measuring PCPs’ 
assessment of the detailed pamphlet, an ordinal level of measurement ranking the responses to 
survey questions.   In retrospect, the change makes good sense because in order for patient’s 
behavior to change, provider’s behavior must change first.  Patients will continue to request PSA 
screens until providers educate them about the pros and cons of screening; therefore, educating 
providers is the logical place to start the implementation of the evidence-based practice of 
prostate cancer screening informed decision making.      
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Problem Recognition and Definition 
Statement of Purpose  
 
 The obligation of a Doctorate of Nursing Practice (DNP) is to change patient care 
practices that do not promote health and well-being.  This challenge is particularly relevant to the 
practice of prostate cancer screening with a PSA blood test.  Providing a detailed  prostate cancer 
screening educational pamphlet  to PCPs  in two Denver  VAMC Clinics is one way to ensure 
that PCPs will inform Denver male veterans about the pros and cons of prostate cancer screening 
before PSA testing is offered.  The outcome of interest is PCPs’ opinion on whether the detailed 
pamphlet offered guidance regarding prostate cancer informed decision making.       
 Attempting to identify individuals in a broad segment of the population for latent 
conditions is a double edged sword because some may benefit while others may be diagnosed 
and treated for cancer unnecessarily (Schwartz, Woloshin, Fowler, & Welch, 2004).  This 
approach to healthcare is particularly true for cancer screening, especially prostate cancer 
screening (Schwartz et al.).   The healthcare profession has developed a culture that believes 
searching for cancer is prudent preventative care, and consequently, prostate cancer screening 
continues without good evidence (Adami, Baron, & Rothman, 1994).  Searching for indolent 
cancer does not promote health and well-being (Perez- Stable, 2009).  One way to reverse this 
practice is to inform men about the pros and cons of screening before offering a PSA test (Krist, 
Woolf, Johnson, & Kerns, 2007).  This project proposes that providers need to learn about the 
pros and cons of prostate cancer screening, including the recommendation for informed decision 
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making, in order for screening behaviors to change (Partin et al., 2004).  The impact of this 
evidence-based practice is to decrease the identification of latent prostate cancers and the 
corresponding treatments, resulting in increased morbidity and decreased quality of life for male 
veterans.    
Problem Statement   
 
 Cancer is a heterogeneous disease caused by the development of abnormal cells that 
divide (Encarta, n.d.).   Some cancers are life threatening while others are clinically dormant 
(Paul & Kunz, 2010).   Distinguishing between aggressive and latent cancers is not initially easy; 
therefore, patients are often diagnosed with a cancer which may have regressed, grown slowly, 
or not spread (Paul & Kunz). For instance, prostate cancer is the second most common cancer in 
men besides skin cancer, but the lifetime risk of dying from it is only 2.9% (Hallberg, 2011).   
Enthusiasm for cancer screening in the United States, promoted by the press and various 
treatment centers, leads many patients to opt for screening despite false-positive test results and 
the possibility of unnecessary treatments (Schwartz et al., 2004).   
 Secondary prevention by screening for prostate cancer with a prostate specific antigen 
(PSA) test is not evidence-based practice. The goal of secondary prevention is to decrease 
morbidity and mortality by detecting prevalent, clinically significant cancers before they become 
symptomatic (Fitzgerald, 2005).  Diagnosing and treating preclinical and clinically dormant 
prostate cancers does not meet the criterion for screening because the benefit of testing does not 
outweigh the harm (Perez- Stable, 2009).  In other words, the benefit of saving a one life does 
not balance the harm of needless treatment of 48 men (Schroeder, Hugosson, Roobol, M. et al., 
2009).       
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 The PSA test was originally used to monitor the response to treatment in patients with 
prostate cancer (Albin, 2010).   Mass population PSA testing was initiated in the late 1980’s 
without well conducted trials to support the benefit of screening (Adami, Baron, & Rothman, 
1994).  The PSA test was touted as having high sensitivity and specificity, when in fact its ability 
to identify correctly those who have the disease (sensitivity) is overestimated, and its ability to 
identify correctly those who do not have the disease (specificity) is underestimated (Hoffman, 
Fletcher & Rind, 2010).  The PSA test, the outcome measure, cannot discriminate between 
individuals with and without prostate cancer, the outcome evaluated; thus, the PSA test has a 
poor predictive value.      
 The lack of definitive data on prostate cancer screening outcomes and the risk of 
overdiagnosis and treatment have made prostate cancer screening a controversial issue 
(Hoffman, et al., 2010).   The vast majority of prostate cancers currently detected in the United 
States are  asymptomatic, found on routine PSA testing, and are clinically localized (U.S. 
Department of Health &Human Services, 2008).  The modest absolute reduction in mortality 
from prostate cancer over time comes at the cost of diagnosing and aggressively treating 
nonprogressive cancers (Pignone, 2009).    Additionally, the harms of screening start 
immediately; whereas, the potential benefits are not realized for years to come (Pignone).  For 
example, many men diagnosed with prostate cancer as a result of screening will not experience 
clinical problems for years, even without treatment (Hoffman, Fetcher, O’ Leary, & Rind, 2011).  
However, undergoing curative radical prostatectomy and radiation therapies for localized, low-
risk disease can lead to immediate complications including long-time life risks such as 
impotence and incontinence (Goldhagen, 2011).   These risks are devastating, especially for 
those destined to die with, instead of from, prostate cancer.     
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   The American Urologic Association (AUA),  American Cancer Society (ACS),  U.S. 
Preventative Services Task Force (USPSTF), and other major medical organizations recommend 
that providers discuss the risks and benefits of prostate cancer screening before PSA testing is 
performed  by way of  shared or informed decision making  (Woolf & Krist, 2009).  According 
to Krist et al. (2007), per the USPSTF, “A decision is shared when the patient (1) understands the 
risk of the disease to be prevented; (2) understands the preventive service, including risk, benefit, 
alternatives, and uncertainties; (3) weighs his values regarding the decision; and (4) is engaged in 
the decision at the desired level” (p. 112-113).   Recent data shows that few providers are doing 
this (Gaster et al., 2010).  The problem then is that prostate cancer screening is routinely done 
without informed decision making, and this is not in line with evidenced based practice. 
PICO  
 
 Evidence-based practice studies often detail the specifics of the study using a 
patient/population, intervention, comparison, outcome of interest (PICO) format (Houser & 
Oman, 2011).   The question is, does the detailed prostate cancer screening pamphlet guide 
providers with informed decision making regarding PSA testing?   
P: The population of interest is PCPs in the Saturday Intake Clinic and Firm A Primary Care 
Clinic.   
I: The intervention is the detailed prostate cancer screening educational pamphlet and 
corresponding discussions.  
C: The comparison is the frequency of prostate cancer screening informed decision making in 
Denver VAMC Firm B Primary Care Clinic without the guide of the pamphlet.  
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O:  The outcome of interest is PCPs opinion about the pamphlet offering guidance with prostate 
cancer informed decision making. 
 
Project Significance, Scope, and Rationale   
 
 The USPSTF states that the evidence is insufficient to recommend for or against prostate 
cancer screening;  men age 75 years or older should not be screened, and shared decision making 
should include discussion of potential risks    (Lin, Lipsitz, Miller, & Janakiraman, 2007).   In 
October of 2011, the USPSTF revised their guidelines recommending against screening for 
prostate cancer with a PSA test, regardless of age, race, or family history (Hoffman et al., 2011).   
Despite the recommendations, shared decision making is not routine practice because the patient 
requests the test, the provider favors testing, the PSA is simply added to a requisition for other 
blood tests, or a PSA is ordered without the patient understanding its purpose and consequences 
(Woolf & Krist, 2009).  Provider reasons for not discussing the risks and benefits of screening 
include lack of time and competing demands, forgetfulness, limited patient health literacy, and 
fear of liability (Guerra, Jacobs, Holmes, & Shea, 2007).  
   Since the emerging role of the DNP is to ensure integration and application of evidence-
based practice to patient care, a nurse-sensitive outcome area is to ensure informed decision 
making about prostate cancer screening at the Denver VAMC.   In order for screening behaviors 
to change, health care provider’s behaviors need to change, and that requires education.  
Providers need to know that the existing evidence from randomized control trials does not 
support the routine use of screening for prostate cancer with prostate specific antigen, with or 
without digital rectal exam (Djulbegovic et al., 2010).  The detailed prostate cancer screening 
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pamphlet will educate providers about the limitations of prostate cancer screening with the 
ultimate goal of patient informed decision making resulting in decreased interest in PSA testing 
with subsequent improved health outcomes (Casserett, Karlawish, & Sugarman, 2000).   
Theoretical Foundation for Project and Change  
 
  A DNP is educated to improve health care by looking at the whole picture through 
empiric science, personal knowing, ethics, and aesthetics.  Emancipatory knowing integrates the 
four fundamental patterns of knowing.  Praxis, the process of emancipatory knowing, involves 
instituting healthcare changes designed to provide the highest level of care (Chinn & Kramer, 
2008).  Prostate cancer screening and treatment was born out of empiric knowledge.  This 
practice leads to nearsighted care because the other forms of knowing were omitted.  Adami 
(2010) sums up the practice of prostate cancer screening well, “Although cancer screening is 
intuitively appealing, the logistic complexities, ethical dilemmas and potential harms of 
intervention in healthy populations are often underestimated” (p.300).  Therefore, patients need 
to be asked if they would be willing to accept a high risk of side effects from treatment in return 
for a small chance of living longer, along with other personal knowing, ethical, and aesthetic 
questions.  For example, does the patient want to know if he has prostate cancer, even if the 
cancer might never do him any harm, or, how important is sex in his life?  (Hoffman et al., 
2011).       
 A conceptual model outlines the Capstone Project starting with the initial model and two 
revisions (see Appendices D, E, and F). The final model was started with the outcome, 
provider’s opinion about guidance provided by the pamphlet. The population was further defined 
by concepts borrowed from the Health Belief Model, a model developed by Rosenstock in 1966, 
and furthered by Becker and colleagues in the 1970s and 1980s, to explain preventative 
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behaviors (Kane & Radosevich, 2011).  The intervention, prostate cancer screening educational 
pamphlet, was appropriately given a less impressive spot than the perceived threat of prostate 
cancer, depicted in the large oval.  The perceived threat of prostate cancer, propagated by the 
mass media and other cancer screening enthusiasts, results in misinformed decision making 
(Ablin, 2010).    
 The Health Belief Model suggests that an individual’s perception about the seriousness 
and susceptibility of prostate cancer is the driving force behind screening.  The perceived threat 
of prostate cancer is modified by age, education level, social class, personality, mass media, 
knowing a prostate cancer victim, philosophy of life, and advice from family, friends, and other 
health care providers.  A belief in the efficacy of prostate cancer treatment leads to screening 
(Kane & Radosevich, 2011).  In fact, most Americans believe that finding cancer early saves 
lives, and 56% of those surveyed want screening for clinically irrelevant cancers (Perez-Stable, 
2009).   On the other hand, studies of prostate cancer screening decision aides consistently show 
that enhanced knowledge is associated with decreased interest in screening (Hoffman et al., 
2009).   For example, one study randomly assigned 176 men to usual care, a face-to-face 
discussion of PSA testing, a videotape, or a combination of videotape and discussion.   PSA 
testing was selected by 98 percent of men assigned to usual care compared to 50 percent of men 
that were assigned to combined discussion and videotape intervention (Frosch, Kaplan, & Felitti, 
2001).  
 The concept of causal inferences in epidemiology is similar to the exploration of benefits 
and harms of treatment in outcomes research (Kane & Radosevich, 2011).   One or more of nine 
guidelines can be used for judging whether an association is causal; however, a temporal 
relationship is the most important because it clarifies the order between exposure and disease and 
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the length of interval between the two (Gordis, 2009).   The temporal relationship of prostate 
cancer diagnosis and disease specific morbidity or mortality is important not only for clarifying 
the order in which the two occur but also in regard to the length of the interval between diagnosis 
and disease specific morbidity or mortality (Gordis).   In other words, a positive PSA test leading 
to a positive prostate biopsy is not temporally related to morbidity or mortality because some 
prostate cancers grow so slowly they wound never have caused symptoms (Lin et al., 2008).   
 The causal guidelines inferences were modified in 1986 to include categorization of the 
evidence by the quality of its source (Gordis, 2009).  The USPSTF uses an eight step analytic 
plan to evaluate the evidence for a screening program by reviewing relevant randomized trials.  
By assessing the strength of evidence the USPSTF moves from causal inferences to policy 
recommendations (Gordis).   Since 2002, the USPSTF has maintained that the evidence is 
insufficient to recommend for or against screening; since 2008, the USPSFT has maintained that 
the evidence is sufficient to recommend against screening for men 75 years and older (Lin et al., 
2008), and since October, 2011, the USPSTF has recommended that the evidence is sufficient to 
recommend against screening healthy men (Bankhead, 2011).      
 Only a small part of the causal chain was depicted while constructing this conceptual 
model with the outcome of provider’s opinion about guidance provided by the prostate cancer 
educational pamphlet.  Unfortunately, an educational pamphlet is not enough to end the 
continued practice of prostate cancer screening in asymptomatic men because there are 
multideterminants of health preference which comprise the entire causal process (Earp & Ennett, 
1991).  One major determinant of health preference is a person’s belief, including a commitment 
to prostate cancer screening, despite false-positive test results or the possibility that testing could 
lead to unnecessary treatment (Schwartz, Woloshin, Fowler, & Welch, 2004).     
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Literature Selection/ Systematic Process Supports Problem  
 
 Prostate cancer diagnosis and treatment is a therapy/harm clinical question.  In order to 
prove or disprove prostate cancer screening efficacy,  a systematic review of randomized 
controlled trial was searched for in the health sciences databases (Houser & Oman, 2011).  The 
trials revealed that there is no strong evidence that PSA testing decreases mortality;  there is no 
evidence about the best treatment for clinically localized prostate cancer  (Clements et al., 2007),  
and patient/provider treatment preferences  reflect  geography and perceptions more than 
evidence-based recommendations (U.S. Department of Health & Human Services, 2008). 
 In 2009, two ongoing randomized trials of PSA screening provided the first quantitative 
estimates of the survival benefits due to early detection (primary empirical resources). The 
prostate arm of the National Cancer Institute-sponsored Prostate, Lung, Colorectal, and Ovarian 
(PLCO) Cancer Screening Trial found no survival benefits from annual PSA screening combined 
with digital rectal exam (Andriole et al., 2009).  A larger similar trial, the European Randomized 
Study of Screening for Prostate Cancer (ERSPC), initiated in the early 1990s, with men aged 50 
to 74 years, found a 20% reduction in prostate cancer screening every four years (Schroder et al., 
2009). This finding means that 1410 men needed to be screened, and 48 men needed to receive 
early treatment, in order to prevent one cancer death at ten years (Adami, 2010).   
 The Cochrane Collaboration updated their 2006 Screening for prostate cancer (Review) 
in 2010 (secondary empirical resource).  The database included electronic searches of the 
PROSTATE registrar, MEDLINE, EMBASE, CANCERLIT, NHSEED and hand searching of 
five prominent urology and cancer journals. Inclusion criteria included comparing mass 
screening for prostate cancer to no screening and exclusion criteria included not being a 
randomized controlled trial. A meta-analysis of five randomized controlled trials, selected from a 
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review of 205 potentially relevant articles, concluded that prostate cancer screening did not 
significantly decrease prostate cancer-specific mortality.  Only the European trial reported a 
reduction in mortality as outlined above (Ilic, O’Connor, Green, & Wilt, 2010).     
 A high level of evidence is needed when making clinical treatment decisions that involve 
a high risk-benefit ratio, such as a potential cancer diagnosis leading to controversial treatment, 
therefore it is imperative to have solid evidence supporting clinical practice guidelines (Houser 
& Oman, 2011).  The USPSTF, responsible for developing clinical practice guidelines for 
prevention and screening, ranks studies by their quality and evidence, followed by estimates of 
the balance of benefits and harms. Critical gaps in the 2002 USPSTF review prompted the 2007 
evidence update (secondary empirical resource).  Articles in PubMed and the Cochrane Library 
from January, 2002 to July, 2007 were searched for evidence on health outcomes associated with 
PSA screening , harms of screening for prostate cancer, and the natural history of PSA-detected, 
nonpalpable localized prostate cancer.  Three hundred ninety, 420, and 91 potentially relevant 
articles were identified to address the three respective areas of concern.  Sixty eight articles were 
obtained for full text review and ten articles met inclusion criteria. The USPSTF concluded that 
PSA screening is associated with psychological harms and its potential benefits remain uncertain 
(Lin, et al., 2008, p.194).    
 Prostate cancer data in the U.S. is retrieved from individual state population-based or 
central cancer registries designed to provide outcome data to help improve patient care (Garvin, 
2007).  The Surveillance, Epidemiology, and End Results (SEER) Program was established after 
the National Cancer Act of 1971 mandated systematic collection of cancer data for use in the 
prevention, diagnosis, and treatment of cancer (Garvin).  The SEER program collects cancer 
incidence and survival data from nine states, five metropolitan areas, and the Alaska Tumor 
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Registry encompassing about 26 percent of the U.S. population.  Patient demographics, primary 
tumor site, stage at diagnosis, first course of treatment, and follow-up for vital statistics are the 
data collected (NCI, February 2010).  
 Stephenson et al. (1996) hypothesized that when an increase in incidence is observed 
following the introduction of a screening test, a subsequent decrease in incidence is bound to 
happen as prevalent cases are removed from the population and screening intensity decreases, a 
phenomenon they called a cull effect.   The method used to test their hypothesis involved 
comparing prostate cancer rates from the SEER national registry to the age-adjusted prostate 
carcinoma trends which they tracked from the population-based Utah Cancer Registry. The 
authors concluded that the Utah Cancer Registry Data from 1993 and 1994 indicates that the 
incidence of prostate carcinoma is rapidly decreasing after similarly rapid increases.   The rapid 
and highly correlated rise in prostate cancer incidence observed in both SEER and the Utah 
incidence rates between 1988 and 1991 raised concerns about the diagnosis and treatment of 
clinically insignificant cancers and increased invasive prostate cancer treatment without good 
evidence (Stephenson et al.).      
 The exhaustive medical literature review was halted after the same patterns and 
references kept recurring.  The repeating themes correlate with the key points identified by 
England’s National Health Service Prostate Cancer Risk Management Programme (PCRMP) for 
men to be aware of prior to taking a PSA test: 
• The PSA test facilitates the early detection of prostate cancer at a stage when potentially 
curative treatments can be offered. 
• There is currently no strong evidence that PSA testing reduces mortality from prostate 
cancer. 
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• Not all men with raised PSA will have prostate cancer/the PSA test will not detect all 
prostate cancers. 
• Prostate cancer is diagnosed through a prostate biopsy which can be uncomfortable or 
painful. 
• Prostate biopsies will not detect all prostate cancers. 
• Prostate cancers range from aggressive to slow growing forms – slow growing tumors 
may not result in symptoms or shorten life expectancy.  
• There is no evidence about the optimum treatment for localized prostate cancer.  
• Some treatments for prostate cancer can have significant side effects (Clements et al., 
2007, Table 1).  
 Establishing prostate cancer screening efficacy and safety involves both clinical and 
epidemiological research.  Distinguishing causation from association, establishing validity of 
outcome measures, estimating lead time, and studying the natural history of disease are 
epidemiological studies relevant to prostate cancer screening.  Epidemiologists unanimously use 
the PSA as an example of a test with poor validity and consistently insinuate that it was 
irresponsible to introduce prostate cancer screening without well-conducted randomized trials 
because now it is virtually impossible to conduct those studies (Gordis, 2009).    
 Three epidemiologists from the University of Washington and the Fred Hutchinson 
Cancer Research Center in Seattle estimated lead time and overdiagnosis associated with PSA 
screening (primary qualitative descriptive epidemiologic study).  These researchers 
conceptualized the observed incidence of prostate cancer as the sum of secular trends (incidence 
without PSA testing) and the excess incidence over and above the secular trend (incidence based 
on screening and unknown lead times). The authors developed two likelihood models to estimate 
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mean lead time under specified distributional assumptions and with a smooth secular trend. This 
novel likelihood approach allowed the authors to make formal inferences about the lead time and 
overdiagnosis associated with PSA screening in the U.S. and provided a first glimpse of a secular 
trend in disease incidence (Telesca, Etzioni, & Gulaiti, 2007).   
 Telesca et al. (2007) contend that one of the main costs associated with the PSA test is 
that it markedly increases overdiagnosis by detecting cancers that would not otherwise have been 
diagnosed within the patient’s life.  The cost is related to the lead time, or the time by which 
screening advances diagnosis, resulting in overdiagnosis, because death from other causes 
precedes the date of symptomatic disease and/or occurs during the lead time. The authors also 
provided some provocative insights about racial disparities in prostate cancer with estimated lead 
times of 4.50 years for whites and 6.43 years for blacks.  In addition to black men’s aggressive 
clinically detected cancers, blacks may be subject to a higher frequency of latent disease because 
the higher incidence of aggressive prostate cancer in blacks was based on data from symptomatic 
disease cases prior to the PSA era (Telesca et al., p.15).   
  Prevalence is the proportion of the population affected by a disease at a moment in time; 
it is not a measure of risk since it does not take into account the duration of the disease.  
Incidence is a measure of risk because it is the number of new cases of a disease that occur 
during a specified period of time (Gordis, 2009).  Another relevant epidemiologic article studied 
these concepts using a novel highly technical method to estimate the asymptomatic incidence 
and duration of prostate cancer; according to Etzioni, Cha, Feuer, and Davidov (1998), “Prostate 
cancer is known as a disease with extremely high prevalence relative to its clinical incidence in 
the population” (p. 775).  It is precisely this combination of asymptomatic incidence and duration 
that is of interest to researchers trying to explain the natural history of prostate cancer and how it 
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can lead to effective screening strategies.  Comparison of the lifetime risks of preclinical and 
clinical disease confirmed that prostate cancer is a slow growing disease and approximately 50 to 
75 percent of new cases are likely to remain asymptomatic (Etzioni et al., p. 784). 
 Adami (2009), a Harvard epidemiologist and former surgeon, who currently researches 
various cancers, predicts that historians may consider the prostate cancer pseudo-epidemic “a 
disaster of contemporary medicine” (p. 298).  In 1994, Adami questioned the ethics of a prostate 
cancer screening trial, “To intervene in healthy people is not ethical without the widespread 
evidence of a net benefit- the evidence for which, in our opinion, is still uncertain” (p. 959).  He 
works closely with Swedish researchers and concurs with the growing number of health agencies 
that advise against prostate cancer screening with a PSA (Adami).    
 The next step in the prostate cancer screening review was to explore the literature on 
informed decision making. The previously mentioned article by Clements et al. (2007) from the 
United Kingdom (UK) is an open access article, which means it can be reproduced and 
distributed as long as it is correctly cited.  The National Screening Committee in the UK 
recommends against prostate cancer screening but the public concern about prostate cancer led 
the Department of Health to introduce the PCRMP in 2001. The program recommends that the 
PSA be available to interested men provided they are aware of the pros and cons. This qualitative 
study used semi-structured interviews with 21 general practitioners (GPs) from 18 GP practices 
in Oxfordshire to explore GPs’ reports of consultations with asymptomatic men.  The study 
concluded that despite GPs’ understanding of the importance of informed decision making, the 
information provided was inconsistent because of provider preferences and their need to counter 
most men’s positive opinion about screening. The authors contend that written information and a 
return visit would provide a more balanced picture, and they discussed how providing 
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information to patients about clinical issues that are not evidence based is problematic (Clements 
et al., Discussion section, para. 3).  
 The National Survey of Medical Decisions (DECISIONS Study), an original 
investigation by Hoffman et al. (2009), evaluated the medical decision–making process for PSA 
testing.  The study design was a random-digit-dial survey of a national probability sample of 
3010 English-speaking adults 40 years and older.  A telephone survey of a subsample of 375 
men who had either undergone PSA testing or discussed prostate cancer screening with a 
provider in the past two years was reported.  This study was the first to systematically use the 
same survey methodology to assess one of nine common medical decisions ranging from 
initiating antihypertensive to screening for prostate, colorectal, or breast cancer. The conclusion 
of these authors was that  health care provider’s opinions strongly influenced screening decisions 
and  shared decision making was lacking because  subjects had limited knowledge, did not 
receive both sides of the story, and their preferences were not routinely considered (Hoffman et 
al.).   
 Another study by Partin et al. (2004), about informed decision making, was a randomized 
trial examining the effect of two prostate cancer screening educational interventions done at four 
Midwestern Veteran Affairs medical facilities (University of Minnesota).  One thousand, one 
hundred fifty-two male veterans age 50 and older with primary care appointments were 
randomized to usual care, pamphlets, or a video.  Two weeks prior to their primary care 
appointment, subjects received a mailed pamphlet, video, or no educational interventions.  One 
week after their appointment, subjects completed a phone survey to assess knowledge, 
preferences, and decision making participation.  VA utilization databases were used to assess 
PSA testing rates two weeks and one year post target appointment.  The Social Cognitive Theory 
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was the conceptual model employed.  Based on the results, pamphlet subjects were more likely 
than controls to discuss screening with their provider but video subjects were not. Video and 
pamphlet subjects were less likely to intend to have a PSA, relative to controls.  PSA testing 
rates did not differ significantly across groups at one year. Possible confounding variables 
include PSA tests being drawn without patient knowledge, provider enthusiasm for screening, 
and a wash between those that were affected by the education, resulting in decreased screening 
for some and increased screening for others. Providers need to receive the intervention as well as 
the patients in order for screening behaviors to change (Partin et al.).     
Market/Risk Analysis 
Project Strengths, Weaknesses, Opportunities, Threats 
 The timing is this Capstone Project’s strength because the latest studies and  USPSTF 
clinical practice guidelines are finally confirming and recommending what has been researched 
and gently recommended for twenty years;  namely, prostate cancer screening is not supported 
by randomized clinical trials (Andriole et al., 2009; Djulbegovic et al., 2010; Ilic et al., 2010) and  
“healthy men do not need prostate cancer screening with PSA because the test does not save 
lives and often leads to unnecessary testing, interventions, and treatment” (Bankhead, 2011, para. 
1). The prostate cancer screening educational pamphlet will arrive just in time to educate 
providers, patients, and families about the confirmed futility of wide-spread prostate cancer 
screening among asymptomatic men (Adami, 2010).   
 The Project’s weakness is the lack of enthusiasm among physician stakeholders.  The 
Assistant to the Chief of Staff delegated the Project to the Chief of Ambulatory Care, and both 
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physicians warned not to proceed with the Project without their approval, including review by 
Urology.  Unfortunately, the Chief of Ambulatory Care backed out of the Project because he 
believes in prostate cancer screening, and the Chief of Urology was indifferent.  Curb-side 
advice from two VAMC oncologists was that PSA screening saves lives (T. Braun & E.  Pajon, 
personal communication, July, 2011).     
Driving /Restraining Forces  
 
 The driving force to the Project is the continuation of wide-spread PSA testing among 
asymptomatic men despite limited evidence of benefit and overwhelming evidence of harm 
(Adami, 2010).  Providing information to patients about prostate cancer screening, when there is 
no established evidence base, is problematic (Clements et al., 2007).   Asking a patient to decide 
if he wants PSA testing after the personal recommendation of a “highly qualified” television talk 
show host is absurd when thousands of doctors cannot settle the dispute (Suss, 2008).  The 
restraining force to the Project is the flip side of the driving force, which is the United States 
commitment to cancer screening (Schwartz et al., 2004).   Even though   PSA testing cannot 
detect prostate cancer and, more importantly, it cannot distinguish between lethal and latent 
cancers (Ablin, 2010), the organizational culture still fosters wide-spread testing for PSA among 
asymptomatic men. 
 Zaccagnini and White state (2011), “As the lines between quality improvement activities 
and research blur, the tendency for these projects to undergo review by IRBs is stronger than in 
the past” (p. 456).  The Capstone Project, a quality improvement initiative  or small scale 
intervention linked to the assessment of a prostate cancer screening educational pamphlet, 
required approval by three institutions, including two internal review boards ; therefore, 
restraining forces to the project included the time required to complete the Regis, VA, and 
19 
 
 
 
Colorado Multiple Institutional Review Board (COMIRB) training followed by Regis IRB, VA, 
and COMIRB applications and approvals  (see Appendices O,P,Q , R, and S).  Training included 
four Collaborative Institutional Training Initiatives (CITI) and VA privacy training (see 
Appendices N and O).  Finally, approval by the VA Research and Development (R & D) 
Committee was required after IRB approval (see Appendix T).   
 Barriers to providers’ discussions of prostate cancer screening fell under the category of 
patient, provider, or system.  The barriers included health literacy, cognitive dysfunction, and 
mental illness, forgetfulness or provider’s belief about screening, and lack of time, lack of 
consensus within the medical profession, and fear of litigation (Guerra et al., 2007).  Fear of 
liability is a valid concern because the structure of the U.S. legal system supports local screening 
practices and not ordering a PSA test can be considered a malpractice error of omission (Guerra 
et al., 2007).  For example, in July 2003, a Virginia jury found a family practice guilty of 
malpractice when a patient decided against PSA screening, after informed decision making, and 
subsequently was found to have a high PSA and terminal prostate cancer (Merenstein, 2004).  
Need, Resources, and Sustainability 
 
 There is a need for prostate cancer screening informed decision making at the Denver 
VAMC because random PSA blood tests are currently done without standard education on the 
pros and cons of screening.  According to the latest guidelines, patients should receive education 
about the pros and cons of prostate screening before proceeding or not proceeding with testing 
(Woolf & Krist, 2009).    In order for screening behaviors to change, providers need to learn 
about the pros and cons of prostate cancer screening, including the recommendation for informed 
decision making (Partin, M. et al., 2004).  A detailed prostate cancer screening educational 
pamphlet will help educate and guide providers.  
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 The Denver VAMC is part of the Eastern Colorado Health Care System (ECHCS), which 
is part of the VA, the largest integrated health-care system in the country (DeYoe, 2011).  There 
are 319 providers in the ECHCS including physicians, dentists, nurse practitioners, and other 
licensed independent practitioners.   All enrolled veterans are eligible for preventative care 
services, ambulatory diagnostic and treatment services, hospital inpatient diagnostic and 
treatment services, and prescription drugs prescribed by a VA provider. Prevention includes 
immunizations, physical examinations (including eye and hearing exams), health care 
assessments, screening tests, and health education programs.  Medical, surgical, mental health 
and substance abuse are provided as outpatient and inpatient services (Hughes, 2011; U.S.  
Department of VA, 2011).   It is clear to see from the preceding description that the VA plays a 
major role in prostate cancer screening.   
 The population that needs to be informed is Denver VAMC male patients starting at age 
45 years old for high risk patients and 50 years old for all others.  High risk patients are first-
degree family relatives with prostate cancer because heritable factors account for 42% of the risk 
(Gordis, 2009, p. 279), and race because blacks have the highest risk (Perez-Stable, 2009, 
Prostate Cancer section, para 2).  The setting is Denver VAMC primary care, with overlap into 
other clinics where prostate specific antigen (PSA) blood tests could potentially be ordered, such 
as specialty clinics (Hughes, 2011).    
 The corporate workload database for the VA is located nationally in the Austin 
Computerized Data Center. Statistics for the Denver VAMC are incorporated within the ECHCS.  
There are 400,664 veterans in the ECHCS primary service area (DeYoe, 2011, p. 39); from 
October 1, 2009 to September 30, 2010, a total of 67, 832 veterans were seen as outpatients 
(eligibility categories help explain why less than one fifth of the veterans utilize the ECHCS).  
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The number 67,832 reflects all patients, not all visits, since each patient may be seen multiple 
times; the number includes 6,976 females, 60,854 males, and two unknowns. The Denver 
VAMC cared for 57, 330 patients, including 51,250 males and 6,080 females.  The average age 
for all Denver VAMC patients is 58 years with following breakdown: age 24 or less, 873 ; age 
25 to 34, 5,456 ; age 35 to 44, 5,335; age 45 to 54, 8,834 ; age 55 to 64, 17,942 ; age 65 to 74, 
10,257 ; age 75 to 84, 6,038 ; age 85 to 94, 2,527 ;  and, age 94+,  68 (A. Carver,  personal 
communication, March 30, 2011).     
 Most prostate cancers detected in the U.S. are asymptomatic, clinically localized, and 
found on routine PSA testing (U.S. Department of Health & Human Services, 2008); this 
correlates with the new cases of prostate cancer at the Denver VA. Prostate cancer data for 2008 
to 2010 was obtained from the ECHCS Tumor Registry.  There were 209 cases of prostate 
cancer diagnosed since 2008 except for new patients arriving with the diagnosis.  At least 75% of 
the cases were clinically localized. The largest groups of men to receive the diagnosis (76%) 
were in their fifties and sixties (N. Jones, personal communication, April, 20, 2011; Hughes, 
2011).  
 The project is sustainable because the above population description illustrates the greatest 
number of veterans falling within the group that providers need to educate, namely male veterans 
from age 45 years and above.  Providers undoubtedly will be bombarded with questions about 
why PSA screening is no longer recommended in healthy men (Hallberg, 2011).  The pamphlet 
will provide providers with the tool to explain the reasons behind the latest recommendations. 
The ultimate goal is to have the pamphlet distributed though-out the clinics with yearly updates.  
Stakeholders and Project Team     
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 The group with an investment in the Project includes the patients, providers, and system.  
The Project was initiated to protect patients against unnecessary invasive diagnostics and 
treatments. Educating providers about the latest research and guidelines will ensure patient 
protection through informed decision making. The system includes Project approval by the Regis 
University, the Denver VAMC, and the University of Colorado Denver IRBs.  Completion of 
CITI courses in the Protection of Human Research Subjects and Health Insurance Portability and 
Accountability Act (HIPPA) is required by the three institutions; the VAMC also requires 
completion of a security course on the VA Talent Management System.       
 The project team includes eight Denver VAMC PCPs, including four providers in the 
Saturday Intake Clinic and four providers in the Firm A Clinic. The ECHCS Medical Media 
Program Manager is responsible for the pamphlet design and production. The author is involved 
with distributing the pamphlets and informing the providers about the Project. The data 
collection and interpretation is carried out by the author with oversight by a PhD-prepared RN 
mentor.         
Cost Benefit Analysis       
 
 The Food and Drug Administration approved the PSA test for prostate cancer screening 
in 1994 (Albin, 2010). Each year approximately 30 million American men undergo PSA 
screening with an annual bill of at least three billion dollars, much of it paid by Medicare and the 
VA (Albin, 2010, para 1, 3).  The cost of prostate cancer screening is overdiagnosis, or the 
detection of disease through screening that would not otherwise have been detected within the 
patient’s lifetime (Telesca et al., 2007).  The USPSTF cites a false positive test rate of up to 80% 
which can lead to unnecessary biopsies and therapies with possible adverse side effects of 
incontinence and impotence (Schepman, 2011, para 4). The cost of making and distributing the 
23 
 
 
 
educational pamphlet and asking selected PCPs about their opinion on guidance provided by the 
pamphlet is miniscule; the benefit is less interest in prostate cancer with subsequent positive 
health and financial outcomes.         
Project Objectives 
Mission/Vision/Goals  
 A population needs assessment revealed that there is a need for a change in screening 
practices at the Denver VAMC (Jacobsen & O’Connor, 1999).   In other words, the time has 
come to close the gap between what is, and what should be, in performing, prostate cancer 
screening at the Denver VAMC (Hughes, 2011).  The preceding analysis identified Denver 
VAMC’s current prostate cancer screening practices; the mission, vision and goals provide 
directions to where the Denver VAMC should be regarding prostate cancer screening practices 
(Kruschke  & Stoeckel, 2011).    
 The mission statement asks what the Denver VA PCPS do, who they do it for, and why they 
do it (Kruschke & Stoeckel, 2011).  The mission of this project is to ensure that Denver VAMC 
PCPs are fully aware of the latest research and guidelines regarding prostate cancer screening in 
order to provide accurate information to male veterans starting at age 50 years, or 45 years for 
high risk patients.  The vision statement provides an inspirational image of the future (Kruschke 
& Stoeckel).   The vision of this Project is for PCPs to practice health care ethically by rejecting 
unproven prostate screening behaviors in favor of scientific evidence. Denver VAMC PCPs must 
meet the following goals in order for the mission and vision to occur:            
• To be knowledgeable about the latest prostate cancer screening research and guidelines. 
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• To explain the risk of prostate cancer to male veterans.   
• To explain PSA screening to male veterans, including the risks, benefit, alternatives, and 
uncertainties.   
• To consider the male veteran’s values in deciding about PSA screening.  
•  To engage the male veteran in decision making at the desired level (Krist et al., 2007).  
The preceding goals are simply the steps of shared decision making recommended by the 
USPSTF (Krist et al.)  
Process/Outcomes Objectives  
 Objectives are the means by which goals are met; according to Kruschke & Stoeckel 
(2011), they are “specific, measurable, achievable action items that are realistic and time-bound” 
(p. 17).  Outcome objectives state a specific time frame for achievement of the intended 
outcome; whereas, process objectives clearly outline the steps needed to achieve the outcomes 
objectives (Zaccagnini and White, 2011).   The Project findings and results are organized by 
objective; therefore, measurable objectives are needed to form data collection. The outcome 
objectives for Provider Opinion about Guidance Provided by a Prostate Cancer Screening 
Educational Pamphlet are the means by which Denver PCPs will use the steps of shared decision 
making recommended by the USPSTF.  The measurable Project objectives include: 
1. Design and print a prostate cancer screening educational pamphlet using data from a 
systematic review of randomized controlled trials of prostate cancer screening efficacy. Include 
the first quantitative estimates of the survival benefits due to early detection provided by the two 
large ongoing randomized clinical trials of PSA testing, the ERSPC study and the prostate arm of 
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the National Cancer Institute-sponsored PLCO Cancer Screening Trial (Andriole et al., 2009; 
Schroeder, Hugosson, Roobol et al., 2009).   
2.  Educate providers in Firm A Clinic and Saturday Intake Clinic about the prostate cancer 
screening practice issue by sending weekly messages about the latest USPSTF guidelines, major 
medical organization’s recommendations and attached relevant articles via Office Outlook.  
3. Measure participating PCPs perceptions of guidance provided by the detailed prostate 
cancer screening pamphlet using the eight question survey.   
 The Time Table of Accomplishments (see Appendix L) clearly outlines the process by 
which the outcome objectives were achieved.  It is clear to see from the list of accomplishments 
that the process needed to achieve the Capstone Project outcomes objectives entails one step 
forward, and two steps back, but constant movement toward meeting the mission of ensuring that 
Denver VAMC PCPs are fully aware of the latest research and guidelines regarding prostate 
cancer screening in order to provide accurate information to male veterans.   
Evaluation Plan 
  A logic model illustrates how and why a project will work (Kellogg, 2004).  The initial 
Prostate Cancer Screening Informed Decision Making Logic Model (see Appendix G) was 
simplified after VA IRB pre-review on September 14, 2011 and simplified again after the oral 
presentation in  the DNP Capstone Project class NR 706B.   The Logic Models (see Appendix H 
and I) provide clarity and focus on specifics.  “If…then…” statements connect the program’s 
parts depicted in rows under the columns of Resources/Inputs, Activities, Outputs, Outcomes, 
and Impacts (Kellogg).  Reading the Model from left to right starts with the first two columns, 
the planned work, and ends with the intended results, the last three columns (Kellogg).  
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 The outputs, outcomes, and impacts of PCPs in two VA clinics utilizing the prostate 
cancer screening educational brochure to help guide prostate cancer screening informed decision 
making, followed by all Denver VAMC PCPs using the brochure, are the most important 
components to monitor because they gauge the success of the Project.  The ultimate success of 
this Project will be when the vision for PCPs to practice health care ethically, by rejecting 
unproven prostate screening behaviors in favor of scientific evidence, is realized.  In reality,    
proving that the proposed change took place is easier said than done because life is complicated 
with influences and forces beyond one’s control.  Therefore, demonstrating progress toward the 
ultimate impact of less interest in PSA screening, leading to less incidence of prostate cancer, 
and leading to improved quality of life is more about documenting this Project’s contribution,  
rather than documenting that the change actually occurred in a given time period  (Kellogg, 
2004).   
Population/Sampling Parameters/Setting   
 A convenience sample of VAMC PCPs in the Saturday Intake Clinic and PCPs in Firm A 
Clinic comprise the study group. The comparison data is the incidence of prostate cancer 
screening informed decision making with PCPs in Firm B Clinic, the comparison group, without 
the guide of the pamphlet.   The outcome of interest to be quantified are the providers’ opinions 
measured on an interval scale of yes, somewhat or maybe, or  no  about whether the detailed 
prostate cancer screening educational pamphlet offered guidance for informed decision making. 
The outcomes of interest to be qualified are PCPs’ discussions about their current prostate cancer 
screening practices as well as the responses from PCPs in the comparison group.  There will be 
no inclusion or exclusion criteria to control for the extraneous variable of the providers’ initial 
belief prior to the intervention.  The PCPs will be fully informed of the project via Microsoft 
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Office Outlook e-mail and will receive the detailed prostate cancer screening education 
pamphlets to review before their primary care clinics (see Appendix C).  
Evidence-Based Practice Methodology and Measurement  
 
 A quantitative pilot study design will be used to answer the PICO question. The 
variables, reiterated in statistical terms, include the dependent variable of provider opinion on 
whether the pamphlets offered guidance regarding prostate cancer informed decision making. 
The independent variable is the prostate cancer screening educational pamphlets and 
corresponding discussions. The extraneous variable is provider health belief. The survey (see 
Appendix J) used to measure provider opinion about guidance provided by the pamphlet is 
discussed in pages 31 to 33.  
 The Capstone Project is a quality improvement initiative with no defined research 
question; it is a small-scale intervention linked to assessment of a prostate cancer screening 
pamphlet.  The quantitative data collected measures provider opinion about guidance provided 
by the pamphlet.  Anecdotal information received from provider e-mails describes Firm B PCPs’ 
screening practices without the pamphlet, the comparison data.  The statistical method for 
evaluation of the quantitative data collected in the survey is limited to frequencies.  This analytic 
option is appropriate because the purpose of data collection for this process improvement Project 
is to implement evidence-based practice into primary care rather than to evaluate a research 
project.  In other words, the collected data and Project findings are used to measure a change in 
practice rather than collecting data to make the project reproducible (Zaccagnini & White, 2011).  
The Project’s ultimate goal is prostate cancer screening informed decision making resulting in 
improved health outcomes for Denver VAMC male patients (Cassarett, Karlawish, & Sugarman, 
2000).    
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Protection of Human Rights Procedure Complete  
 
 The Belmont Report:  Ethical Principles and Guidelines for the Protection of Human 
Subjects of Research  was developed in 1976 after four days of intensive discussions between 
members of the National Commission for the Protection of Human Subjects of Biomedical and 
Behavioral Research.  The statement includes  a distinction between research and practice; a 
discussion of the three basic ethical principles of respect for persons,  beneficence , and justice;  
and  remarks about applications of these principles through informed consent,  assessment of 
risks and benefits , and selection of subjects (Ryan et al., 1976).  Some of these principles can be   
applied to the dilemma of uninformed prostate cancer screening and the subsequent outcome of 
using the detailed prostate cancer educational pamphlet.  The ultimate impact is to stop the 
intrusion into asymptomatic unsuspecting men’s lives with a harmful screening practice 
disguised as preventative care.   
 Mass population PSA testing was initiated in the late 1980s without a persuasive 
randomized trial or other compelling scientific evidence (Adami, Baron, & Rothman, 1994).  
The novel screening practice resulted in an unprecedented cancer incidence increase from 1988 
to 1992 followed by a steep and then modest decline (Adami, 2010).  Because of cultural cancer 
screening enthusiasm, the practice of prostate cancer screening preceded research.  In October, 
2011, the USPSTF upgraded their recommendation not to screen healthy men with a PSA blood 
test because the test does not save lives and often leads to unnecessary testing, interventions, and 
treatment (Bankhead, 2011).  
 Research and practice often occur together and according to the Belmont Report (Ryan et 
al., 1976), “This need not cause any confusion regarding whether or not the activity requires 
review; the general rule is that if there is any element of research in an activity, that activity 
29 
 
 
 
shoulder undergo review for the protection of human rights” (p.3).  The blurred distinction 
between research and practice has resulted in a trial of prostate cancer screening in the western 
world since 1988 without review for the protection of human rights (Adami et al., 1994).      
 The Capstone Project is about doing what is “Right” and “Proper” and about what the 
evidence-based practice recommends.   The moral and ethical principle of respect for persons 
includes autonomy, or one’s right to choose, and protection for those with diminished autonomy 
(Ryan, et el, 1976).  Providing PCPs with a prostate cancer screening educational pamphlet will 
result in patient informed decision making, a prerequisite for autonomy.  Patient preference, or 
autonomy, is the guiding principle here, and if a man wants to be screened, knowing the negative 
consequences, that is his prerogative.  On the other hand, health illiteracy and cognitive 
impairment precludes autonomy, making the patient vulnerable.  The truth of the matter is almost 
all patients are  vulnerable because,  according to Suss (2008),  “If thousands of doctors can’t 
agree on whether PSA screening  results in any benefit, then it makes no sense to ask the patient 
to settle the dispute” (p. 1288).   In other words, many patients may make foresighted decisions 
not understanding that the ability to detect a disease by screening does not always equate to a 
benefit to those screened (Gordis, 2009).    
 The principle of beneficence is about the balance of good versus harm.  Offering 
asymptomatic men a diagnostic intervention associated with increased cancer diagnosis, modest 
mortality reduction, and substantial morbidity constitutes harm (Adami, 2010). The modest 
absolute reduction in prostate cancer over time comes at the cost of diagnosing and treating 
clinically irrelevant cancers (Pignone, 2009).   Additionally, the harms of screening start 
immediately; whereas, the potential benefits are not realized for years to come (Pignone, 2009). 
The harms of treatment may include erectile dysfunction and urinary incontinence after radical 
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prostatectomy, defecation problems following radiation therapy, and hot flashes/feminization 
with hormone therapy (Hoffman, Fletcher, & Rind, 2010).   Informed decision making is no 
license to subject patients to harmful interventions (Adami et al., 1994); thus, prostate cancer 
screening is not beneficent.  
 Justice is fair and moral treatment of people includes not basing treatment decisions on 
demographics. Unfortunately, prostate cancer is not an equal opportunity disease, with older age, 
race (black), and family history the only well-established risk factors (Jemal et al., 2011).  The 
introduction of the PSA test has led to a large percentage of African American males undergoing 
aggressive treatments for cancers that may well be indolent.  For example, increased screening in 
active-duty air force personnel between 2005 and 2008 resulted in a three times higher rate of  
prostate cancer among white servicemen,  and eleven times higher rate for black servicemen, 
compared to rates between 1991-1994 (Goldhagen, 2011,para 4 ).  Of those with low risk 
disease, significantly more active duty servicemen elected curative surgery than retirees (93% vs. 
53%) (Goldhagen, para 6).    
 Telesca et al. (2007) estimated lead time and overdiagnosis associated with PSA 
screening from prostate cancer incidence trends with lead times of 4.50 years for whites and 6.43 
years for blacks (p.15).  The finding of a longer lead time among blacks is surprising because of 
the known higher incidence and poorer survival in blacks. The authors conclude that, in addition 
to black men’s aggressive clinically detected cancers, they also may be subject to higher 
frequency of latent disease because the higher incidence of aggressive prostate cancer in blacks 
was based on data from symptomatic disease cases prior to the PSA era (Telesca et al.).      
 Information, comprehension, and voluntariness are part of the informed consent process.  
The detailed prostate cancer screening educational pamphlet will satisfy the three elements of 
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informed consent.   The often perfunctory shared decision making will become more detailed 
with the risks and benefits of prostate cancer screening clearly spelled out in the pamphlet.  
Hopefully, vulnerable male veterans will be better equipped to make a systematic assessment of 
the risks and benefits of screening.    
Instrumentation Reliability/Validity and Intended Stats  
 
 Choosing the appropriate statistical test is necessary to answer the Project’s questions 
about provider opinion about guidance offered.  Surveying the providers will be the method of 
data collection. The data gathered from each of the eight providers in the sample will describe 
the guidance provided by the pamphlet, thus descriptive rather than inferential statistics is 
appropriate.  Providers’ opinions on guidance offered by the pamphlet are ordinal level 
measurements of outcome data that can be ranked. The responses to the survey questions will 
have verbal labels of yes, somewhat or maybe, and no with corresponding codes of 1, 2, and 
3(see Appendix J). The numerical codes cannot be rearranged; therefore, the numbers are not 
arbitrary. Since it is not meaningful to measure averages with variables measured on nominal 
and ordinal scales, the analytic option for this Project is limited to frequencies (Polit, 2010).    
Finally, generalizability of the outcomes will be limited, and clear conclusions about cause and 
effect will not be possible because there is no randomization and no control group.  
 The survey (see Appendix J) was easily developed because the questions are intuitive. An 
eighth question was added to assess the format of the pamphlet after Project implementation.  
The eight survey questions are simple, direct, short, concrete, and single concept questions.  The 
survey is valid because it actually measured what was intended to be measured; provider opinion 
on guidance offered by the pamphlet including format.    Finally, completion of the survey by the 
eight Project participants will avoid nonresponce bias (Zatz, 2011).   
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 A frequency distribution will be constructed from the ordinal data measuring provider 
opinion about guidance offered by the pamphlets.  The data will be reported as percentages. A 
bar graph will be constructed to display frequency information with the categories listed on the 
horizontal axis and the frequencies or percentages on the vertical axis (Polit, 2010).   
 Comparison of the PCPs’ screening practices without the pamphlet and other 
observations made during project implementation and application will be used to change 
prostate cancer screening practices at the Denver VAMC including the Eastern Colorado 
CBOCs. The treatment that will be done with the  data collected includes continued  
reinforcement about the requirement  for  informed prostate cancer screening, continued 
education  about the USPSTF  recommendations not to screen healthy men with a PSA blood 
test, and continued pamphlet production and distribution. In other words, completion of the 
Capstone Project will be the beginning of prostate cancer screening evidence-based practice 
within the ECHCS. 
Timeframe, Budget, and Resources  
 The goal of assessing informed decision making with the guidance of a prostate cancer 
screening educational pamphlet is to improve the process, outcomes, and efficiency of   prostate 
cancer screening practices at the Denver VA (Cassarett, et al., 2000).    The timeframe for this 
Project is outlined in Appendix K followed by a chronological list of accomplishments in 
Appendix L.  There needs to be ten minutes of PCPs time to inform patients about the pros and 
cons of screening using the detailed prostate cancer educational pamphlet; the design and 
pamphlet production will be done by the ECHCS Medical Media Program Manager; and weekly 
Microsoft Office e-mail messages/discussions will be sent to educate providers. These are the 
three main resources needed for implementation and application of the evidence-based practice 
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Project. The budget is the hypothetical amount of money needed for the Project including 
pamphlet production (see Appendix M).       
Project Findings and Results    
 The first objective, to design and print a prostate cancer screening educational pamphlet 
using the latest evidence-based practice began with the writing of the detailed pamphlet.  The 
mentor thought the detailed pamphlet was too long; therefore, the basic pamphlet was created for 
patients, with four pre and post questions.  The ECHCS Medical Media Program Manager 
discussed the design and production of the prostate cancer screening educational pamphlets with 
the author. The  UpToDate  Journal and Right’s manager was contacted for approval to use their 
graphics, which he subsequently edited and approved.   A fifth question was added to the basic 
pamphlet to avoid bias because the Project mentor thought the pamphlet was slanted against 
prostate cancer screening.  Finally, the written portion of the pamphlets was complete, use of 
UpToDate graphics was approved, and a picture of a can of worms representing the dilemma 
caused by screening was added.  The ECHCS Medical Media Program Manager created the 
detailed pamphlet for COMIRB review using the can of worms picture for the cover and the 
UpToDate graphics inside the folded pamphlet.    
  Two hundred detailed pamphlets were printed for the Project implementation. The 
pamphlets went fast the first week because PCPs were sending patients home with them. On 
January 7, 2012 a request was made for 500 to 1000 more pamphlets, but the request was put on 
hold by the Project’s new mentor, a PhD-prepared RN, the Denver VAMC Patient Safety 
Specialist. The mentor advised against distributing the pamphlets to the patients because the 
purpose of the Project is to assess the pamphlet.  The question, “Is the format of the pamphlet user 
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friendly” was added to the survey (see Appendix J) to address the issue of pamphlet font and 
format per the Project mentor’s advice.  The survey now included assessment of the brochure 
format in addition to measuring provider’s opinions about guidance provided by the detailed 
pamphlet.        
  Sending a patient home with the detailed pamphlet is an ideal method to inform the 
patient and his family about the often indolent natural history of prostate cancer, the limitations 
of PSA testing, and the inconsistent evidence thus far from major prostate cancer screening trials 
(Hoffman, 2011).  According to Hoffman, “Decisions about prostate-cancer screening should be 
based on the preferences of an informed patient” (p. 2017); therefore, public approval and 
distribution of the pamphlet is imperative to ensure that evidence-based practice is the basis of 
clinical care at the Denver VA. 
 The second outcome objective, to educate providers in Firm A Clinic and Saturday Intake 
Clinic about the practice issue, began by sending the following Office Outlook e-mail message to 
Denver VA PCPs: 
 Subject: Quality Improvement Project  
 In October, 2011 the United States Preventative Service Task Force recommended 
 against screening health men with a prostate specific antigen (PSA) blood test. Other 
 major medical organizations recommend informed or shared decision making prior to 
 offering PSA testing.  A quality improvement initiative project will be done to assess 
 prostate cancer screening guidance provided by an educational pamphlet (see 
 attachment). Four volunteer primary care providers (PCPS) from Firm A, and four 
 volunteer PCPs from the Saturday Intake Clinic, are needed to assess the pamphlet. The 
 comparison group will be an assessment of the guidance provided from four volunteer 
 PCPs in Firm B without the uses of the educational pamphlet. Thank-you for your help in 
 implementing this evidenced based practice at the Denver VAMC (P. Hughes, personal 
 communication, December 22, 2011).      
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Replies to the above message started the following day including one physician and four nurse 
practitioners (NP)volunteering to test the pamphlet with age appropriate men during primary care 
clinic visits.  
 The design of the Project was to have four PCPs in Firm A Clinic and four PCPs in the 
Saturday Intake Clinic test the detailed prostate cancer screening educational pamphlet followed 
by completing the eight question survey. Instead, only three PCPs in Firm A Clinic and five 
PCPs in Saturday Clinic tested the pamphlet.   The three study PCPs in Firm A included one 
physician and NPs. The one participating Firm A physician personally responded to the email 
request and the two participating Firm A NPs were personally recruited.  The five study PCPs in 
the Saturday Intake Clinic are NPS.   
 The Evidenced-Based Clinical Practice Guidelines/Clinical Quality Program Specialist 
NP working for the VA Office of Quality & Safety participated in the email discussions.  He was 
the only provider to respond to the request for suggestions on the detailed pamphlet before it was 
sent to public affairs for approval to distribute to patients and families.   After the suggested 
grammatical errors were corrected the pamphlet was sent to public affairs and was subsequently 
approved for public use.   
 Each participating  provider received copies of the detailed pamphlet, the  latest  NEJM  
article  on screening for prostate cancer ( Hoffman, 2011),  the  VA R&D Approval Letter, and   
weekly Office Outlook email messages about the Project including  prostate cancer screening 
guidelines, dilemmas, and  discussions. The messages and informative articles were also sent to 
all Denver VAMC PCPs, the Chief of Ambulatory Care, the Chief of Urology, and the Nurse 
Practitioner Supervisor.  Unbeknownst to the author, providers in the ECHCS CBOCs received 
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many of the email messages, leading to requests for posters and pamphlets from PCPs in 
Colorado Springs and Pueblo.    
 Coincidently, the Deputy Chief of Staff’s poster on the Principles of Shared Decision 
Making was displayed at the Denver VAMC in early February, just a few weeks after the Project 
started.  The Deputy Chief of Staff was familiar with the Project because of a former meeting in 
April, 2011 when a return visit for informed consent prior to PSA screening was vetoed and the 
Chief of Ambulatory Care was assigned as the initial Project mentor.  It was timely and 
advantageous that the poster was displayed at the same time as the Project; therefore, the 
following message was sent to providers:  
 Dr. Lithium Lin’s poster on the Principles of Shared Decision Making is displayed in the 
 prosthetic hallway.  Plan of care, participation, perception, pros & cons, and preferences 
 surround patient centered shared decision making.  The 6 P’s (principles) of shared  
 decision making can be used for patients that request prostate cancer screening. 
       The American Urologic Association, American Cancer Society, U.S. Preventative 
 Services Task Force, and other major medical organizations recommend that providers 
 discuss the risks and benefits of prostate cancer screening before PSA testing is 
 performed  by way of shared or informed decision making  (Woolf & Krist, 2009).  
 According to Krist et al. (2007), per the US Preventative Services Task Force 
 (USPSTF), “A decision is shared when the patient (1) understands the risk of the disease 
 to be prevented; (2) understands the preventive service, including risk, benefit, 
 alternatives, and uncertainties; (3) weighs his values regarding the decision; and (4) is 
 engaged in the decision at the desired level” (p. 112-113).    
 References: 
  Krist, A., Woolf, S., Johnson, R., and Kerns, W. (2007). Patient education on prostate 
 cancer  screening and involvement in decision making. Annals of Family Medicine. 
 5:112-119 (P. Hughes, personal communication, February 16, 2012).  
Having the Deputy  Chief of Staff on board is critical to the implementation of the evidence-
based  practice of informed prostate cancer screening because he is responsible for 
communications with ECHCS medical staff and assisting with changes in medical practice 
(Houser & Oman, 2011).     
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Statistical Data   
 
 The third outcome objective, to measure participating PCP’s perception of guidance 
provided by use of the detailed prostate cancer screening pamphlet with male veterans aged 50-
75 ,  was accomplished  using an eight question survey (quantitative data) (see Appendix J). The 
eight completed surveys indicated that the pamphlet did offer Denver PCPs guidance in 
informing patients about prostate cancer screening.  The survey also specified that the detailed 
pamphlet format is appropriate (Figure 1).  Eight (100 percent) PCPs found the detailed prostate 
cancer screening pamphlet informative, with appropriate graphics and a user friendly format. 
Seven (87.5%) PCPs found the pamphlet useful for family members; whereas, one (12.5%) 
provider found the pamphlet somewhat, or maybe, useful for family members.  Seven (87.5 
percent) PCPs said the pamphlet was easy to read; whereas, one (12.5%) provider said the 
pamphlet was somewhat, or maybe, easy to read. Seven (87.5 percent) PCPs found the pamphlet 
to be unbiased; whereas, one (12.5%) provider found it biased.  Half of the PCPs (n=4) thought 
the brochure would change decisions of vets to get a PSA; whereas, three (37.5 percent) PCPs 
though the brochure would somewhat, or maybe, change decisions of vets, and one PCP (12.5 
percent) though the brochure would not change the decision of vets to get a PSA.   
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Figure 1: Survey Results 
 
Reliability of Findings   
 Reliability refers to how consistently an instrument measures the attribute it is designed to 
measure (Polit, 2010). The eight question survey (see Appendix J) is the instrument designed to 
measure the attribute of guidance provided to PCPs by the pamphlet.   Since the survey was filled 
out by PCPs in close proximity to the time they used the pamphlet there was absolutely no recall 
bias. Since the positive answer to question four is “no” the error of measurement   which occurs 
when a survey is filled out haphazardly did not occur (Polit, 2010).  In other words, the seven 
PCPs that found the pamphlet helpful answered “no” appropriately when asked if the pamphlet is 
biased instead of haphazardly answering   “yes”.  Likewise, the one provider that  holds a strong 
0.00%
20.00%
40.00%
60.00%
80.00%
100.00%
Yes 
Maybe 
No
39 
 
 
 
belief in the benefits of prostate cancer screening answered “yes”, the pamphlet is biased, instead 
of  haphazardly answering  “no”.  A provider’s health belief is a subjective bias which decreases 
the reliability of prostate cancer screening brochure survey; for example, the provider that though 
the pamphlet is biased also answered “no” the pamphlet would not change decisions of vets to get 
a PSA.    
 The comparison data  was received serendipitously when an e-mail message was sent,  
asking for four volunteer PCPs in Firm B to discuss their prostate cancer screening practices 
without the guidance of the attached pamphlet.  The request was preceded by a detailed paragraph 
describing the current prostate cancer screening dilemma and ended with an inaccurate statement,  
“For example, today a PCP in Firm C told me that PSAs are routinely ordered on all male patients 
over 50” (P. Hughes, personal communication, February 6, 2012).  The incorrect statement 
resulted in email rebuttals by two physicians followed by a discussion about the Project at the 
physicians monthly Journal Club.  Apparently none of the physicians routinely order PSAs 
because it no longer is a clinical reminder.   Some physicians are concerned about the potential 
legal implications of not even talking about PSA screening and having the patient getting it done 
somewhere else and being diagnosed with prostate cancer (and bringing a lawsuit against the VA 
for not diagnosing it); therefore, some physicians will routinely have the discussion. A highly 
respected physician recommends doing the right thing by following the USPSTF recommendation 
not to screen healthy men.  The ten Journal Club physicians are aware of the latest USPSTF 
guidelines.  
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 In retrospect, the incorrect statement was a godsend because it caused indifferent 
physicians to respond defensively.  In fact, the above two physician responses were the only 
responses received from the multiple providers on Firm B. Despite the response from only two 
providers, instead of the requested four, the Capstone Project was unexpectedly the topic of 
discussion at the physicians’ Journal Club on February 7, 2012.  Since there were ten physicians 
at the monthly Journal Club, and one physician stated that “None of the physicians routinely 
order PSAs”; it is safe to assume that at least four Firm B Clinic physician providers do not 
routinely order PSA tests on healthy veterans.     
 The potential legal implication of not discussing prostate cancer screening with patients is 
a valid concern, resulting in some providers routinely ordering PSAs.  For instance, in a study 
aimed at identifying factors that facilitate or prevent prostate cancer screening discussions, three 
physicians stated they will default to ordering a PSA due to medical-legal concerns if they are 
unable to have a discussion with the patient (Guerra et al., 2007).  Patient barriers that prevent 
physicians from discussing prostate cancer screening include comorbidities, limited 
education/health literacy, competing preventative health discussions, mental illness, and the 
patients already deciding they want PSA screening (Guerra et al).  Interestingly, being well 
educated does not preclude problems with health literacy (Hoffman, 2009). The preceding 
findings correlate with Denver VAMC providers’ reasons for ordering PSA tests without a 
patient discussion.  
 The Chief of Ambulatory Care informed the Health Promotion Disease Prevention 
(HPDP) Program Manager about the Project because the HPDP’s project was concurrently 
taking place to reduce PSA screenings in men over 75 years. The first short meeting took place 
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on February 28, 2012, followed by emails and phone communication. The HPDP Program 
Manager was included in email messages about the Capstone project from then on. 
 In 2012,  The HPDP Program Committee chose to address the  potential over utilization 
of PSA screening within the ECHCS because there was speculation that PSAs were routinely 
being ordered in men over 75 years despite the VHA Clinical Recommendations against 
screening for this population. Two physicians, a urologist, and a PCP worked with the HPDP 
Program Manger to study the issue and develop interventions, if necessary. Data from the 
Veterans Integrated Service Network (VISN) 19 Data Warehouse included ECHCS VA patients 
≥ 75 years who had a PSA drawn November, 2010 to November, 2011.  One thousand seven 
hundred sixty nine patients ≥ 75 years had a PSA done within the 12 month time frame. Five 
hundred and three patients with a history of prostate cancer were eliminated from the 
denominator, assuming the PSA was used for monitoring not screening, leaving 1266 patients 
having a PSA drawn for unknown reasons. A random sample of 50 patients from the 1266 was 
indentified for chart review to look for reasons for PSAs being ordered; three were eliminated 
because they were found to have prostate cancer.   Eighty-seven percent  (n=41) of PSAs done in 
men ≥ 75 was for routine screening  which is not in line with the VHA and USPSTF guidelines. 
The planned interventions are to send out a MEMO to ECHCS providers about the 
recommendations not to routinely screen men ≥ 75 years and to create a flag in the CPRS lab 
package that would appear when a PSA is ordered for men ≥ 75 years without a diagnosis of 
prostate cancer (L.Shainline, personal communication, March 6, 2012).    
Results Discussed According to Evidence-Based Practice  
 
  The results of the preceding QI project correlate with clinical observations made over the 
past 15 years.  In other words, the vast majority of PSAs done at the VA ECHCS are randomly 
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drawn, including being ordered on men too old to ever benefit from screening. The USPSTF has 
recommended against screening men age 75 years or older for years (Lin et al., 2008), yet the 
preceding project shows that screening in this group is quite routine.  Despite the response from 
the Journal Club physicians that PSAs are not routinely ordered, the evidence reveals quite the 
opposite. Therefore, the Capstone QI Project is here just in time to educate providers about the 
recommendations for prostate cancer screening informed decision making for men ≤ 75 who 
request to be screened. The Project will facilitate evidence -based practice by providing a 
detailed pamphlet to guide providers and educate patients. The HPDP Program QI Project is here 
just in time to ensure evidence -based practice at the ECHCS by educating providers not to order 
PSAs on veterans ≥ 75 years, including flagging PSA orders placed for male veterans ≥ 75 years.      
 The Capstone Project helped improve the process of prostate cancer screening at the 
Denver VAMC. The pamphlet, and corresponding discussions, educated providers about the 
USPSTF recommendations not to screen healthy men, and provided a guide for providers to 
inform patients who request to be screened (Bankhead, 2011; Lin et al., 2008).  Public approval 
of the pamphlet, followed by mass production and distribution in the ECHCS primary care 
clinics, will ensure that the standard of care for prostate cancer screening is based on scientific 
evidence.  In other words, by using data from the two large ongoing randomized clinical trials of 
PSA screening, the pamphlet will help bridge the gap between evidence and practice.  
Additionally, public approval of the pamphlet will help ensure that male veteran patients do not 
undergo PSA testing without the type of shared decision making that practice guidelines 
recommend (Woolf & Krist, 2009).      
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Limitations, Recommendations, Implications for Change  
Limitations 
  The limitations to the project are the small number of participants, particularly physician 
participants.   Recruiting Firm A Clinic physician volunteers to test the pamphlet and engaging 
Firm B Clinic physicians in discussions about their prostate screening practices without the 
pamphlet was difficult.  The small number of PCPs and patient encounters may have prevented 
new themes from emerging from the data (Guerra et al., 2007).  In other words, since there were 
only eight participants, there may be a wide range of experiences not captured (Clements et al 
2007).   Furthermore, VA providers care for patients who are mostly low income and/or service 
connected; therefore, the findings are less generalizable to providers who care for a more affluent 
and/or heterogeneous population.   
  The value of the qualitative findings obtained from providers’ discussions, and lack 
thereof, increased the depth of understanding about prostate cancer screening practices at the 
Denver VAMC. A common theme from PCP’s direct and indirect discussions is that routine 
PSAs are not done at the Denver VA, although clinical experience and the VA HPDP Program 
QI project reveal quite the opposite.   Additionally, Denver VA medical specialist’s opinions 
about PSA screening are far more optimistic than some of their PCP cohorts.  For example, two 
VA oncologists stated that PSA screening saves lives (T. Braun & E.  Pajon, personal 
communication, July, 2011), and the Chief of Urology agrees that PSAs should not be done on 
men ≥ 75 years (E. Park, personal communication, August, 2011).   The Chief of Urology’s 
recommendation, through the HPDP Program QI Project, to stop PSA screening in men ≥ 75 
years seems to be too little, too late.  In other words, the USPSTF has recommended against 
screening men ≥ 75 years for years  (Lin et al., 2008)  and now recommends  against prostate 
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cancer screening with a PSA test, regardless of age, race, or family history (Hoffman et al., 
2011).    
Recommendations and Implications for Change 
 
 Improved healthcare outcomes depend on inter-professional collaboration in developing 
uniform standards of care (Regis University Loretto Heights School of Nursing, 2010).  The lack 
of consensus about the utility of PSA screening among medical specialties leads to inconsistent 
practice guidelines with the recommendation for shared decision making between patient and 
clinician as the only standard of care (Hoffman et al., 2011).   For example,  the  AUA  
recommends offering PSA screening at age 40;  the  ACS  recommends offering PSA screening 
at age 50; and the USPSTF recommends not screening  healthy men with a PSA because the test 
does not save lives and often leads to downstream consequences of PSA testing (Hoffman, 2011;  
Bankhead, 2011) .  Major medical organizations need to come up with one standard prostate 
cancer screening guideline instead of asking the patients to decide if they want to undergo PSA 
testing.  As Suss (2008) stated, “I don’t think it is a good idea for experts to ask their clients or 
patients to make choices about means.  If thousands of doctors can’t agree on whether PSA 
screening results in any benefit, then it  makes no sense to ask the patient to settle the dispute” 
(p.1288); therefore, shared decision making is somewhat of a misnomer.   
 The USPSTF recommends against PSA testing in healthy men (Bankhead, 2011; 
Hoffman, 2011).   The AUA  and the ACS  recommend shared decision making about PSA 
screening starting at age 40 and 50 respectively (Hoffman, 2011) . Medical specialists who 
perform prostate surgeries and treat cancer are less skeptical about PSA testing than the 
USPSTF, an independent committee of experts, supported by the U.S. Government. The 
independent committee of experts undergoes a rigorous process to ensure that evidence is used 
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for developing clinical practice guidelines for prevention and screening. The Task Force grades 
its recommendations based on the strength of evidence from randomized clinical trials and the 
magnitude of net benefit (benefits minus harms).  Members include experts in primary care, 
prevention, evidenced-based medicine, research methods, public health, and health policy 
(Gordis, 2009).  Therefore, it makes good sense to use the USPSTF recommendations as the gold 
standard of care, rather than recommendations from medical organizations that stand to profit 
from PSA screening.    
 Prostate cancer screening efficacy and safety involves both clinical and epidemiological 
research.  Distinguishing causation from association, establishing validity of outcome measures, 
estimating lead time, and studying the natural history of prostate cancer are epidemiological 
studies which can be used to critically appraise current practice, develop practice guidelines, and 
drive organizational change in order to improve healthcare outcomes ( Regis University Loretta 
Heights School of Nursing, 2010).  Based on cancer epidemiology data (Etzioni et al., 1998; 
Telesca et al), prostate cancer screening with a PSA should be abandoned because as Gordis 
(2009) puts it, “Even the best of intentions and passionate evangelism cannot substitute for 
rigorous evidence that supports or does not support the benefit of screening” (p.331).  As of 
October 2011, the rigorous evidence does not support the benefit of screening for prostate cancer 
with a PSA blood test (Bankhead, 2011).    
 Evidence-based practice is based on clinical expertise, patient choice, and valid research 
evidence (Tymkow, 2011).  Cancer screening enthusiasm often leads to patient choice 
conflicting with scientific evidence; such is the case for people committed to cancer screening 
regardless of its implications.  Addressing the social problem of cancer screening enthusiasm 
requires assuming a leadership role to ensure accountability for quality, safe, evidenced based 
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patient care (Regis University Loretta Heights School of Nursing, 2010). Health care marketing 
must stop portraying screening as an obligation in order to reduce the public risk of over testing 
and over treating (Schwartz et al., 2004).    In other words, according to Woolf & Krist (2009), 
“What is ultimately required is a deeper change in culture  among providers and consumers of 
health care to delay dissemination, resist the assumption that newer is better, wait for evidence, 
tolerate observation over intervention, and accept uncertainty” (p. 1559).   
 Finally, changing health care policy will help reverse one of the major reasons behind 
PSA screening, fear of liability. The change will result in cultural and organizational changes 
which decrease or eliminate legal consequences for failing to diagnose cancer through screening.    
The VAMC has already has made the change by excluding PSA screening from their 
computerized view alerts.  In other words, in order to encourage patients to participate in 
screening decision making, the VAMC’s electronic medical record has built in physician 
reminders and checklists related to preventative care and counseling.  Since PSA screening is no 
longer a clinical reminder, not ordering a PSA test should not be considered a malpractice error 
of omission.  Unfortunately, the community standard of care may not coincide with the VAMC’s 
national standard of care.   
 The legal standard of health care is not defined uniformly through-out the United States 
because state statutes define it. For states with no relevant statute, case law governs the standard 
of care for providers in the state. Twenty-nine states and Washington D.C. use a national 
standard of care and twenty-one states or jurisdictions use some version of the locality rule 
(Lewis, Gohagan, & Merenstein, 2007).   The 1880 locality rule protected rural physician based 
on the premise that they did not have the same opportunities as their colleagues in the big cities; 
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therefore, they were no held to the same standard of care.  Even though many states abandoned 
the locality rule by the 1970s, the rule is still invoked in medical malpractice case (Lewis, et al.). 
 The persistence of the locality rule has serious implications for providers and may serve 
to promote the practice of substandard health care (Lewis, Gohagan, & Merenstein, 2007). The 
“community standard” or “locality rule” has traditionally been a problem between plaintiffs and 
defendants in medical malpractice cases leading to dozens of reported decisions from the 
appellate courts (Ford, 2011).  In a medical malpractice lawsuit, it is necessary for the plaintiff to 
prove that the physician did not follow the necessary standard of care; however, the standard of 
care can be different depending on where the provider works (Truglio et al., 2011).   The courts 
have never applied a consistent set of standards for the locality rule; in fact, a military lawyer 
assigned to defend the veterans’ administration against malpractice claims, arising under state 
law, gave up trying to decipher the inconsistent cases on the locality rule (Ford).  Depending on 
the jurisdiction, expert witnesses (health care providers) base their support or criticism of the 
case on either the national or community standard.  Since the author practices in Colorado and 
Colorado still adheres to some form of the locality rule, it is necessary to be knowledgeable 
about Colorado’s applicable standard of care.   
 According to Longest (2010), “Public policies do not exist in isolation” (p. 204); 
therefore, analysis of the public policy environment is part of the larger external environment 
which health care organizations need to evaluate to determine the externally imposed threats and 
opportunities to their performance (Longest).  Health care providers’ performance of the national 
evidenced- based practice standard of prostate cancer screening informed decision is threatened 
by the antiquated locality rule. Colorado’s version of the locality rule holds general practitioners 
to a community standard; whereas, specialists are held to a national standard (Lewis, et al., 
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2007).  Colorado’s locality rule and other states that adhere to some form of the locality rule 
must be amended to national standards of care for all providers which will result in uniformity 
and state wide evidence-based practice.      
 Prostate cancer screening is not evidence-based practice but customary care.  Current 
guidelines recommend against prostate cancer screening in healthy men (USPSTF, 2011) or   
informed/shared decision making for those who want to be screened (Woolf & Krist, 2009).  
Fear of litigation is one of the reasons providers continue with uninformed prostate cancer 
screening.  Fear of litigation is a valid concern because the structure of the United States legal 
system supports local screening practices, and not ordering a PSA test can be considered a 
malpractice error of omission (Guerra et al., 2007).    According to Keene (as cited in Sorrel, 
2010), “medical standards should drive legal standards, not the other way around” (para, last).  
Therefore, since it is the state’s responsibility to act as guardians of the public’s health and 
regulators of the healthcare system and pursuit of health (Longest, 2010), it is time for the 
Colorado Assembly to modify the locality rule to national standards.   
Conclusion 
 In 2009, the first quantitative estimates of the survival benefit due to early detection of 
prostate cancer have not been shown to have a significant impact on mortality (Adami, 2010).  
Existing evidence from randomized controlled trials reveals that early detection of prostate 
cancer through PSA screening comes at the price of additional testing, unnecessary invasive 
treatments, and impaired quality of life yet to be quantified (Djulbegovic et al., 2010).  However, 
since the triad of evidence-based practice  includes best scientific evidence, clinical experience, 
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and patient preferences (Houser & Oman,2011) individual patients’ values are  key factors in 
deciding whether to offer screening( Djulbegovic et al.).   
 The success of evidence based practice depends on paying close attention to the synergy 
of time and circumstance, critically analyzing results of studies which could improve patient 
care, and then acting at the right time to change the organizational culture which supports 
antiquated practices. Current guidelines recommend that PCPs discuss the advantages and 
disadvantages of prostate cancer screening prior to testing, but this is not routine. Time, effort, 
resources, fear of litigation, and cultural enthusiasm for cancer screening are some of the reasons 
informed decision making is often not done (Woolf & Krist, 2009).  The challenges in 
implementing the required practice change of informed prostate cancer screening with the 
guidance of the detailed pamphlet includes  fostering commitment among those involved such as 
patients, providers, and policy makers.  Despite the challenges, the onus and moral obligation of 
VAMC health care providers are to educate patients about the risks and benefits of screening 
before undergoing PSA testing.    
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toward the PSA 
test.  Data 
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identification of 
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and regular 
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researchers 
helped to ensure 
Opinion of a 
Urologist about 
the usefulness of 
the PSA blood 
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Outcome 
Measures 
and Results 
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treatment effects 
of prostate cancer 
treatment. 
Authors comment 
that if a screening 
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inadequate 
sensitivity and 
specificity is used 
to detect cancers 
with an unknown, 
often benign, 
natural course, 
and as a result 
patients are 
subjected to an 
experimental 
treatment with 
substantial side 
effects, the net 
effect of 
screening could 
be harmful.   
Primary outcome 
was prostate 
cancer mortality 
at 7 and 10 years 
follow up; 
number of 
prostate cancers 
diagnosed 
reported. After 7-
10 years of 
follow- up the 
rate of death from 
prostate cancer 
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not differ 
significantly 
between the two 
groups.    
All GPs reported 
undertaking some 
discussions with 
asymptomatic 
men about the 
PSA test. They 
described 
focusing most of 
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the false-positive 
and false-
negative rates of 
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risks associated 
with a prostate 
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reported less 
discussion of the 
potential for 
diagnosing 
indolent cancers, 
the dilemmas 
regarding 
treatment options 
for localized 
prostate cancer 
and the potential 
benefit of testing. 
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variation existed 
between GPs in 
The author notes 
a correlation 
between PSA, 
cancer, and 
benign prostatic 
hypertrophy and 
notes that a rapid 
rise in PSA is 
associated with 
more aggressive 
cancers. He then 
goes on to state 
"we" recommend 
decreasing the 
PSA threshold for 
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4ng/ml to 2ng/ml  
because it 
SEEMS to detect 
more localized 
cancers.   
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GP's presentation 
of information 
appeared to be 
affected by their 
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the PSA test.   
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Author 
Conclusions/ 
Implications 
of Key 
Findings 
No prevention 
trial is ethically 
acceptable if the 
purpose is simply 
to provide 
evidence of net 
harm. To 
intervene in 
healthy people is 
not ethical 
without the 
widespread 
perception of a 
net benefit. As of 
yet the ethical 
justification for 
prostate cancer 
screening trial has 
yet to be heard.   
After 7-10 years 
of follow- up the 
rate of death from 
prostate cancer 
was very low and 
did not differ 
significantly 
between the two 
study groups.    
The GPs in this 
study appear to 
recognize the 
importance of 
discussions 
regarding PSA 
testing; however, 
a full and 
balanced picture 
of the associated 
advantages and 
limitations does 
not seem to be 
consistently 
conveyed. Factors 
specific to PSA 
testing which 
appeared to have 
an impact on the 
GPs discussion 
were the GPs 
personal opinions 
of the PSA test, 
and the need to 
counter men's 
primarily positive 
views of the 
benefits of PSA 
testing. 
Awareness of 
their views on the 
consultations may 
help GPs give 
men a more 
balanced 
presentation of 
the benefits and 
limitations of the 
PSA test.  
The author 
acknowledges 
that the price of 
detecting cancers 
early comes at the 
expense of more 
biopsies, 
treatment-related 
morbidity, and 
overtreatment of 
some men but 
then endorses 
doing more 
biopsies. He 
concludes until a 
better test comes 
along PSA is here 
to stay. 
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Strengths/ 
Limitations 
Strengths are the 
high 
qualifications of 
the authors.   
Limitation is this 
is an opinion.  
According to the 
2010 Cochrane 
Screening for 
Prostate Cancer 
(Review) there 
was adequate 
sequence 
generation; 
adequate 
allocation 
concealment; 
intervention and 
data on diagnosed 
cancers and 
mortality not 
blinded; 
incomplete 
outcome data was 
not addressed; it 
was free of 
selective 
reporting and free 
of other bias.    
This study is the 
first to address 
the discussions 
about PSA testing 
that takes place 
during GP 
consultations 
with 
asymptomatic 
men concerned 
about prostate 
cancer, and as 
such provides a 
valuable insight 
into the extent to 
which the 
implications of 
undergoing a 
PSA test are 
discussed. The 
value of 
qualitative 
research lies in 
the depth of 
understanding 
gained from 
detailed 
descriptions of 
specific 
experiences; 
therefore the 
number of 
participants in a 
qualitative study 
is necessarily 
small.  The small 
number of 
participants may 
mean that there 
were a range of 
experiences that 
were not 
captured.  
Interviews reliant 
on recall of 
events can suffer 
from recall bias. 
This opinion of a 
practicing 
urologist is biased 
with the author 
talking out of 
both sides of his 
mouth. 
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A further 
limitation is that 
GPs for this study 
were recruited 
from one regional 
area.   
Funding 
Source 
No funding 
source 
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contracts from the 
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Institute.  
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Kline, Aeterna 
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Ferring 
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Pharmaceuticals, 
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Roche provided 
lecture fees, grant 
support, and 
research support 
to individual 
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for the time spent 
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interview. The 
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by Cancer 
Research UK and 
the NHS cancer 
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The author 
declares no 
conflict of 
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researchers.    
Comments 
Hans-Olov 
Adami is highly 
qualified to give 
expert opinion.  
He has a long 
background as a 
practicing 
surgeon with a 
focus on 
oncology. He 
conducts clinical 
and 
epidemiologic 
research in 
parallel. His 
clinical research 
includes 
randomized trials, 
prognostic 
studies, and 
studies of clinical 
issues using an 
observational 
study design. His 
focus is on cancer 
epidemiology and 
is currently 
working on 
prostate cancer 
with research 
ranging from 
genetic 
association 
studies to 
randomized trials 
of radical surgical 
treatment, and 
prediction of 
outcome using 
Excellent large 
randomized 
control study with 
low risk of bias.  
One of two 
(European trial)  
ongoing 
randomized trials 
of PSA screening, 
to provide the 
first quantitative 
estimate of the 
survival benefit 
due to early 
detection of 
prostate cancer.  
This USA trial 
found no survival 
benefit from 
annual PSA 
screening 
combined with 
digital rectal 
exam.   
This article 
identified barriers 
faced by GPs in 
providing PSA 
screening 
education 
including time 
constraints and 
personal 
opinions. GPs 
were less likely to 
discuss the 
potential for 
diagnosing 
indolent cancers 
and the lack of 
evidence for the 
effectiveness for 
prostate cancer 
treatments. An 
interview study is 
pending which 
looks at 
consultations 
prior to PSA 
testing from 
men's 
perspective.   
This article is an 
opinion of a 
Urologist and was 
written in 2005 
when PSAs were 
given more 
credence than 
today.  
69 
 
 
 
molecular and 
genetic markers.     
 
  
70 
 
 
 
  Article 24  
Article 12 Article 22 Article 9 
Article Title 
and Journal 
Asymptomatic 
incidence and 
duration of 
prostate cancer. 
American Journal 
of Epidemiology.  
 Patient-Centered 
Discussion about 
Prostate Cancer 
Screening: A 
Real-World 
Approach.  
Annals of Internal 
Medicine   
Are physicians 
discussing 
prostate cancer 
screening with 
their patients and 
why or why not? 
A pilot study.  
Journal of 
General Internal 
Medicine.   
The prostate 
cancer pseudo-
epidemic.  Acta 
Oncologica 
Author  / 
Year 
Etzioni, R., Cha, 
R., Feurer, R., 
Davidov, O. 
(1998). 
Gaster, B.,  
Edwards, K., 
Brown Trinidad, 
S., Gallagher, T., 
Braddock, C. 
(2010)  
Guerra, C., 
Jacobs, S., 
Holmes, J., Shea, 
J. (2007).  
Adami, Hans-
Olov(2010)  
Database 
and 
Keywords 
Database:CINHL 
with Full Text  
 
Keywords in the 
article include 
disease 
progression; 
natural history; 
prevalence; 
prostatic 
neoplasms; SEER 
program.  
 
Article includes 
19 references.  
 
Database:CINHL 
with Full Text  
 
 Keywords used 
to search for the 
article included 
prostate cancer 
screening, clinical 
guidelines, shared 
decision making.  
 
Article  includes 
52 references 
 
 
 
Database:CINHL 
with Full Text  
 
Key words in the 
article  include  
prostate-specific 
antigen; prostate 
cancer screening; 
mass screening; 
physician practice 
patterns; 
physician-patient 
relations; 
communication 
barriers; informed 
decision making.  
 
Article  includes 
39 references 
Database:CINHL 
with Full Text 
 
Key words (Major 
subjects) include 
early intervention, 
health screening, 
incidence, PSA, 
prostatic 
neoplasms 
 
Article includes 
26 references and 
six tables/charts 
displaying 
statistics.   
71 
 
 
 
Research 
Design 
Single descriptive 
study  
Ideas and 
opinions 
Qualitative pilot 
study involving 
in-depth, 
semistructured 
interviews with 
18 purposively 
sampled, 
academic and 
community-based 
primary care 
physicians.  
This article is a 
lecture by Dr.     
Adami, presented 
at SOF meeting in 
Uppsala, Sweden, 
March 18-20, 
2009. It is a 
review of studies 
of the natural 
history and 
treatment impact 
of prostate cancer 
carried out in 
Sweden and other 
Nordic countries 
during the last 
two decades.  
Level of 
Evidence 
Level 6: Single 
descriptive study.  
Level 7 : 
Opinions of 
authorities/experts 
Level 6: Single 
descriptive or 
qualitative study  
Level 1: 
Systematic review 
Study Aim / 
Purpose 
The goal of this 
paper is to 
estimate the 
length of the 
asymptomatic 
period in prostate 
cancer, that is, the 
time of onset of 
the disease until 
the appearance of 
symptoms leading 
to its diagnosis.  
Also estimate the 
duration of the 
preclinical period, 
which the authors 
define as the time 
from onset of the 
disease until its 
clinical diagnosis, 
whether due to 
symptoms or not. 
Recent data 
suggest that few 
providers are 
discussing 
prostate cancer 
screening with 
their patients 
despite national 
guidelines that 
recommend it.  
The authors 
propose a 
process-approach 
(Ask-Tell-Ask) 
that promotes 
tailored 
conversations and 
value-based 
recommendations.  
This study aimed 
to identify factors 
that facilitate or 
prevent prostate 
cancer screening 
discussion.  
To present 
indirect evidence, 
incidence and 
mortality trends, 
and summarize 
studies of the 
natural history 
and treatment 
impact of prostate 
cancer.  
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Population 
Studied / 
Sample Size 
/ Criteria / 
Power 
Estimate the age-
specific incidence 
of new (stage A1) 
prostate cancers 
using preclinical 
prevalence data 
from autopsy 
studies performed 
between 1941 and 
1964 and clinical 
incidence data for 
the years 1960-
1986 from the 
Surveillance, 
Epidemiology, 
and End Results 
(SEER) program 
of the National 
Cancer Institute.    
Not applicable   18 participating 
physicians  
The information 
in this article is 
extracted from 
multiple studies: 
One study of the 
natural history of 
early prostate 
cancer involved 
watchful waiting 
of 223 
symptomatic 
patients  in 
Orebro County in 
Sweden before 
the PSA era 
(1977-
1984);Another 
study of survival 
benefit of radical 
local treatment 
includes a multi-
center randomized 
controlled trail of 
695 men newly 
diagnosed with a 
clinically 
localized prostate 
cancer, and with a 
PSA value less 
than 50 PG/nl and 
no evidence of 
metastases 
randomized to 
radical 
prostatectomy or 
watchful waiting.  
In 2009, the 
European and 
USA ongoing 
randomized trials 
of PSA screening 
were mentioned 
with 162,387 men 
from seven 
countries 
followed for an 
average of 9 years 
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in the European 
trial and 76 693 
men in the USA 
trial.  
Methods / 
Study 
Appraisal / 
Synthesis 
Methods 
Begin by 
estimating the 
number of new 
cases of 
asymptomatic 
disease in any 
given age interval 
from the 
incidence data 
above. Then, the 
preclinical 
prevalence 
estimates are 
divided by the 
derived 
preclinical 
incidence 
Provides a time-
efficient model 
which emphasizes 
the provider's role 
as an interactive 
guide rather than 
a one-way 
supplier of 
information in 
discussing the 
pros and cons of 
prostate cancer 
screening.     
Barriers and 
facilitators of 
prostate cancer 
screening 
discussions were 
ascertained using 
both interviews 
and chart-
stimulated recall-a 
technique 
utilizing patient 
charts to probe 
recall and provide 
context to 
physician 
decision-making 
during clinic 
Extrapolated 
findings from 
multiple studies 
and incidence and 
mortality trends. 
Prostate cancer is 
an extreme 
example of 
autopsy-detected 
tumors. The 
prevalence of 
such lesions is 
about 20% 
already among 
men aged 45 
years and 
increases with 
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estimates to yield 
estimates of the 
average duration 
of asymptomatic 
disease.  
encounters. 
Analysis was 
performed using 
consensus 
conferences based 
on grounded 
theory techniques.     
age; these lesions 
detected at 
autopsy did not 
cause symptoms 
or contribute to 
death.  
Primary 
Outcome 
Measures 
and Results 
The estimated 
mean duration 
among white men 
is between 11 and 
12 years and 
appears to be 
approximately 1 
year shorter for 
blacks than for 
whites. 
Comparison of 
the lifetime risks 
of preclinical and 
clinical disease 
suggests that 
approximately 
75% of prostate 
cancers will never 
become diagnosed 
if clinical 
incidence remains 
at levels observed 
in 1984-1986, 
prior to the 
introduction of 
PSA screening in 
the population.  
Ask-Tell-Ask 
approach will 
improve the 
quality of care by 
encouraging more 
informed 
decisions about 
prostate cancer 
screening.   
All 18 
participating 
physicians 
reported that they 
generally 
discussed prostate 
cancer screening 
(PCS) with 
patients, though 6 
reported 
sometimes 
ordering PSA 
tests without 
discussion.  A 
PCS discussion 
occurred in only 
16(36%) of the 44 
patient-physician 
encounters when 
patients were due 
for PCS that also 
met criteria for 
chart-stimulated 
recall. Barriers to 
PCS discussion 
were patient 
comorbidity, 
limited 
education/health 
literacy, prior 
refusal of care, 
physician 
forgetfulness, 
acute-care visits, 
Orebro study with 
continued follow 
up beyond 20 
years; as of 2001, 
9% of men still 
alive, only 16% 
had died from 
prostate cancer, 
whereas 75% had 
died from other 
causes. Multi-
center trial of 695 
men at 12 years 
follow-up, 47 
(12.5%) of the 
surgery group and 
68(17.9% of the 
watchful waiting 
group had died of 
prostate cancer 
yielding a relative 
risk of 0.65 
comparing 
watchful waiting 
to radical 
prostatectomy. 
The absolute risk 
reduction at 12 
years was 5.4 % 
which translates 
into 19 patients 
needing to be 
treated with 
radical 
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and lack of time. 
Facilitators of 
PCS discussion 
included patient-
requested 
screening, highly 
educated patients, 
family history of 
prostate cancer, 
African American 
race, visits for 
routine physicals, 
review of 
previous PSA 
results, extra time 
during 
encounters, and 
reminder systems.   
prostatectomy in 
order to avert one 
prostate cancer 
death. The 
absolute risk 
difference in the 
European trial 
was 0.71 cancer 
deaths/1000 men 
screened, 
meaning that 
1410 men must be 
screened and 48 
cases of prostate 
cancer treated to 
avert one death. 
At 10 years in the 
US trial there 
were 92 prostate 
cancer deaths 
among 38343 
men randomized 
to screening but 
only 82 among 
38350 men 
randomized to no 
screening; the 
difference was not 
statistically 
significant. 
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Author 
Conclusions
/ 
Implications 
of Key 
Findings 
The asymptomatic 
incidence and 
sojourn time 
estimates are 
biologically 
plausible and are 
consistent with 
the literature on 
PSA growth in 
prostate cancer 
cases. They 
confirm what has 
already been 
suspected for 
some time, 
namely, that 
prostate cancer is 
a relatively slow-
growing 
neoplasm, and 
they suggest that 
among whites, 50-
75 percent of new 
cases are unlikely 
to surface 
clinically. The 
estimates should 
be useful to 
researchers 
studying the 
natural history of 
the disease and 
designing 
effective and cost-
effective 
screening 
programs.  
Shared decision 
making about 
prostate cancer 
screening is 
crucial, given the 
continued 
uncertainty about 
its risks and 
benefits.  
Prostate cancer 
screening 
discussions 
sometimes do not 
occur. Important 
barriers to 
discussion are 
inadequate time 
for health 
maintenance, 
physician 
forgetfulness, and 
patient 
characteristics. 
Future research 
should explore 
using educational 
and decision 
support 
interventions to 
involve more 
patients in PCS 
decisions.   
The prostate 
cancer mortality 
rate has varied 
little over 40 
years, but the 
detection of 
clinically 
insignificant 
cancers through 
PSA testing has 
entailed a drastic 
increase in the 
recorded 
incidence. For 
ethical and 
scientific 
reasoning--
reinforced by 
recommendations 
from respected 
authorities- 
careless PSA 
testing among 
men who are 
poorly informed 
or ignorant that 
PSA is analyzed 
in their blood 
sample must 
come to an end.  
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Strengths/ 
Limitations 
Limitations: The 
mathematical 
relation, average 
duration equals 
prevalence 
divided by 
incidence, has a 
long history in the 
epidemiologic 
literature. An 
implicit 
assumption is that 
the condition of 
interest is 
progressive in the 
sense that it will 
terminate unless 
prevented, for 
example by 
competing 
mortality. 
Therefore, this 
approach is not 
valid for non-
progressive 
diseases or for 
diseases that can 
regress. Given the 
possibility that 
prostate cancer 
cases may exist in 
whom the tumor 
might remain 
indolent no matter 
how long they 
lived (infinitely 
indolent), this is a 
limitation of the 
approach. 
This model is 
based on 
emerging theory 
and evidence in 
the field of patient 
communication 
with the goal of 
engaging patients 
and addressing 
their concerns.    
Strengths of this 
study include the 
open- ended 
interview and 
chart-stimulated 
recall which 
allowed for the 
identification of 
many important 
barriers to PCS 
discussion. Chart-
stimulated recall 
is an innovative 
method by which 
to achieve 
triangulation in 
qualitative 
research when 
conducting 
physician 
interviews and 
increases the 
validity of data 
obtained by 
physician 
interview. Also 
helps address the 
discrepancy 
between 
physicians ' 
perceived and 
actual behavior 
related to 
recommending 
cancer screening 
tests as well as 
recording bias 
inherent in 
methods based on 
chart abstractions.  
The study is 
limited because of 
the small number 
of physicians and 
patient encounters 
which may have 
prevented the 
In this 
groundbreaking 
article, the author, 
Professor, 
Department of 
Epidemiology, 
Harvard School of 
Public Health, 
former practicing 
surgeon with a 
focus on 
oncology, states 
that future 
historians may 
indeed consider 
the prostate 
cancer pseudo-
epidemic a 
disaster of 
modern medicine. 
There are no 
limitations to this 
study.  
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authors from 
reaching thematic 
saturation, the 
point at which no 
new themes 
emerged from the 
data. The study 
was conducted in 
1 large health 
system with a 
predominantly 
urban and 
suburban sample 
of physicians 
therefore the 
results are not 
generalizable.        
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Comments 
Epidemiologist 
have a much 
better handle on 
the true nature of 
screening 
including lead 
time bias, false 
positive and 
negatives, and the 
prevalence of 
indolent disease.  
Epidemiologists 
try to understand 
the natural history 
of a disease in 
order to develop 
efficient screening 
strategies.  
Much needed 
educational tool 
which encourages 
evidence based 
practice.    
This study 
confirms the fact 
that prostate 
cancer screening 
education is 
sporadic and 
random and 
therefore evidence 
based practice is 
not occurring.  
The author is 
highly qualified 
since he is 
working 
predominantly on 
prostate cancer 
with research 
ranging from 
genetic 
association 
studies to 
randomized trials 
of radical surgical 
treatment, and 
prediction of 
outcome using 
molecular and 
genetic markings 
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country is made 
available by the 
World Health 
Organization. 
Incidence and 
mortality rates 
(number of cases 
or deaths per 
100,000 persons 
per year) were 
estimated in 
GLOBOCAN by 
country, using the 
most recently 
available data 
collected at the 
International 
Agency for 
Research on 
Cancer or 
available in 
routine reports 
from the 
registries 
themselves.   168 
references.   
Research 
Design 
A randomly 
selected national 
sample of 3010 
English-speaking 
US adults 40 
years and older. 
Included in the 
survey were 375 
men who had 
either undergone 
or discussed 
(with health care 
providers) PSA 
testing in the 
previous 2 years.  
Systematic 
review of 205 
potentially 
relevant articles 
with 5 RCTs 
meeting the 
inclusion criteria 
for meta-analysis. 
Description of 
global cancer 
statistics with 
incidence data 
derived from 
population-based 
cancer registries.  
Population-based, 
cohort study with 
a mean 
observation 
period of 21 
years.  
Level of 
Evidence 
Level 6: Single 
descriptive or 
qualitative study. 
Level 1: 
Systematic 
reviews/meta-
analysis of all 
RCTs 
Level 6: Single 
descriptive or 
qualitative study  
Level 4: Cohort 
study.  
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Study Aim / 
Purpose 
Objectives were 
to characterize 
the decision-
making process 
and evaluate 
factors associated 
with discussing 
screening before 
a making a PSA 
testing decision 
and undergoing 
PSA testing 
following a 
discussion.  
To determine 
whether 
screening for 
prostate cancer 
reduces prostate 
cancer-specific 
mortality, all-
cause mortality, 
and its impact on 
quality of life, 
including adverse 
events. 
Provide an 
overview of the 
global cancer 
burden, including 
the estimated 
number of new 
cancer cases and 
deaths in 2008 
and the incidence 
and mortality 
rates by region 
for selected 
cancer sites.  
To examine the 
long-term natural 
history of 
untreated, early 
stage prostate 
cancer.  
Population 
Studied / 
Sample Size 
/ Criteria / 
Power 
A randomly 
selected national 
sample of 3010 
English-speaking 
US adults 40 
years and older. 
Included in the 
survey were 375 
men who had 
either undergone 
or discussed 
(with health care 
providers) PSA 
testing in the 
previous 2 years.  
Five RCTs with a 
total of 341,351 
participants were 
included in this 
review. All 
involved PSA 
testing, though 
the interval and 
threshold for 
further evaluation 
varied across 
trials. The age of 
participants 
ranged from 50 to 
74 years and 
duration of 
follow up from 7 
to 15 years. 
Global cancer 
statistics: About 
12.7 million 
cancer cases and 
7.6 million cancer 
deaths are 
estimated to have 
occurred 
worldwide with 
56% of the cases 
and 64% of the 
deaths in the 
economically 
developing 
world.        
A consecutive 
sample of 223 
patients (98% of 
all eligible) with 
early-stage (TO-
T2 NX MO 
classification), 
initially untreated 
prostatic cancer. 
Patients with 
tumor 
progression were 
hormonally 
treated (either by 
orchiectomy or 
estrogens) if they 
had symptoms.   
Methods / 
Study 
Appraisal / 
Synthesis 
Methods 
The DECISIONS 
study consisted of 
a random-digit-
dial telephone 
survey of a 
national 
probability 
sample of 
English-speaking 
US adults 40 
years and older. 
Participants 
completed a set 
of screening 
questions and 
This updated 
version of the 
2006 review 
identified 106 
potentially 
relevant articles 
for full text 
review in 
addition to the 99 
in 2006 resulting 
in review of 205 
articles. Two 
RCTs in 2006 
and three more in 
2010 met the 
National 
incidence rates 
were estimated 
using one of 
several methods, 
dependant on the 
availability and 
quality of data, in 
the following 
order of 
priority:1) 
National 
Incidence data, 
2)National 
mortality data 
Setting: 
Regionally well-
defined catchman 
area in central 
Sweden 
(recruitment 
March 1977 
through February 
1984). The TNM 
system and the 
World Health 
Organization 
classification of 
malignant 
diseases were 
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were then eligible 
for decision-
specific question 
modules if they 
had taken a 
medical action or 
discussed taking 
that action with 
health care 
providers for 1 of 
9 common 
medical decisions 
within the past 2 
years. Modules 
covered decisions 
related to cancer 
screening tests 
for prostate, 
colorectal, or 
breast cancer as 
well as other 
topics.  
inclusion criteria. 
Data from the 
trials were 
independently 
extracted by two 
authors.   The 
methodological 
quality of three of 
the studies had a 
high risk of bias. 
and local registry 
data, 3)Regional 
incidence data 
from one or more 
cancer registries 
but no mortality 
data, 4) 
Frequency data, 
5) No data 
available.  
Country-specific 
incidence and 
mortality rates 
were prepared for 
27 types of 
cancer, by sex 
and 10 age 
groups. A full 
description of the 
data and methods 
used for each 
county are 
available in 
GLOBOCAN 
2008.       
used. PSA was 
not available 
when the cohort 
was recruited.   A 
total of 654 cases 
of prostate cancer 
were diagnosed 
and 223 patients 
were ultimately 
included in the 
cohort study and 
followed up from 
diagnosis until 
death of the end 
of the observation 
period. Scheduled 
tests were 
performed to 
follow the 
progression of 
disease and the 
medical records 
of all diseased 
patients were 
reviewed. 
Progression and 
survival rates 
were determined 
and multivariable 
analyses were 
used to quantify 
the independent 
effects of follow-
up time, age at 
diagnosis, grade, 
and stage.        
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Primary 
Outcome 
Measures 
and Results 
Overall, 69.9% of 
subjects 
discussed 
screening before 
making a testing 
decision, 
including 14.4% 
who were not 
tested. Health 
care providers 
most often 
(64.4%) raised 
the idea of 
screening, and 
73.4% 
recommended 
PSA testing. 
Health care 
providers 
emphasized the 
pros of testing n 
71.4% of 
discussion but 
infrequently 
addressed the 
cons (32.0%). 
Although 58.0% 
of subjects felt 
well-informed 
about PSA 
testing, 47.8% 
failed to correctly 
answer any of the 
3 knowledge 
questions. Only 
54.8% of subjects 
reported being 
asked for their 
screening 
preferences. A 
health care 
provider 
recommendation 
(odds ratio, 2.67; 
95% confidence 
interval, 1.08- 
6.58) was the 
Primary 
outcomes prostate 
specific and all-
cause mortality. 
Secondary 
outcomes: 
incident prostate 
cancers by stage 
and grade at 
diagnosis; 
metastatic disease 
at follow up; 
quality of life; 
harms of 
screening; and 
costs associated 
with screening 
programs. No 
statistically 
significant 
reduction in 
prostate cancer-
specific or all-
cause mortality 
among the whole 
population of 
men randomized 
to screening 
versus controls.  
Breast cancer in 
females and lung 
cancer in males 
are the most 
frequently 
diagnosed cancer 
deaths for each 
sex in both 
economically 
developed and 
developing 
countries, except 
lung cancer is 
preceded by 
prostate cancer as 
the most frequent 
cancer among 
men in 
economically 
developed 
countries. The 
increased 
incidence of 
breast cancer in 
developed 
countries is due 
in part to 
postmenapausal 
therapy or oral 
contraceptives.  
Prostate cancer 
incidence rates 
vary by more that 
25-fold 
worldwide, with 
the highest rates 
recorded 
primarily in the 
developed 
countries of 
Oceania, Europe, 
and North 
America largely 
because of PSA 
screening which 
detects clinically 
important tumors 
After complete 
follow-up, 39 
(17%) of all 
patients 
experienced 
generalized 
disease. Most 
cancers had an 
indolent course 
during the first 
10-15 years. 
Follow-up from 
15(when 49 
patients were still 
alive) to 20 years 
revealed a 
substantial 
decrease in 
cumulative 
progression-free 
survival (45.0% 
to 36.0%), 
survival without 
metastases (from 
76.9% to 51.2%), 
and prostate 
cancer-specific 
survival (from 
78.7% to 54.4%).  
The prostate 
cancer mortality 
rate increased 
from 15 per 1000 
person-years 
during the first 15 
years to 44 per 
1000 person-
years beyond 15 
years of follow-
up.    
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only discussion 
characteristic 
associated with 
testing Valuing 
HCP information 
was also 
associated with 
testing (odds 
ratio, 1.26; 95% 
confidence 
interval, 1.04-
1.54).  
as well as other 
slow-growing 
tumors which 
might otherwise 
escape diagnosis. 
In contrast, males 
of African 
descent in the 
Carribean have 
the highest cancer 
mortality rates in 
the world.  
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Author 
Conclusions
/ 
Implications 
of Key 
Findings 
Recommendation
s and information 
from health care 
providers 
strongly 
influenced testing 
decisions. 
However, most 
prostate cancer 
screening 
decisions did not 
meet criteria for 
shared decision 
making because 
subjects did not 
receive balanced 
discussions of 
decision 
consequences, 
had limited 
knowledge, and 
were not 
routinely asked 
for their 
preferences.   
Prostate cancer 
screening did not 
significantly 
decrease prostate 
cancer-specific 
mortality in a 
combined meta-
analysis of five 
RCTs. Only one 
study (ERSPC) 
reported a benefit 
in a subgroup of 
men aged 55 to 
69. Within this 
subgroup it was 
determined that 
1410 men needed 
to be invited to 
screening and 48 
additional men 
subsequently 
diagnosed with 
prostate cancer 
needed to receive 
early intervention 
to prevent one 
additional 
prostate cancer 
death at 10 years.  
Any benefits 
from prostate 
cancer screening 
may take up to 10 
years to accrue; 
therefore, men 
who have a life 
expectancy less 
than 10 t0 15 
years should be 
informed that 
screening for 
prostate cancer is 
unlikely to be 
beneficial. 
The global 
burden of cancer 
continues to 
increase largely 
because of the 
aging and growth 
of the world 
population and an 
increasing 
adoption of 
cancer-causing 
behaviors, 
particularly 
smoking, within 
economically 
developing 
countries. A 
significant 
proportion of the 
worldwide 
burden of cancer 
could be 
prevented 
through the 
application of 
existing cancer 
control 
knowledge, 
implementing 
programs for 
tobacco control, 
vaccination(for 
liver and cervical 
cancers), and 
early detection 
and treatment, as 
well as public 
health campaigns 
promoting 
physical activity 
and healthier 
dietary patterns. 
Much needs to be 
learned about the 
causes of several 
major cancers 
including prostate 
Although most 
prostate cancers 
diagnosed at an 
early stage have 
an indolent 
course, local 
tumor 
progression and 
aggressive 
metastatic disease 
may develop in 
the long term. 
These findings 
would support 
early radical 
treatment, 
notably among 
patients with an 
estimated life 
expectancy 
exceeding 15 
years.   
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and colorectal 
cancers.   
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Strengths/ 
Limitations 
The study had 
several important 
limitations. The 
results were 
susceptible to 
recall bias 
because authors 
relied on patient 
self-report to 
characterize the 
testing process 
and there could 
be up to a 2-year 
lag time from the 
discussing 
screening to 
being surveyed. 
Another 
limitation was the 
lack of 
assessment of 
health literacy, 
defined as "the 
degree to which 
individuals have 
the capacity to 
obtain, process, 
and understand 
basic health 
information and 
services needed  
to make 
appropriate health 
decisions" .  
Patients with 
health literacy 
deficits have 
greater difficulty 
understanding 
and recalling 
complex medical 
information and 
are less likely to 
actively 
participate in the 
decision-making 
process.  
Excellent 
comprehensive 
systemic review. 
The 
methodological 
quality of three of 
the studies had a 
high risk of bias. 
Limitations: The 
global and 
region-specific 
estimates are 
built for 182 
countries or 
territories, 
together with a 
set of methods 
based on the 
availability of 
cancer incidence 
and mortality 
data at the 
country or 
regional level. 
Therefore the 
estimates 
presented in 
GLOBOCAN 
2008 are variable 
in accuracy, 
depending on the 
extend and the 
validity of 
available data by 
country, ranging 
from real and 
valid counts of 
cases and deaths, 
to estimates 
based on samples, 
through to those 
based on 
neighboring rates.  
Strengths include 
provision by the 
World Health 
Organization of 
country specific 
cancer mortality 
estimates by sex 
and age group for 
2008, based on 
broad cause-of-
death models. 
These data were 
Strengths: High 
internal validity 
of this population 
based study 
because there was 
complete follow-
up and 
standardized 
procedures were 
used for clinical 
examination, 
ascertainment of 
disease 
progression, and 
classification of 
death.  The slight 
difference 
between cause-
specific and 
relative survival 
times were 
largely consistent 
over time. 
Limitation: 
Difficult to 
validate survival 
data in any new 
cohort study of 
watchful waiting 
since aggressive 
treatment of 
prostate cancer 
has become more 
routine than 25 
years ago when 
the cohort was 
assembled.       
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Strengths include 
addressing an 
important timely 
topic with 
recommendations 
to provide 
alternate 
strategies, such as 
decision aids, to 
ensure a process 
that engages 
patients in 
decision making, 
provides them 
with information 
about alternative 
strategies, and 
facilitates the 
incorporation of 
their preferences 
and values into 
the medical plan.      
used in 
estimating the 
overall burden of 
cancer is several 
countries were no 
or very limited 
information was 
available.  
Funding 
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06-130-01-
CPPB).  
Comments 
The DECISIONS 
study reaffirms 
that men are not 
receiving 
adequate 
information and 
their provider's 
opinion is often 
the deciding 
factor.    
Excellent updated 
systematic review 
of all randomized 
controlled trials 
of screening 
versus no 
screening was 
eligible for 
inclusion in this 
review. This 
article is an 
update of the 
2006 Cochrane 
review which 
identified 
insufficient 
evidence to either 
support, or 
refutes the use of 
routine mass, 
selective or 
opportunistic 
screening for 
prostate cancer. 
The roles of PSA 
testing in the 
reduction of the 
prostate cancer 
mortality rates at 
the population 
level have been 
difficult to 
quantify. Older 
age, race (black), 
and family 
history remain 
the only well-
established risk 
factors and there 
are not 
established 
preventable risk 
factors for 
prostate cancer. 
Much remains to 
be learned about 
the cause of 
prostate cancer.    
This study 
advocates for 
aggressive cancer 
treatment but this 
was prior to PSA 
testing, and no 
screening for 
activities for 
prostate cancer 
took place during 
the period when 
this cohort was 
recruited.    
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  Article 5 Article 20 Article 4 Article 19 
Article Title 
and Journal 
15-Year follow 
up of a 
population based 
prostate cancer 
screening study. 
The Journal of 
Urology 
Patient education 
on prostate 
cancer screening 
and involvement 
in decision 
making. Annals 
of Family 
Medicine.   
Screening 
decreases prostate 
cancer death: first 
analysis of the 
1988 Quebec 
prospective 
randomized 
controlled trial. 
Prostate  
Clinical 
Guidelines: 
Benefits and 
harms of 
prostate-specific 
antigen screening 
for prostate 
cancer: An 
evidence update 
for the U.S.  
Preventative Task 
Force. Annals of 
Internal 
Medicine.   
Author  / 
Year 
Kjellman, A., 
Akre, O., 
Norming, U., 
Tornblom, M., 
Gustafsson, 
O.(2009) 
Krist, A, Woolf, 
S., Johnson., 
Kerns, W. (2007).  
Labie F., Candas 
B., Dupont A., 
Cusan L., Gomez 
J., Suburu, R. et 
al.(1999) 
Lin, K., Lipsitz, 
R., Miller, T., 
Janakiraman, S. 
(2008). 
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Database 
and 
Keywords 
Database:  
Cochrane Library 
 
Keywords in the 
article are 
prostate; prostatic 
neoplasm; 
mortality; 
outcome 
assessment 
(healthcare), 
mass screening. 
 
Article includes  
17 references 
 
Database:  
Cochrane Library  
 
 
Keywords: 
Prostatic 
neoplasm; 
decision making; 
patient 
education/method
s; guideline 
adherence/statisti
cs & numerical 
data; prostate-
specific 
antigen/blood; 
mass 
screening/method
s; 
prevention/cancer
; information 
management.    
 
Article includes  
includes 39 
references 
Database: 
PubMed 
 
Keywords in the 
article are 
prostate cancer; 
screening; PSA; 
hormonal 
therapy. 
 
 
 
 
Article includes  
 49 references 
 
 
Data Sources in 
the identified in 
the article: 
PubMed and the 
Cochrane Library 
(search dates, 
January 2002 to 
July 2007), 
referenced lists of 
retrieved articles, 
and expert 
suggestions.   
 
Keywords for 
three topics.   
1) Evidence on 
health outcomes 
associated with 
PSA screening: 
prostate 
neoplasm, 
screening, 
prostate-specific 
antigen, early 
diagnosis, PSA 
velocity, PSA 
doubling time, 
prostate specific 
antigen doubling.   
 2) Evidence on 
the harms of 
screening for 
prostate cancer:  
prostate 
neoplasm, 
screening, false 
positive 
reactions, adverse 
effects, mass 
screening/adverse 
effects, mass 
screening/psychol
ogy, anxiety, 
quality of life, 
health 
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knowledge, 
attitudes, 
practice.   
3) Evidence on 
natural   history 
of PSA-detected, 
nonpalpable, 
localized prostate 
cancer:  prostatic 
neoplasms, 
natural history, 
epidemiology, 
disease 
progression, 
survival analysis, 
watchful waiting, 
active 
surveillance, 
population 
surveillance, 
expectant 
management, 
conservative 
management.                                                                                                          
Research 
Design 
Randomized 
controlled trial in 
Stockholm, 
Sweden. Male 
participants were 
identified through 
census records. 
The study reports 
on a 15 year 
follow -up of 
participants on 
prostate cancer 
outcome.   
Randomized 
controlled study 
comparing paper-
based and Web-
based decision 
aids vs. no 
previsit education 
as a control.  
Randomized 
controlled trial in 
Quebec, Canada. 
Participants were 
men identified 
from electoral 
roles and 
allocated 2:1 in 
favor of 
screening. The 
study reports on 
an 11-year 
follow-up of 
participants on 
prostate cancer 
outcome.  Men 
age 45-80 years 
Data extraction: 
Studies were 
reviewed, 
abstracted, and 
rated for quality 
by using 
predefined U.S. 
Preventative 
Services Task 
Force criteria.   
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with screening 
group 31,133 and 
control group 
15,353.  
Level of 
Evidence 
Level 2:RCTs Level 2: 
Evidence from 
one or more 
RCTs.  
Level 2:RCTs Level 1: 
Systematic 
reviews/meta-
analysis of 
randomized 
controlled trials.  
Study Aim / 
Purpose 
Report on a 15-
year follow up of 
participants on 
prostate cancer 
outcome; 
evaluating the 
long-term 
survival in 
attendees and 
nonattendees of a 
onetime 
screening for 
prostate cancer.   
Many clinicians 
lack resources to 
engage patients in 
shared decision 
making for 
prostate cancer 
screening. This 
study evaluated 
whether previsit 
educational 
decision aids 
facilitate shared 
decision making.    
Evaluate the 
impact of prostate 
cancer screening 
on cancer-
specific mortality  
To examine new 
evidence on 
benefits and 
harms of 
screening 
asymptomatic 
men for prostate 
cancer with PSA.  
Population 
Studied / 
Sample Size 
/ Criteria / 
Power 
Participants were 
all men aged 
between 55-70 
years living in the 
catchment area of 
Stockhom South 
Hospital. Men 
with an earlier 
diagnosis of 
prostate cancer 
were excluded 
from the study. 
Numbers include 
screening group-
2374 and control 
group 24,772  
A total of 497 
men participated 
(75 control, 196 
brochures, 226 
Web site). 
46,486 men aged 
45-80 years 
registered in the 
electoral roll of 
the Quebec city 
area were 
randomized in 
1988 between 
screening and no 
screening. 
Screening 
included 
measurement of 
serum PSA using 
3.0ng/ml as upper 
limit of normal 
Systemic Review 
of articles 
addressing three 
questions: 1) 
Health outcomes 
associated with 
PSA screening, 
390 potentially 
relevant articles, 
2) Harms of 
prostate cancer 
screening, 421 
potentially 
relevant articles, 
3) Natural history 
of PSA-detected 
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and digital rectal 
examination 
(DRE) at first 
visit. At follow-
up visits, serum 
PSA only was 
used.    
prostate cancer, 
91 potentially 
relevant articles.     
Methods / 
Study 
Appraisal / 
Synthesis 
Methods 
Compare mass 
screening for 
prostate cancer to 
no screening: 
Interventions 
were one time 
screening versus 
control (not 
invited for 
screening). The 
screening 
consisted of 
DRE, PSA test 
and TRUS. 
TRUS guided 
biopsies were 
performed if 
abnormal 
findings occurred 
during the DRE 
and/or TRUS. A 
repeat TRUS was 
performed if the 
PSA was greater 
than 7ng/nl.   
Men aged 50 to 
70 years 
undergoing a 
health 
maintenance 
examination at a 
large family 
practice were 
enrolled.  
Compared mass 
screening for 
prostate cancer to 
no screening: 
Interventions 
were annual 
screening versus 
control (not 
invited for 
screening). TRUS 
biopsy was only 
performed if PSA 
was above 
3.0ng/ml for the 
first time or 
increased by 
more than 20% 
from last 
measurement. 
Randomized, 
controlled trials 
and meta-analysis 
of PSA screening 
and cross-
sectional and 
cohort studies of 
screening harms 
and of the natural 
history of 
screening-
detected cancer 
were selected to 
answer the three 
aforementioned 
questions.   
Primary 
Outcome 
Measures 
and Results 
Incidence rate 
ratios were 
calculated using 
Poisson 
regression 
models. Increased 
risk of death in 
nonattendees and 
The primary 
outcome was 
patient-reported 
level of control 
over the decision 
to be screened. 
Secondary 
outcomes 
Primary outcome 
was prostate 
cancer mortality 
at 11 years 
follow-up. Also 
reported was 
prostate cancer 
death incidence 
No good-quality 
randomized, 
controlled trials 
of screening for 
prostate cancer 
have been 
completed. In one 
cross-sectional 
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decreased 
mortality in 
screening 
attendees. The 
difference 
mortality rate was 
attributable to 
death from causes 
other than 
prostate cancer. 
included 
frequency of 
screening, patient 
knowledge, 
decisional 
conflict, and time 
spent discussing 
screening.   
Patients exposed 
to either aid were 
no more likely 
than control 
patients to report 
collaborative 
decision. 36% of 
patients in each 
group reported 
equally sharing 
decision 
responsibility. 
Exposure to 
either decision ad 
increased 
patients' 
involvement in 
decision making 
compared with 
the control 
condition (Web 
site, P=.03; 
brochure, P= .03). 
Only 46% of 
control patients 
reported an active 
decision-making 
role, compared 
with 56% of Web 
site and 54% of 
brochure patients. 
Patients exposed 
to a decision aid 
answered a 
greater 
percentage of 
knowledge 
questions  
correctly(54% 
rates in screened 
versus 
unscreened 
cohorts, and 
clinical stage and 
choice of therapy 
in men diagnosed 
with prostate 
cancer.  
and two 
prospective 
cohort studies of 
fair to good 
quality, false-
positive PSA 
screening results 
caused 
psychological 
adverse effects 
for up to one year 
after the test. The 
natural history of 
PSA-detected 
prostate cancer is 
poorly 
understood.    
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control vs 69% 
Web site, P < 
.001, and vs. 69% 
brochure, P < 
.001) and were 
less likely to be 
screened (94% 
control vs. 86% 
Web site, P = .06, 
and vs. 85% 
brochure, P= .04).    
Author 
Conclusions
/ 
Implications 
of Key 
Findings 
No evidence was 
found of a 
beneficial effect 
of the screening 
procedure. 
Significant lower 
life expectancy in 
non-attendees in 
a population 
based prostate 
cancer screening 
study. 
Patients in the 
decision aid 
groups were more 
informed and 
more engaged in 
the screening 
decision than 
their control 
counterparts. 
Exposure did not 
promote shared 
decision-making 
control, however. 
Whether shared 
decision making 
is the ideal model 
and how to 
measure its 
occurrence are 
subjects for 
further research.   
Strong support 
for early 
diagnosis and 
treatment. Early 
diagnosis 
combined with 
treatment of 
localized disease 
decreased death 
from prostate 
cancer by 62%.  
Prostate-specific 
antigen screening 
is associated with 
psychological 
harms, and its 
potential benefits 
remain uncertain   
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Strengths/ 
Limitations 
According to the 
Cochrane 
Screening for 
prostate cancer 
(Review) 
adequate 
sequence 
generation was 
unclear; no 
allocation 
concealment; 
blinding is not 
possible to the 
screening 
intervention ; 
incomplete 
outcome data was 
addressed; 
unclear if free of 
selective 
reporting; free of 
bias and data was 
analyzed 
according to the 
intention-to- 
screen - 
Limitations: 1) 
Outcomes 
measured by 
patient and 
physician 
questionnaires as 
opposed to direct 
observation or 
interview, 2) A 
well-educated, 
computor-savvy 
patient population 
was studied , 3) 
In July 2003, the 
study practice 
lost a well-
publicized 
malpractice case 
involving shared 
decision making 
and prostate 
cancer screening, 
4) 46% of the 
control patients 
reported that they 
viewed  
educational 
material before 
the office visit, 5) 
Study was 
underpowered to 
detect differences 
between the 
brochure and 
Web site groups.     
According to the 
Cochrane 
Screening for 
prostate 
cancer(Review) 
unclear adequate 
sequence 
generation; no 
mention of 
allocation 
concealment; not 
possible to blind 
intervention; 
incomplete data 
was addressed; 
unclear if free of 
selective 
reporting; not 
free of bias, data 
was not analyzed 
according to the 
intention-to-
screen principle   
Limitations: Few 
eligible studies 
were identified. 
Long-term 
adverse effects of 
false-positive 
PSA screening 
test results are 
unknown. 
Strengths: 
Nonrandomized 
studies of PSA 
screening 
excluded.                                                                                                                                                                                                                                                                    
Funding 
Source 
Supported by the 
Stockholm 
County Council 
and the Thure and 
Brita Grafstrom 
Foundation. 
Grant from Odd 
Fellows and 
Karolinska 
Institute. 
Funding support: 
This work was 
funded by the 
American 
Academy of 
Family 
Physicians 
Foundation under 
the Joint Grant 
Awards Program.  
Funding not 
mentioned  
Potential 
financial conflicts 
of interest: None 
disclosed.   
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Comments 
Contradictory 
results 
Simple paper and 
Web-based 
decision-making 
aides were 
equally effective 
at promoting 
patient activation 
in the decision-
making process. 
Further research 
can be done to 
define and 
measures shared 
decision making 
and usefulness of 
aids.   
According to the 
2010 Cochrane 
Screening for 
prostate cancer 
(Review)  
crossover and 
contamination 
were issues; 
From a total of 
31,133 men 
randomized to the 
screening group 
only 
7348(23.6%) 
were actually 
screened and of 
the 15,353 
randomized to the 
control group, 
1122(7.3%) were 
screened for 
prostate cancer.    
The USPSTF 
recommendation 
for prostate 
cancer screening 
has consistently 
been a grade I; 
The evidence is 
insufficient to 
recommend for or 
against routinely 
providing (the 
service). 
Evidence that 
(the service) is 
effective is 
lacking, of poor 
quality, or 
conflicting, and 
the balance of 
benefits and 
harms cannot be 
determined.   It is 
fascinating that 
wide-spread 
testing for PSA 
among 
asymptomatic 
men continues 
when the 
USPSTF has 
consistently given 
prostate cancer 
screening, the 
service, such a 
low 
recommendation.    
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  Article 7 Article 23 Article 13 Article 29 
Article Title 
and Journal 
Prostate-specific 
antigen: friend or foe. 
Urologic Nursing 
Randomized 
trial examining 
the effect of 
two prostate 
cancer 
screening 
educational 
interventions 
on patient 
knowledge, 
preferences, 
and behaviors. 
Journal of 
General 
Internal 
Medicine. 
Cancer part 1: 
Prevention and 
screening Cancer 
screening 2009: 
Setting evidence-
based priorities. 
Audio-Digest 
Internal 
Medicine   
Editorial: 
Health care 
reform: 
Weighing the 
benefits and 
downsides of 
prostate-
specific antigen 
screening. Arch 
Intern Med  
Author  / 
Year 
Linn, M., Ball, R., 
Maradigiegue,A.(2007)
. 
Partin, M., 
Nelson, D., 
Radosevich, D., 
Nugent, S., 
Flood, A., 
Dillon, N., 
Holtzman, J., 
Haas, M., Wilt, 
T.(2004).    
Perez-Stable. 
(2009) 
Pignone,M. 
(2009)  
Database 
and 
Keywords 
Database: CINHL with 
Full Text 
 
Author’s database 
includes systematic 
review of 52 references 
from 1991-2007 using 
Evidence-Based 
Medicine Reviews, 
Medline, and CINAHL.  
 
Author’s keywords are 
prostate-specific 
antigen, PSA, prostate 
cancer, prostatectomy, 
prostatic hyperplasia, 
prostate cancer 
screening, and prostate 
cancer costs. 
Database: 
CINHL with 
Full Text 
 
Author’s 
keywords are 
prostate 
neoplasm; 
prostate-
specific 
antigen; mass 
screening; 
decision-
making; patient 
education.  
From the 37th 
Annual 
Advances in 
Internal 
Medicine, 
presented by the 
University of 
California, San 
Francisco, and 
School of 
Medicine. No 
mention of key 
words.  
Database: 
Google Scholar   
 
Keywords to 
find article PSA 
screening  
 
 
 
Article includes 
17 references s  
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Research 
Design 
A review of the 
medical evidence and 
controversy related to 
PSA screening. A 
search of Evidence 
Based Medicine 
Reviews, Medline, and 
CINHL along with 
government statistics 
and research material is 
the methodology 
employed.  Included 
are CEU, exam 
questions, review, 
tables/charts  
Randomized 
controlled trial.  
Lecture  Editorial  
Level of 
Evidence 
Level 4: Case study Level 2: 
Evidence from 
one or more 
RCTs   
Level 7: 
Opinions of 
authorities/ 
experts 
Level 7: 
Opinion of 
expert/authority  
Study Aim / 
Purpose 
The purpose of this 
article is to review the 
medical evidence and 
controversy 
surrounding PSA 
screening  
To assess the 
effect of video 
and pamphlet 
interventions 
on patient 
prostate cancer 
screening 
knowledge, 
decision-
making 
participation, 
preferences, 
and behaviors.  
Setting evidence-
based priorities 
for cancer 
screening in 
2009. 
To weigh the 
benefits and 
downsides of 
prostate-
specific antigen 
screening  
Population 
Studied / 
Sample Size 
/ Criteria / 
Power 
This is a review article 
and did not study a 
population  
One thousand, 
one hundred 
fifty-two male 
veterans age 50 
and older with 
primary care 
appointments at 
participating 
facilities were 
randomized and 
893 completed 
follow-up.  
Setting four 
Midwestern 
Veterans 
Examined 
criteria for 
cancer screening 
including 
evidence based 
recommendation
s for colon, 
breast, lung, and 
prostate cancer 
screening.   
This is an 
editorial but a 
table was 
presented with 
outcomes for 2 
cohorts of 1000 
men aged 60 
years and at 
average risk to 
demonstrate the 
balance of 
benefit versus 
harm of PSA 
screening.   
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Affairs medical 
facilities.  
Methods / 
Study 
Appraisal / 
Synthesis 
Methods 
In addition to 
reviewing relevant 
literature this article is 
a comprehensive 
review of PSA 
screening history and 
background to include: 
PSA history; Screening 
recommendations; 
Epidemiology;PSA 
screening movements 
Cochrane Review 
screening 
Controversies;  
Financial 
considerations; and 
Case study of medico-
legal considerations. 
Interventions: 
Patients were 
randomized to 
mailed 
pamphlet, 
mailed video or 
usual 
care/control.  
Outcomes 
assessed by 
phone survey 2 
weeks 
postinterventio
n included a 
10-iten 
knowledge 
index; correct 
responses to 
question on 
prostate cancer 
natural history, 
treatment 
efficacy, the 
PSA's 
predictive 
value, and 
expert 
disagreement 
about the PSA; 
whether  
screening was 
discussed with 
provider; 
screening 
preference; and 
PSA testing 
rates.   
Lecture  Editorial.  
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Primary 
Outcome 
Measures 
and Results 
This is a review article 
and did not have 
primary outcome 
measures and results.  
Mean 
knowledge 
index scores 
were higher for 
video and 
pamphlet, 
subjects versus 
controls. Video 
and pamphlet 
subjects 
reported 
significantly 
higher 
percentages of 
correct 
responses 
relative to 
controls to 
questions on 
prostate cancer 
natural history, 
treatment 
efficacy, and 
expert 
disagreement, 
but not PSA 
accuracy. 
Pamphlet 
subjects were 
more likely that 
controls to 
discuss 
screening with 
their provider 
but video 
subjects were 
not. Video and 
pamphlet 
subjects were 
less likely to 
intend to have a 
PSA, relative to 
controls.  PSA 
testing rates did 
not differ 
significantly 
across groups.    
Approximately 
80% of men 
between 50 and 
80 year of age 
have had PSA 
test. 
Approximately 
15% lifetime 
risk; 
approximately 
30% of men have 
prostate cancer at 
autopsy. Studies 
show similar 
survival 
associated with 
watchful waiting 
and active 
therapy.    
Table of 1000 
cohorts 
compared  
diagnosed as 
having prostate 
cancer:  
screening (53) 
versus (23) not 
screened;  
biopsies 
required ( 39) 
versus (23) ; 
adverse effects 
( impotence, 
incontinence or 
both) (26)  
versus (12)  ; 
prostate cancer 
deaths (3 
)versus (4); 
other deaths( 
113) versus( 
113) .   
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Author 
Conclusions
/ 
Implications 
of Key 
Findings 
Although PSA testing 
has become a primary 
screening method for 
prostate cancer in the 
US, this test has come 
under scrutiny. PSA 
screening lacks a high 
level of specificity due 
to frequent false-
positive results. 
Additionally, major 
health organizations 
differ in their screening 
recommendations for 
use of the PSA test. 
The medical 
community and 
patients must 
understand the benefits 
and possible detriments 
of this screening test. 
Providers should 
approach each man 
individually when 
recommending a PSA 
test, noting that many 
risk factors must be 
considered in a 
screening protocol for 
prostate cancer. 
Mailed 
interventions 
enhance patient 
knowledge and 
self-reported 
participation in 
decision 
making, and 
alter screening 
preferences. 
The pamphlet 
and video 
interventions 
evaluated are 
comparable in 
effectiveness. 
The lower-cost 
pamphlet 
approach is an 
attractive 
option for 
clinics with 
limited 
resources.  
Public opinion 
about screening 
is that finding 
cancer early 
usually or always 
saves lives; 56% 
of those 
surveyed want 
screening, even 
for clinically 
irrelevant 
cancers.  
The decisions 
about whether 
to be screened 
for men aged 
50 to 75 years 
hinges on 
whether the 
known 
downsides of 
overdiagnosis 
and treatment- 
related adverse 
effects are 
counterbalance
d by a 
sufficiently 
large chance 
that screening 
will result in a 
reduction in the 
risk of death 
from prostate 
cancer. Two 
recently 
reported 
randomized 
trials conclude 
that, at best, 
prostate cancer 
screening leads 
to a modest 
absolute 
reduction in 
prostate cancer 
mortality 
overtime.  
However, this 
benefit comes 
at a large cost 
in terms of 
increasing the 
diagnosis and 
treatment of 
cancers that 
would not have 
gone on to 
cause any 
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problems.  
Moreover, the 
harms of 
screening begin 
to accrue 
immediately, 
whereas the 
potential 
benefits are 
realized only 
many years 
later.  
Strengths/ 
Limitations 
This systematic review 
of 52 references from 
1991-2007 is 
comprehensive, reliable 
and objective.  
Strengths 
include 
providers 
blinded to the 
fact that their 
patients were 
participating in 
a trial.  Follow-
up interviewers 
were blinded 
from 
intervention 
assignment, but 
the statisticians 
conducting the 
analysis were 
not. All authors 
were involved 
in the 
development of 
the pamphlet 
but none were 
Interesting 
informative 
nonbiased 
lecture.  
Strength is a 
succinct 
summary of 
harms and 
benefits with an 
illustrative table 
of cohort of 
1000 men.  
Limitation is  
level 7  
evidence.   
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involved in the 
development of 
the video.  
Limititations 
include the 
generalizability 
to the 
population 
since this 
involved VA 
patients who 
are usually low 
income and/or 
service 
connected.    
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12 months that 
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Comments 
This systematic review 
of 52 referenced from 
1991-2007 is 
comprehensive, reliable 
and objective. 
Informative article that 
traces the origins of the 
PSA and lists the 
inconsistent 
recommendations for 
prostate cancer 
screening among nine 
major health care 
organizations.  
This study hit 
close to home 
because it took 
place at four 
Midwestern 
Veterans 
Affairs medical 
facilities.   A 
low-cost 
pamphlet is an 
attractive 
option because 
it is easy to 
implement.  
 This informative 
lecture about 
setting evidence-
based priorities 
is in line with 
promoting 
evidence based 
practice.    
Excellent 
editorial which 
simplifies the 
issue.  
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  Article 3 Article 1 Article 25 Article 28 
Article Title 
and Journal 
Clinical 
consequences of 
screening for 
prostate cancer: 
15 years follow-
up of a 
randomized 
controlled trial in 
Sweden 
European 
Urology  
Screening and 
Prostate-Cancer 
Mortality in a 
Randomized 
European Study 
The  New 
England Journal 
of Medicine  
Enthusiasm for 
cancer screening 
in the United 
States. JAMA.  
Risk profiles and 
treatment patterns 
among men 
diagnosed as 
having prostate 
cancer and a 
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below 4.0 ng/ml. 
Arch Intern 
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Article includes 
17 references and 
two editorial 
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includes 31 
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The article 
includes 26 
references.  
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Research 
Design 
From the total 
population of 
men aged 50-69 
years in 
Norrkoping 
(n=9026) every 
sixth man 
(n=1494) was 
randomly 
selected to be 
screened for 
prostate cancer 
every third year 
over a 12-year 
period. The 
remaining 7532 
men were treated 
as controls .In 
1987 and 1990 
only DRE was 
performed, in 
1993 and 1996 
DRE was 
combined with a 
test for PSA.  
Randomized 
,multicenter trial 
of screening for 
prostate cancer, 
with the rate for 
death from 
prostate cancer as 
the primary 
outcome  
Survey using a 
national 
telephone 
interview of 
adults selected by 
random digit 
dialing, 
conducted from 
December 2001 
through July 
2002.   
Data from the 
Surveillance, 
Epidemiology, 
and End Results 
system were used 
to describe 
patient 
characteristics 
and treatment 
patterns in men 
with newly 
diagnosed 
prostate cancer.  
Level of 
Evidence 
Level 2: RCTs Level 2 : 
randomized 
controlled 
trials(RCTs)   
Level 6: Single 
descriptive or 
qualitative study. 
Level 6: Single 
descriptive or 
qualitative study.   
Study Aim / 
Purpose 
To characterize 
prostate cancers 
detected in a 
population-based 
screening 
programme and 
to evaluate the 
effectiveness of 
screening with 
three-year 
intervals.  
The European 
Randomized 
Study of 
Screening for 
Prostate Cancer 
was initiated in 
the early 1990s to 
evaluate the 
effect of 
screening with 
prostate-specific-
antigen (PSA) 
testing on death 
rates from 
prostate cancer.  
To determine the 
public's 
enthusiasm for 
early cancer 
detection.  
To determine the 
risk profile and 
treatment patterns 
among men 
diagnosed as 
having prostate 
cancer and a 
prostate-specific 
antigen level 
below 4.0 ng/ml.  
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Population 
Studied / 
Sample Size 
/ Criteria / 
Power 
Participants were 
Norrkoping males 
aged 50-69 years 
of age. The 
screened cohort 
diminished from 
1492 men at the 
start of the study 
to 1118 in 1996 
due to migration 
and death.  Data 
on survival was 
complete for the 
whole cohort 
including those 
who migrated.  
A total of 
162,387 men in 
the core age 
group underwent 
randomization; of 
these men 72,952 
were assigned to 
the screening 
group and 89,435 
to the control 
group. A total of 
62 men in the 
screening group 
and 82 men in the 
control group 
died between 
identification and 
randomization.  
Five hundred 
individuals 
participated 
(woman aged >/= 
40 years and men 
aged >/= 50 
years; without a 
history of 
cancer). 
123934 men 
identified from 
the SEERS 
system with 
newly diagnosed 
prostate cancer 
from 2004 to 
2006.  
Methods / 
Study 
Appraisal / 
Synthesis 
Methods 
Compared mass 
screening for 
prostate cancer to 
no screening; 
RCT in 
Norrkoping, 
Sweden. 
Interventions 
were screening 
every 3 years 
versus control 
(not invited for 
screening). The 
1st and 2nd 
rounds of 
screening were 
DRE; the 3rd and 
4th rounds were 
DRE and PSA 
test. 
Transurethral 
ultrasound biopsy 
was performed if 
DRE abnormal or 
PSA > 4.0ng/ml.   
Compared mass 
screening for 
prostate cancer to 
no screening: The 
researchers 
identified 
182,000 men 
between the ages 
of 50 and 74 
years through 
registries in seven 
European 
countries for 
inclusion in the 
study. The men 
were randomly 
assigned to a 
group that offered 
PSA screening at 
an average of 
once every 4 
years or to a 
control group that 
did not receive 
the screening.   
Responses to a 
survey with 5 
modules: a 
general screening 
module (e.g., 
value of early 
detection, total -
body computed 
tomography); and 
4 screening test 
modules: 
Papanicolaou 
test; 
mammography; 
PSA test; and 
sigmoidoscopy or 
colonoscopy.  
Age-standardized 
treatment rates 
were calculated 
in 5-year age 
strata. Logistic 
regression was 
used to quantify 
the odds ratio of 
men with low- 
and high- risk 
disease and the 
use of radical 
prostatectomy or 
radiation therapy.   
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Primary 
Outcome 
Measures 
and Results 
Primary outcome 
was prostate 
cancer mortality 
at 15 years 
follow-up. Also 
reported was 
clinical stage and 
choice of therapy 
in men diagnosed 
with prostate 
cancer across 
both screened and 
control groups, 
and number of 
prostate cancers 
diagnosed. There 
was no 
significant 
difference in total 
or prostate 
cancer-specific 
survival between 
the groups. 
Primary outcome 
was prostate 
cancer mortality 
and number of 
prostate cancers 
diagnosed. Rate 
ratio for death 
from prostate 
cancer in the 
screening group, 
compared with 
the control 0.80.  
The absolute risk 
difference 0.71 
death per 1000 
men.  1410 men 
would need to be 
screened, 48 
additional cases 
of prostate cancer 
need to be treated 
to prevent one 
death from 
prostate cancer.   
Most adults 
(87%) believe 
routine cancer 
screening is 
almost always a 
good idea and 
that finding 
cancer early 
saves lives(74% 
said most or all 
the time). Less 
than one third 
believe that there 
will be a time 
when they will 
stop undergoing 
routine screening. 
Thirty-eight 
percent of 
respondents had 
experienced at 
least 1 false-
positive screening 
test; more than 
40% 
characterized that 
experience as 
"very scary" or 
the "scariest time 
of my life".  Yet, 
looking back, 
98% were glad 
they had the 
initial screening 
test. Most had a 
strong desire to 
know about the 
presence of 
cancer regardless 
of its 
implications: and 
56% said they 
would want to be 
tested for 
pseudodiseases. 
Seventy-three 
percent would 
Men with a PSA 
level of 4.0 ng/ml 
or lower 
represent 14% of 
incident prostate 
cancer cases. 
Fifty-four percent 
of men diagnosed 
as having prostate 
cancer and PSA 
levels lower than 
4.0 ng/ml harbor 
low-risk disease, 
but over 75% of 
them received 
radical 
prostatectomy or 
radiation therapy.  
Men with screen-
detected prostate 
cancer and PSA 
values lower than 
4 ng/ml were 
1.49 and 1.39 
times more likely 
to receive RP and 
RT, respectively, 
and were less 
likely to have 
high-grade 
disease than men 
who had non-
screen-detected 
prostate cancer. 
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prefer to receive a 
total-body cat 
scan instead of 
$1000 in cash.        
Author 
Conclusions
/ 
Implications 
of Key 
Findings 
Although PSA 
had not been 
introduced in the 
clinical practice 
at the start of the 
study, still able to 
show that 
possible to 
perform a long-
term population-
based randomized 
controlled study 
with standardized 
management and 
that screening in 
general practice 
is an efficient 
way of detecting 
localized prostate 
cancer. 
PSA-based 
screening reduced 
the rate of death 
from prostate 
cancer by 20% 
but was 
associated with a 
high risk of 
overdiagnosis.   
The public is 
enthusiastic about 
cancer screening.  
This commitment 
is not dampened 
by false-positive 
test results or the 
possibility that 
testing could lead 
to unnecessary 
treatment. This 
enthusiasm 
creates an 
environment ripe 
for the premature 
diffusion of 
technologies such 
as total-body 
CAT scans, 
placing the public 
at risk of over 
testing and 
Most men 
diagnosed as 
having prostate 
cancer with a 
PSA threshold 
below 4.0ng/ml 
had low-risk 
disease but 
underwent 
aggressive local 
therapy. 
Lowering the 
biopsy threshold 
but retaining our 
inability to 
distinguish 
indolent from 
aggressive 
cancers might 
increase the risk 
of overdiagnosis 
and 
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overtreatment.   overtreatment.   
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Strengths/ 
Limitations 
According to 
the 2010 
Cochrane 
Screening for 
prostate cancer 
(Review) there 
was no 
adequate 
sequence 
generation; no 
allocation 
concealment; 
not  blinded to 
the screening 
intervention; 
unclear 
incomplete 
outcome data 
addressed; 
unclear if  free 
of selective 
reporting      
According to the 
2010 Cochrane 
Screening for 
prostate cancer 
(Review) there 
was adequate 
sequence 
generation; 
allocation 
concealment 
unclear; 
intervention not 
blinded but 
causes of death 
evaluated in a 
blinded manner; 
incomplete 
outcome data was 
addressed; it was 
free of selective 
reporting but 
unclear if the 
study was free of 
other bias. 
Potential 
limitations: 5% 
of adults living 
in households 
without phones 
were not 
represented. 
Although 
response rate 
was good, 72% 
among 
individuals 
known to be 
eligible and 
51% among 
those estimated 
to be eligible, 
systematic bias 
between 
respondents 
and 
nonrespondents 
is still possible.  
Findings about 
false-positive 
PSA tests 
results are 
based on only 
10 men and 
should be 
interpreted 
cautiously.    
The analysis 
was limited by 
the nature of 
the data source. 
The SEER 
system collects 
information 
from all 
patients in 16 
registries. The 
Gleason scores 
and PSA values 
recorded by the 
SEER system 
reflect the 
information 
that was used 
to make 
clinical 
decisions. The 
SEER system 
does not record 
information 
such as 
percentage of 
free PSA or the 
number of 
positive scores 
found on 
biopsy 
analysis. The 
major strength 
is the large 
sample size 
that is 
population 
based and 
includes 
patients from 
defined 
geographic 
areas in all 
clinical settings 
rather than 
selected 
institutes.     
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Comments 
Excellent large 
randomized 
control study 
with complete 
follow up data 
at 15 years but 
high risk of 
bias.  This 
study shows it 
is possible to 
perform a 
randomized 
controlled study 
of prostate 
cancer 
screening, with 
a registration 
allowing for 
unbiased 
comparisons 
between the 
screened group 
and control 
group. This is 
the first 
published 
population-
based 
randomized 
controlled trial 
on prostate 
cancer 
screening with 
complete data 
on tumor stage, 
tumor grade 
and treatment 
for the control 
group as well as 
the intervention 
group. 
Excellent large 
randomized 
control study 
with low risk of 
bias.  To prevent 
1 death from 
prostate cancer 
1410 men would 
need to be 
screened and 48 
additional cases 
of prostate cancer 
would need to be 
treated; that 
seems like a high 
price to pay.      
The public’s 
enthusiasm 
about cancer 
screening is 
short sighted 
and is driven in 
part by a 
paternalistic 
health care 
system.   
Medicine and 
health care 
needs to get out 
of the business 
of prediction, 
including 
tampering with 
Mother Nature, 
and back into 
the business of 
healing.  The 
increased breast 
cancer 
incidence 
observed in 
many Western 
countries in the 
late 1980s and 
1990s was due 
in part to use of 
postmenopausal 
hormone 
therapy. Oral 
contraceptive 
use is 
associated with 
increased breast 
cancer 
incidence. 
Prostate cancer 
is a hormone 
driven disease, 
yet some men 
are treated with 
testosterone. 
The 
counterintuitive 
By doing 
biopsies on 
patients with 
PSA values in 
the "normal" 
range the 
sensitivity and 
specificity of 
the PSA test 
can be 
determined.  
Usually 
patients with 
low PSA levels 
are not brought 
back for 
sequential 
and/or 
simultaneous 
testing because 
prostate 
biopsies and 
transrectal 
ultrasounds are 
no fun, 
expensive, and 
invasive.  Data 
will now be 
available in 4 
cells which is 
precisely what 
is needed to 
determine the 
validity of the 
PSA test.   
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practice of 
treating normal 
physiologic 
states, such as 
fertility, painful 
periods, 
menopause, and 
andropause 
with hormones 
know to cause 
cancer is what 
the public 
should be 
enthusiastic 
about stopping.   
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Author’s database 
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United States.  
 
The article 
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references.  
Database 
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Author’s database 
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and Surveillance, 
Epidemiology, 
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(SEER) national 
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Keywords 
include prostate 
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screening, 
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mortality, and 
prostate specific 
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The article 
includes 50 
references  
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The article 
includes 2 
references.  
Database 
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includes prostate 
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Key words 
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references 
 
 
Research 
Design 
The Prostate 
Cancer Outcomes 
Study, a 
population-based 
longitudinal 
cohort study with 
up to 24 months 
of follow up.   
Tracked age-
adjusted prostate 
carcinoma 
incidence trends 
from the 
population-based 
Utah Cancer 
Registry and 
compared them 
with rates from 
the Surveillance, 
Epidemiology, 
and End Results 
(SEER) Program.  
The journal 
article is a letter 
by Dr. Suss, a 
Canadian Family 
Practice Doctor 
and Assistant 
Professor in the 
Department of 
Family Medicine 
at the University 
of Manitoba in 
Winnipeg 
Research design: 
Conceptualized 
observed 
incidence as the 
sum of the 
secular trend in 
incidence, which 
reflects incidence 
in the absence of 
PSA, and the 
excess incidence 
over and above 
the secular trend, 
which is a 
function of 
population 
screening patterns 
and unknown 
lead time.     
Level of 
Evidence 
Level 4: Cohort 
study. 
Level  6:Single 
descriptive study  
Level 7:  
Opinions of 
authorities/ 
experts 
Level 6: Single 
descriptive or 
qualitative study  
Study Aim / 
Purpose 
To measure 
changes in 
urinary and 
sexual function in 
men who have 
undergone radical 
prostatectomy for 
clinically 
localized prostate 
cancer.  
The Utah Cancer 
Registry data 
were examined 
for a decrease in 
prostate cancer 
incidence.  
The author 
questions whether 
it is right to ask 
patients to decide 
if they want to be 
screened for 
prostate cancer. 
The primary goal 
is to estimate the 
lead time 
distribution 
associated with 
PSA screening 
utilizing 
population 
screening and 
disease incidence 
trends to make 
inferences.   
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Population 
Studied / 
Sample Size 
/ Criteria / 
Power 
A total of 1291 
black, white, and 
Hispanic men 
aged 39 to 79 
years diagnosed 
as having primary 
prostate cancer 
between October 
1, 1994, and 
October 31, 1995, 
and who 
underwent radical 
prostatectomy 
within six months 
of diagnosis for 
clinically 
localized disease.   
 Conservatively 
estimated Utah 
prostate 
carcinoma 
incidence for 
1994. The state of 
Utah had a 
current 
population of 
1,907,936 with 
167,840 men 
older than age 50 
years.  
Not applicable  Not applicable  
Methods / 
Study 
Appraisal / 
Synthesis 
Methods 
Men diagnosed as 
having primary 
prostate cancer 
between 
10/1/1994 and 
10/31/1994 who 
were residents of 
areas covered by 
6 population 
based SEERs 
registries. A total 
of 11137 eligible 
cases were 
identified, and 
5672 were 
randomly 
sampled for 
PCOS. Of the 
sampled cases, 
4736(83.5%) 
were contacted 
and invited to 
participate, and 
3533(62.3%) 
completed a 6-
and/or 12-month 
survey.   Medical 
record abstracts 
were completed 
for 3486 (98.7%) 
Rapid case 
ascertainment 
methods used to 
estimate Utah 
prostate 
carcinoma 
incidence for 
1994.  
Reflection  The present 
analysis includes 
men aged 50-64, 
whereas the 
previous study 
considered only 
men aged 65 and 
above.  After 
conceptualizing 
observed 
incidences two 
likelihood models 
were developed: 
likelihood model 
for  the excess 
incidence given 
the secular trend 
and used it to 
estimate the mean 
lead time under 
specified 
distributional 
assumptions and 
a likelihood 
model for 
observed 
incidence and use 
it to 
simultaneously 
estimate the mean 
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of the sampled, 
participating 
cases.  For 
analysis of 
surgery, all PCOS 
patients aged 39 
to 79 years with 
histologically 
confirmed,  
clinically 
localized prostate 
cancer who 
underwent radical 
prostatectomy as 
primary treatment 
within 6 months 
of diagnosis date 
and who had both 
survey and 
medical records 
data(n=1301).  
lead time together 
with a smooth 
secular trend. 
Variances and 
confidence 
intervals are 
estimated using 
via a parametric 
bootstrap.     
Primary 
Outcome 
Measures 
and Results 
Primary outcome 
measures are 
distribution of 
and change in 
urinary and 
sexual function 
measures 
reported by 
patients at 
baseline and 6, 
12, and 24 
months after 
diagnosis.  At 18 
or more months 
following radical 
prostatectomy, 
84.4 % of men 
were incontinent 
and 59.9% were 
A rapid and 
highly correlated 
rise in prostate 
carcinoma 
incidence has 
been observed in 
both SEER and 
Utah incidence 
rates between 
1988 and 1991, 
the last year for 
which SEER data 
are available. In 
1992, Utah 
incidence rates 
peaked at 236.2 
per 100,000.  In 
1993 and 1994, 
Utah incidence 
Dr. Suss uses the 
analogy of his car 
mechanic asking 
him what type of 
fuel filter he 
wants. He knows 
nothing about 
fuel filters (the 
means), he knows 
he wants his car 
to run well at a 
reasonable price 
(the end). A 
healthy 50-year-
old male wants to 
live as long as 
possible without 
incontinence and 
impotence (the 
Outcome 
measures and 
results: Estimates 
correspond to 
overdiagnosis and 
frequencies of 
approximately 
22.7% and 34.4% 
for screen-
detected whites 
and blacks, 
respectively.   
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impotent.    rates fell to 195.0, 
and an estimated 
164.0 per 
100,000 
respectively.  
end) so why ask 
him whether he 
wants a PSA 
screening test. 
Author 
Conclusions
/ 
Implications 
of Key 
Findings 
Study suggests 
that radical 
prostatectomy is 
associated with 
significant 
erectile 
dysfunction and 
some decline in 
urinary function. 
These results may 
be particularly 
helpful to 
physicians and 
their patients with 
prostate cancer 
who face difficult 
treatment 
decisions. 
Population-based 
data from the 
Utah Cancer 
Registry indicates 
the incidence of 
prostate 
carcinoma is 
decreasing 
rapidly after a 
similarly rapid 
increase.  
Documented 
increases in 
incidence for 
years prior to 
1992, as well as 
projections for 
1992 through 
1995, raised 
concerns 
including 
economic impact, 
rising rate of 
treatment without 
documented 
therapeutic 
efficacy, 
treatment related 
morbidity, and 
screening leading 
to identification 
and treatment of 
clinically or 
biologically 
The author 
contends we 
should leave the 
means to the 
experts, such as 
car mechanics 
and doctors, and 
the ends with 
individuals who 
are experts at 
what they want. It 
is difficult to do 
this though when 
the American 
Cancer Society 
recommends 
discussing the 
pros and cons 
with patients so 
they can make an 
informed decision 
about having a 
PSA screening 
test (means). 
Likelihood-based 
approach allows 
authors to make 
formal inferences 
about the lead 
time and 
overdiagnosis 
associated with 
PSA screening in 
the United States. 
The model 
provided the first 
glimpse of a 
secular trend in 
disease incidence 
and finally the 
authors provided 
some provocative 
insights about 
racial disparities 
in prostate 
cancer.   
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unimportant 
cancers.   
Strengths/ 
Limitations 
This study 
provided the first 
description of 
outcomes 
experienced by a 
cohort of 
unselected, 
population-based 
patients who have 
undergone radical 
prostatectomy. In 
addition to its 
population based 
design, strength 
of the study is the 
large number of 
patients.  
Limitations 
include only 
62.3% sampled 
men participating 
and a 24-month 
survey was not 
completed by 
19.2% of those 
who had 
completed an 
earlier survey. 
Recall bias is 
Quantitative data 
comparing 
prostate cancer 
rates from two 
reputable sources 
showing that the 
increase in 
prostate 
carcinoma 
incidence 
between 1984 -
1991 was largely 
attributed to the 
increased use of 
PSA in prostate 
carcinoma 
detection and 
screening 
including media 
coverage.   
The author 
concludes that it 
is unreasonable to 
have patients 
make choices 
about means 
when thousands 
of doctor’s can’t 
agree if PSA 
screening results 
in any benefit.  
Strengths and 
limitations: This 
article presented 
a novel method 
for making 
formal inferences 
about lead time 
and overdiagnosis 
from population 
incidence trends 
in the context of 
PSA screening. 
The model 
approach is based 
on the additive 
relationship 
between the 
excess incidence, 
which depends on 
the lead time, and 
the secular 
incidence trend; 
this provides a 
formal method 
for inferring a 
plausible secular 
trend. The 
limitations to the 
analysis are 
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another potential 
limitation since 
baseline 
(prediagnosis) 
function was 
assessed on the 6-
month survey.        
uncertainty about 
the PSA 
screening 
frequencies and 
cancer detection 
rates thus the 
confidence 
intervals are 
narrow.  A 
second limitation 
is the use of a 
specified 
parametric 
distribution for 
the lead time.      
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Comments 
Informative 
population-based 
longitudinal study 
with up to 24 
months of follow-
up.  
A screening 
phenomenon 
called a "cull 
effect” explains 
the shortcomings 
in prostate cancer 
incidence 
predictions 
starting in 1992. 
When a testing 
method is applied 
to a relatively 
static population 
of prevalent 
disease, an initial 
rapid rise in 
detection and 
hence incidence 
will be observed. 
As the cull effect 
removes 
individuals with 
prostate cancer 
from the 
population, the 
population 
becomes 
progressively 
depleted of 
detectable cases.    
This journal 
reflection is very 
insightful and a 
delight to read.  
Technical article 
with multiple 
graphs of 
incidence trends 
and statistical 
formulas through-
out.  
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  Article 21 Article 30 
Article Title 
and Journal 
Trials of decision aids for prostate 
cancer screening: A systematic 
review. American Journal of 
Preventative Medicine.  
Editorial: Health care reform: Shared 
decision making for prostate cancer 
screening: Do patients of clinicians 
have a choice?  Arch Intern Med   
Author  / 
Year 
Volk, R., Hawley, S, Kneuper, S., 
Holden, W., Stroud, L., Cooper, C., 
…Pavlik, V. (2007) 
Woolf, S., Krist, A. (2009).   
Database 
and 
Keywords 
Medline was searched with key words 
"prostate cancer screening" and 
"decision making" for articles 
published through 2006. A 2003 
Cochrane review, a 2002 evidence 
report by the Agency for Healthcare 
Research and Quality, and a review 
by Evans et al. were examined to 
identify studies on prostate cancer 
screening decision making. Reference 
lists from relevant articles were also 
reviewed. Finally, published abstracts 
and subsequent full papers from 
annual meetings of the Society for 
Medical Decision Making, the 
American Society of Preventive 
Oncology, and the Society of 
Behavioral Medicine were examined.      
 
 
 
Database searched: CINAHL with 
Full Text.     
 
Keywords: decision making, health 
screening, PSA.  
 
Article has 20 references   
 
Research 
Design 
A systematic review  Editorial  
Level of 
Evidence 
Level 1: Systematic review Level 7 :Opinion of expert/authority  
Study Aim / 
Purpose 
Patient decision aids are used to 
promote informed decision making. 
This review examines the methods 
and findings of studies that have 
evaluated the impact of prostate 
cancer screening decision aids on 
patient outcomes.  
The uncertainty of PSA testing -and 
thus the logic for shared decision 
making (SDM)--persists, but there are 
questions about whether SDM occurs 
in practice, how well it is performed, 
and whether clinicians support SDM 
or find it feasible.  This editorial aims 
to see if patients of clinicians have a 
choice.   
Population 
Studied / 
Sample Size 
/ Criteria / 
Power 
Eighteen eligible trials, involving 
6221 participants, were identified. 
Sixteen studies enrolled primary care 
patients, while the remaining two 
studies were community based.   
This is an editorial. Discussed 
Hoffman et al's telephone survey of 
375 men who had either undergone 
PSA testing or discussed prostate 
cancer screening with a clinician in 
the previous 2 years.  
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Methods / 
Study 
Appraisal / 
Synthesis 
Methods 
MEDLINE, the Cochrane Registry, 
reference lists, and abstracts from 
professional meetings were searched 
through December 2006. Studies were 
included if a patient education 
intervention for prostate cancer 
screening had been evaluated against 
a control condition.  
Editorial  
Primary 
Outcome 
Measures 
and Results 
Summary of outcome findings from 
18 published controlled trials of 
patient decision aids for prostate 
cancer screening are listed on five 
horizontal pages. Knowledge of 
prostate cancer screening was the 
most common outcome, with 14 of 18 
studies including such a measure. 
Intention to be screened was lower 
among decision-aid participants than 
control participants in six of the nine 
studies.  The patient decision aides 
improved patient knowledge and 
made patients more confident about 
their decisions. The aids appeared to 
decrease interest in PSA testing and 
screening behavior among patients 
seeking routine care (relative 
risk=0.88, 95% confidence interval, 
p=0.008); the aides had no impact on 
the screening behavior of patients 
seeking screening services. Patients 
who received patient decision aids 
were more likely to prefer watchful 
waiting as a treatment option  if they 
were found to have prostate cancer 
than were controls(RR=1.53, 95% 
CI=1.31-1.77, p <0.001)    
According to Hoffman's study 70% 
recalled a discussion that preceded the 
testing decision, but only one-third 
remembered discussing any 
counterarguments to screening.    
Author 
Conclusions/ 
Implications 
of Key 
Findings 
Prostate cancer screening decision 
aids enhance patient knowledge, 
decrease decisional conflict, and 
promote greater involvement in 
decision making. The absence of 
outcome measures that reflect all 
elements of informed decision making 
continues to limit the field.  
The larger cultural context helps 
explain the inertia of the health care 
system in implementing SDM. 
Making SDM feasible also requires 
changes in the practice environment, 
beginning with tort reforms that 
protect clinicians who give patients an 
informed choice about cancer 
screening , as well as reimbursement 
reform to facilitate the time 
investment for such counseling.       
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Strengths/ 
Limitations 
This level one study had no apparent 
limitations. The strength relates to its 
in depth review with  18 trials, 
involving 6221 participants, and high 
quaility searches including Cochrane 
reviews.       
Provocative editorial. Limitation is 
Level 7 evidence.  
Funding 
Source 
The project was funded in part by 
grants from the Centers for Disease 
Control and Prevention and the 
Agency for Healthcare Research and 
Quality.  
No financial disclosure  
Comments 
Decision aids help patients take a 
more active role in making a decision 
about prostate cancer screening. There 
needs to be aids for patients with low 
health literacy.  
Points out the problems implementing 
shared decision making.  
 
Systematic Review Evidence Table Format (adapted with permission from Thompson, C. 
(2011).  In J. Houser & K.S. Oman (Eds.), Evidence-based practice: An implementation guide 
for healthcare organizations (p.155). Sudbury, MA: Jones and Bartlett.  
 
Reference:  
Tymkow, C. (2011). Clinical scholarship and evidence-based practice.  In M.E. Zaccagnini & 
 K. W. White, K. W (2011). The doctor of nursing practice essentials: A new model for 
 advanced practice nursing (pp. 61-136).  Sudbury, MA: Jones and Bartlett. 
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Appendix B 
 Basic Prostate Cancer Screening Educational Pamphlet 
Let’s see what you know:   
1) Can the PSA test help find prostate cancer early at a stage when potentially curative 
treatments can be offered?  
     Check Only One: Yes  No  
2) Does prostate cancer usually lead to death? 
      Check Only One: Yes   No  
3) Does all prostate cancer cause harm?  
     Check Only One Yes  No  
4) Is the prostate-specific antigen (PSA) blood test a good cancer screening test?   
    Check Only One: Yes No  
5) What are the major side effects of prostate cancer treatments?  
   Check Only One: None Impotence and Incontinence  Bowel Problems    Nausea 
 
 Screening for prostate cancer with a Prostate Specific Antigen (PSA) blood test starting  
at age 50, and age 45 for high risk men, means looking for cancer before it causes symptoms. 
Men with serious health problems, or age 75 or older, should not be offered screening.  Prostate 
cancer screening can find cancers early when a cure may be possible but it often finds cancer 
which would never have caused problems.   It is very important to know about the risks and 
benefits of screening before the decision to be screened or not is made.   
 The prostate gland is approximately the size of a walnut.  It is located in front of the 
rectum, directly below the bladder, encircling the urethra, the tube which empties urine from the 
bladder (figure 1).  The back of the prostate gland can be felt during a digital rectal exam (figure 
2).  The prostate gland helps control urine flow and normal sexual function. Prostate cancer 
treatment can lead to urinary incontinence and impotence, the inability to have sex.    
 Prostate cancer is the second leading cause of cancer death in U.S. males next to lung 
cancer.  For an American male, the lifetime risk of developing prostate cancer is 16 men out of 
100, but the risk of dying of prostate cancer is only 3 men out of 100.  
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(http://seer.cancer.gov/csr/1975_2004).   Black men, and men with a first degree relative 
diagnosed with prostate cancer before age 65, are at increased risk.    
The key points therefore to be aware of prior to undertaking a PSA test are the following: 
• The PSA test facilitates the early detection of prostate cancer at a stage when potentially 
curative treatments can be offered.  
• There is currently no strong evidence that PSA testing reduces death from prostate 
cancer.  
• Not all men with raised PSA will have prostate cancer/the PSA test will not detect all 
prostate cancer.  
• Prostate cancer is diagnosed through a prostate biopsy which can be uncomfortable or 
painful.  
• Prostate biopsies will not detect all prostate cancers.  
• Prostate cancers range from aggressive to slow growing forms-slow growing tumors may 
not result in symptoms or shorten life expectancy.   
• There is no evidence about the optimum treatment for localized prostate cancer.  
• Some treatments for prostate cancer can have significant side effects. 
   (Clements et al. BMC Family Practice 2007 8:35 doi: 10.1186/147-2296-8-35) 
 
Ask yourself about how you feel about the possible benefits and harms of being screened:  
• Do I want to know if I have prostate cancer, even if the cancer might never do me any 
harm? 
• Would I be treated if I learned that I had prostate cancer?  
• How do I feel about the risks of being treated for prostate cancer? 
• How do I feel about the risks of getting a deadly or aggressive form of prostate cancer?  
• Would I be willing to accept a high risk of side effects from treatment in return for a 
small chance of living longer? 
 (Patient information: Prostate cancer screening (PSA tests) (The Basics) 2011 UpToDate, 
www.uptodate.com) 
 
Let’s see what you now know: 
1) Can the PSA test help find prostate cancer early at a stage when potentially curative 
treatments can be offered?  
     Check Only One: Yes  No  
2) Does prostate cancer usually lead to death? 
 Check Only One Yes No  
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3) Does all prostate cancer cause harm?  
 Check Only One: Yes No  
4) Is the prostate-specific antigen (PSA) blood test a good cancer screening test?   
 Check Only One: Yes No   
5) What are the major side effects of prostate cancer treatments?  
 Check Only One: None Impotence and Incontinence  Bowel Problems    Nausea 
 
 
 
 
 
 
 
 
 
 
 
132 
 
 
 
Prostate gland
 
Figure B - 1: Prostate Gland 
This drawing shows the male anatomy and a close-up of the prostate gland. Reproduced with 
permission from: Patient information: Prostate cancer screening (PSA tests) (The Basics). In: 
UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2011. Copyright © 2011 UpToDate, 
Inc. For more information visit www.uptodate.com. 
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Figure B - 2: Rectal Exam 
During a digital rectal exam, the doctor or nurse puts a finger inside your rectum and feels your 
prostate gland. That way he or she can see how big it is and whether it has bumps or dents or 
anything unusual. Reproduced with permission from: Patient information: Prostate cancer 
screening (PSA tests) (The Basics). In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 
2011. Copyright © 2011 UpToDate, Inc. For more information visit www.uptodate.com. 
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Appendix C  
Detailed Prostate Cancer Screening Educational Pamphlet 
 Screening for prostate cancer with a Prostate Specific Antigen (PSA) blood test starting  
at age 50, and age 45 for high risk men, means looking for cancer before it causes symptoms. 
Prostate cancer screening leads to increased cancer diagnosis, modest mortality reduction 
(death), and substantial morbidity (illness).  It is imperative therefore to be well informed about 
the risks and benefits of screening before the decision to be screened or not is made.   
 The prostate gland is approximately the size of a walnut.  It is located in front of the 
rectum, directly below the bladder, encircling the urethra, the tube which empties urine from the 
bladder (see picture).  The back of the prostate gland can be felt during a digital rectal exam.  
The prostate gland helps regulate bladder control and normal sexual function (erection and 
ejaculation), including storage and production of seminal fluid, a white milky substance which 
nourishes sperm.  
 The prostate gland is prone to problems.  Prostatitis, inflammation of the gland, can cause 
painful urination and ejaculation.   Benign Prostatic Hypertrophy (BPH), a condition common to 
aging men, is caused by the slowly enlarging prostate gland putting pressure on the urethra 
making it difficult to urinate.  And finally, the prostate gland can develop cancer, ranging from a 
silent condition which does not spread and/or cause symptoms, to invasive disease spreading to 
nearby organs and bone, ultimately leading to death.    
 Prostate cancer is the second most frequently diagnosed cancer and the sixth global 
leading cause of cancer death.  Incidence rates vary by more that 25-fold worldwide; the highest 
rates are in developed countries that utilize PSA testing which detects clinically important 
tumors as well as other slow growing cancers that may never have caused problems [1].  In the 
U.S. in the late 1980’s when prostate cancer screening with a PSA blood test came into vogue 
incidence rates rose from 84.4/100,000 cases in 1984 to 163/100,000 cases in 1991 [2].  Since 
the early 1990’s prostate incidence has been declining although it is still the second leading 
cause of cancer death in U.S. males next to lung cancer.  For an American male, the lifetime risk 
of developing prostate cancer is 16 percent, but the risk of dying of prostate cancer is only 2.9 
percent [3].   
 Most prostate cancers detected in the U.S. are asymptomatic, clinically localized, and 
found on routine PSA testing [4]; this correlates with the new cases of prostate cancer at the 
Denver VA. Prostate cancer data for 2008-2010 was obtained from the Eastern Colorado Health 
Care System Tumor Registry. There were 209 cases of prostate cancer diagnosed since 2008 
except for new patients arriving with the diagnosis. At least 75% of the cases were clinically 
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localized. The largest groups of men to receive the diagnosis (76%) were in their fifties and 
sixties.     
 PSA is a glycoprotein found in both normal and cancerous prostate glands.  The absolute 
value of serum PSA is used to determine the extent of prostate cancer and a patient’s response to 
treatment. The use of PSA as a screening test is controversial because its’ ability to identify 
correctly those who have the disease (sensitivity) is overestimated and its’ ability to identify 
correctly those who do not have the disease (specificity) is underestimated [5].  
  Mass population PSA testing was initiated in the late 1980’s without well-conducted 
randomized clinical trials to support the benefit of screening.  In 2009, two ongoing randomized 
trials of PSA screening provided the first quantitative estimates of the survival benefits due to 
early detection. The prostate arm of the National Cancer Institute-sponsored Prostate, Lung, 
Colorectal, and Ovarian Cancer Screening Trial found no survival benefits from annual PSA 
screening combined with digital rectal exam.  A larger similar European trial of men aged 50 to 
74 years found a 20% reduction in prostate cancer mortality following PSA screening every four 
years. This means that 1410 men needed to be screened, and 48 men needed to receive early 
treatment in order to prevent one cancer death at ten years [6].  Both trials found clear evidence 
of overdiagnosis.  
 Diseases diagnosed earlier by screening, versus later when symptoms develop, lead to 
earlier treatments (lead time). Unfortunately patients often die at the same time, thus all lead time 
did was cut off quality years of life. One of the pitfalls of the PSA test is that it markedly 
increases the lead time resulting in overdiagnosis because death from other-causes precedes the 
date of symptomatic disease and/or occurs during the lead time [7]. Therefore the modest 
absolute reduction in prostate cancer over time comes at the cost of treating clinically irrelevant 
cancers.  Additionally, the harms of screening start immediately whereas the potential benefits 
are not realized for years to come [8].  
The key points therefore to be aware of prior to undertaking a PSA test are the following: 
• the PSA test facilitates the early detection of prostate cancer at a stage when potentially 
curative treatments can be offered\ 
• there is currently no strong evidence that PSA testing reduces mortality from prostate 
cancer 
• not all men with raised PSA will have prostate cancer/the PSA test will not detect all 
prostate cancer  
• prostate cancer is diagnosed through a prostate biopsy which can be uncomfortable or 
painful 
• prostate biopsies will not detect all prostate cancers 
• prostate cancers rage from aggressive to slow growing forms-slow growing tumors may 
not result in symptoms or shorten life expectancy  
• there is no evidence about the optimum treatment for localized prostate cancer 
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• some treatments for prostate cancer can have significant side effects [9]. 
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Figure C - 1: Detailed Pamphlet (Front Side) 
 
 
 
Figure C - 2: Detailed Pamphlet (Back Side) 
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Appendix D 
Conceptual Model for Informed Prostate Cancer Decision Making 
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Appendix E 
Conceptual Model for Informed Decision Making with the Guidance of Two 
Prostate Cancer Screening Educational Pamphlets 
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Appendix F 
Conceptual Model for Informed Decision Making with the Guidance of a Prostate 
Cancer Screening Educational Pamphlet 
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Mass media 
Advice from others 
Philosophy of life  
Illness of friends and family  
Health provider’s advice  
    
Denver VAMC PCPs 
in Saturday Intake 
Clinic and Firm A 
Prostate cancer screening 
educational pamphlet Prostate Cancer 
Screening Informed 
Decision Making 
Guidance 
Detailed 
Pamphlet 
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Appendix G  
Logic Model for Prostate Cancer Screening Informed Decision Making (Initial 
Capstone) 
RESOURCES ACTIVITIES OUTPUTS OUTCOMES IMPACTS 
Chief of 
Ambulatory 
Care and 
Urology  
 
Printing 
company   
Approve Prostate 
cancer screening 
pamphlets 
Pamphlets made 
and  distributed to 
clinics  
# of patients to 
receive the prostate 
cancer screening 
educational pamphlet   
Perceived 
threat of 
prostate 
cancer 
(decreased)   
Prostate cancer 
screening 
recommendations  
(decreased)  
Vista and 
Microsoft 
Office 
Outlook E-
mail  
Providers will be 
educated about the 
Evidence Based 
Requirement for 
informed decision 
making including 
the pros and cons 
of screening     
# of providers 
engaging in shared 
decision making   
Asymptomatic  
men deciding 
to be screened 
for prostate 
cancer 
(decreased) 
 
Prostate cancer 
incidence 
(decreased)  
Chemistry lab  Number of PSAs 
drawn will be 
recorded 
# of patients 
diagnosed with stage 
I and II  prostate 
cancer (# of prostate 
biopsies)   
Overdetection  
(decreased) 
Death rates  
(no change) 
Urology 
Department  
Number of 
patients referred 
for elevated PSA 
leading to prostate 
biopsy will be 
recorded   
# of patients 
diagnosed and treated 
for stage I and II  
prostate cancer 
(watchful waiting, 
surgery, radiation, 
cryoablation, 
androgen deprivation 
therapy, high-
intensity focused 
ultrasound therapy )      
Overdetection  
and treatment 
(decreased) 
Quality of life 
(increased) 
Eastern 
Colorado 
Health Care 
System 
Tumor 
Prostate cancer 
data including the 
accession year, 
date of diagnosis, 
clinical stage, 
# of patients 
undergoing radical 
prostatectomy  or 
radiation treatment    
Treatment 
(decreased) 
Treatment-
related urinary, 
sexual, and 
bowel 
dysfunction   
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Registry  pathologic stage, 
treatment, and age 
at diagnosis will 
be recorded  
(decreased)   
Primary Care 
Providers 
(PCPs) 
PCPs will continue 
to educate patients 
about the risks and 
benefits of 
screening and 
treatment   
# of patients 
diagnosed and treated 
for asymptomatic 
prostate cancer   
Psychological 
and physical 
stress 
(decreased)   
Ability to 
continue work 
(increased) 
Primary Care 
Providers 
(PCPs) 
PCPs will continue 
to educate patients 
about the risks and 
benefits of 
screening and 
treatment   
# of patients  visiting 
urology and radiation 
oncology  for 
localized prostate 
cancer   
Surgery and 
radiation  
(decreased)   
Hospitalization 
rates 
(decreased)  
Primary Care 
Providers 
(PCPs) 
PCPs will continue 
to educate patients 
about the risks and 
benefits of 
screening and 
treatment   
 
# patients undergoing 
prostate biopsies, 
surgery, radiation, 
cryoablation, 
androgen deprivation 
therapy, high-
intensity focused 
ultrasound therapy    
Health care 
dollar use 
(decreased)   
 Efficient use of 
health care 
dollars 
(increased)  
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Appendix H  
Logic Model for Informed Decision Making with the Guidance of Two Prostate 
Cancer Screening Educational Pamphlets (Revised Capstone) 
 
RESOURCES ACTIVITIES OUTPUTS OUTCOMES IMPACTS 
Colorado 
Multiple 
Institutional 
Review Board 
(COMIRB)   
 
 
Approve prostate 
cancer screening 
pamphlets 
 
Shawn Fury, ECHCS 
Medical Media 
Program  Manager, 
produces a few   
Detailed and Basic 
prostate cancer 
screening pamphlets 
for the Project.   
Primary Care 
Providers 
(PCP)  in S2 
and Firm A  
receive 
Prostate 
educational 
materials 
(increased)  
 PCPs receive 
guidance from 
prostate cancer 
screening 
educational 
pamphlets 
(increased)   
PCPs in 
Saturday 
Intake Clinic 
(S2) and 
PCPs in Firm 
A Clinic   
Informed about the 
Project, a quality 
improvement 
initiative linked to 
assessment of the 
two prostate 
cancer screening 
educational 
pamphlets   
# of  PCPs to 
participate in the 
small scale 
intervention  
PCPs  use 
educational 
pamphlets to 
guide 
informed 
decision 
making 
(increased) 
 Prostate cancer 
screening 
recommendations  
(decreased) 
 
 Vista and 
Microsoft 
Office 
Outlook E-
mail 
Providers in Firm 
A and S2  will be 
educated about the 
Evidence Based 
Requirement for 
informed decision 
making including 
the latest  USPSTF 
recommendation 
not to screen 
healthy men      
# of providers 
engaging in shared 
decision making   
 
Asymptomatic  
men deciding 
to be screened 
for prostate 
cancer 
(decreased) 
 
Prostate cancer 
incidence 
(decreased) 
 PCPs in S2 
and  Firm A 
Clinic  after 
pamphlet use   
Discussions about 
the usefulness of 
the Detailed and 
Basic pamphlets  
PCPs  evaluation of  
the prostate cancer 
screening educational 
pamphlets  
The  Detailed 
and Basic 
pamphlet 
guided PCPs 
with prostate 
cancer 
The Denver 
VAMC adopts 
the use of the two 
prostate cancer 
screening 
educational 
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informed 
decision 
making  
(increased)   
pamphlets.  
Shawn Fury, 
ECHCS  
Medical 
Media 
Program  
Manager 
The pamphlets are 
mass produced for 
use by the Denver 
VAMC  
All Denver VAMC 
PCPs participate in 
prostate cancer 
screening education 
through Vista 
Microsoft Outlook E- 
mail. (Requirement 
for informed decision 
making including the 
latest USPSTF 
recommendation not 
to screen healthy 
men).         
All Denver 
VAMC 
engage in 
informed 
decision 
making with 
the use of the 
two pamphlets 
(increased) 
 Asymptomatic 
Denver VAMC  
men deciding to 
be screened for 
prostate cancer 
(decreased) 
 
Denver 
VAMC PCPs  
PCPs will 
routinely  educate 
male veterans  
about the risks and 
benefits of 
screening and 
treatment  using 
the guidance of the 
two prostate 
cancer screening 
pamphlets  
Less number of  
asymptomatic  
patients undergoing 
PSA testing   
Unnecessary 
testing, 
interventions, 
and treatments 
(decreased)   
 
Quality of life 
(increased) 
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Appendix I 
Logic Model for Provider Opinion about Guidance Provided by a Prostate Cancer 
Screening Educational Pamphlet (Final Capstone) 
RESOURCES ACTIVITIES OUTPUTS OUTCOMES IMPACTS 
Colorado 
Multiple 
Institutional 
Review Board 
(COMIRB)   
 
 
Approve prostate 
cancer screening 
pamphlet 
 
Shawn Fury, ECHCS 
Medical Media 
Program Manager, 
produces Detailed 
prostate cancer 
screening pamphlets 
for the Project.   
Primary Care 
Providers 
(PCP)  in S2 
and Firm A  
receive 
Prostate 
educational 
material 
(increased)  
 PCPs receive 
guidance from 
prostate cancer 
screening 
educational 
pamphlet 
(increased)   
PCPs in 
Saturday 
Intake Clinic 
(S2) and 
PCPs in Firm 
A Clinic   
Informed about the 
Project, a quality 
improvement 
initiative linked to 
assessment of a 
Detailed  prostate 
cancer screening 
educational 
pamphlets   
# of  PCPs to 
participate in the 
small scale 
intervention  
PCPs  use 
educational 
pamphlet to 
guide 
informed 
decision 
making 
(increased) 
 Prostate cancer 
screening 
recommendations  
(decreased) 
 
 Vista and 
Microsoft 
Office 
Outlook E-
mail 
Providers in Firm 
A and S2  will be 
educated about the 
Evidence Based 
Requirement for 
informed decision 
making including 
the latest  USPSTF 
recommendation 
not to screen 
healthy men      
# of providers 
engaging in shared 
decision making   
 
Asymptomatic  
men deciding 
to be screened 
for prostate 
cancer 
(decreased) 
 
Prostate cancer 
incidence 
(decreased) 
 PCPs in S2 
and  Firm A 
Clinic  after 
pamphlet use   
Discussions about 
the usefulness of 
the Detailed 
pamphlets  
PCPs  evaluation of  
the prostate cancer 
screening educational 
pamphlet  
The  Detailed  
pamphlet 
guided PCPs 
with prostate 
cancer 
informed 
decision 
making  
(increased)   
The Denver 
VAMC adopts 
the use of the 
Detailed  prostate 
cancer screening 
educational 
pamphlet.  
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Shawn Fury, 
ECHCS  
Medical 
Media 
Program  
Manager 
The pamphlet is 
mass produced for 
use by the Denver 
VAMC  
All Denver VAMC 
PCPs participate in 
prostate cancer 
screening education 
through Vista 
Microsoft Outlook E- 
mail. (Requirement 
for informed decision 
making including the 
latest USPSTF 
recommendation not 
to screen healthy 
men).         
All Denver 
VAMC 
engage in 
informed 
decision 
making with 
the use of the 
Detailed  
pamphlets 
(increased) 
 Asymptomatic 
Denver VAMC  
men deciding to 
be screened for 
prostate cancer 
(decreased) 
 
Denver 
VAMC PCPs  
PCPs will 
routinely  educate 
male veterans  
about the risks and 
benefits of 
screening and 
treatment  using 
the guidance of the 
Detailed prostate 
cancer screening 
pamphlet  
Less number of  
asymptomatic  
patients undergoing 
PSA testing   
Unnecessary 
testing, 
interventions, 
and treatments 
(decreased)   
 
Quality of life 
(increased) 
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Appendix J 
Measurement Tool 
Prostate Cancer Screening Brochure Survey Questions: 
1. Is the pamphlet easy to read?   
Yes [  ]   Somewhat or Maybe [   ]   No [    ] 
2. Is the pamphlet informative?   
Yes [  ]   Somewhat or Maybe [   ]   No [    ] 
3. Is the pamphlet biased?   
Yes [    ]   Somewhat or Maybe [   ] No [  ] 
4. Do you think it would change decisions of vets to get a PSA?  
Yes [  ]   Somewhat or Maybe [   ]   No [    ] 
5. Would you be willing to distribute this out to your patients?  
Yes [  ]   Somewhat or Maybe [   ]   No [    ] 
6. Are the graphics appropriate? 
Yes [  ]   Somewhat or Maybe [   ]   No [    ] 
7. Will the pamphlet be useful for family members? 
Yes [  ]   Somewhat or Maybe [   ]   No [    ] 
8. Is the format of the pamphlet user friendly?  
             Yes [  ]   Somewhat or Maybe [   ]   No [    ]   
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Appendix K 
Time Table Chart 
 
8/31/2010 3/1/2011 8/30/2011 2/28/2012
DNR NR 701 Paper
Review of Literature
CITI Training
IRB Process
Proposal Presentation
Project Implementation 
Survey Completion
Analysis and Writing
Final Document
Presentation / Defense
Capstone Project Timeline
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Appendix L 
Detailed Time Table of Accomplishments 
September 2010-March 2012 
September 2010 The author generated a practice safety issue (idea), specifically, the controversy 
of screening for prostate cancer with a PSA blood test.      
 
September -  
October 2010 
The author developed a problem statement that men over 40 years old who 
undergo prostate cancer screening with a PSA blood test, compared to men who 
do not undergo screening, suffer more morbidity and decreased quality of life.  
 
September -  
October 2010 
The  author considered the following questions about prostate cancer that need to 
be answered:  Does a prostate cancer screening educational pamphlet, proceeded 
and followed by the same four test questions, result in informed decision 
making, and if so, does informed decision making result in less PSA blood tests 
drawn ?     
  
September -  
October 2010 
The author developed the PICO: the population of interest is Denver VAMC 
males between ages 50-70; the intervention is a prostate educational pamphlet 
with returned visit with informed consent; the comparison is the number of PSAs 
drawn in a comparable time period without informed decision making; the 
outcomes of interest are informed decision making and less PSAs drawn.       
 
September 
2010- April   
2011  
The author conducted a literature review which supported the problem statement.   
 
March 2011-
April 2011  
The author conducted a needs assessment of Denver VAMC male veterans 
including collecting data from the Veteran’s Health Study, an observational 
study of health outcomes in patients receiving VA ambulatory care between 
1993-1996 in four VA Boston are outpatient clinics (Selim et al., 2004).     
 
March 2011-
April 2011  
The author contacted Nelson Jones for prostate data for 2008-2010 from the 
Eastern Colorado Health Care System (ECHCS) tumor registry.   
 
January 2011-
September 2011 
The author contacted, or met with, Dr. Hans-Olov Adami (Harvard School of 
Public Health, Department of Epidemiology); VA Research Coordinators;  VA 
Health System’s Specialist;  VA Education personnel; two nurse practitioners in 
Urology; Planetree, a consultant firm hired by the VA to improved patient  
centered care, and; finally, a meeting with the Assistant to the Chief of Staff and 
the Chief of Ambulatory Care in April, 2011 followed by communication with 
the Chief of Urology, two VA Oncologists, and continued meetings with the 
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Chief of Ambulatory Care.   
 
May 2011 The author revised the Capstone after the April meeting because a return visit for 
informed consent is not practical.    
 
June 2011 The author developed two prostate cancer screening educational pamphlets.    
 
June 2011  The author completed Regis Collaborative Institutional Training Initiative (CITI) 
training in preparation for starting the Regis IRB process.   
 
July 2011 The author met with Shawn Fury, the ECHCS Medical Media Program Manager, 
to discuss design and production of the two prostate cancer screening 
educational pamphlets.  
 
July 2011  The author began the Regis and VA IRB process including the Exempt 
Application for Colorado Multiple Institutional Review Board (COMIRB).   
 
July –August,  
2011 
The author contacted Jason Davis, the Journal and Right’s manager at UpToDate 
, for approval to use their graphics which he subsequently edited.    
 
August –
September,  
2011 
The author added a fifth question to the Basic pamphlet to avoid bias. 
 
September, 
2011 
The author’s mentor, the Chief of Ambulatory Care backed out of the project, 
and was replaced by a PhD RN mentor working in patient safety. 
 
September- 
November,  
2011 
The author communicated and met with a VA Research PhD, RN  
      September-
October, 2011  
The author completed VA and UCHSC CITI courses in the Protection of Human 
Research Subjects and Health Insurance Portability and Accountability Act 
(HIPPA) and   completion of a security course on the VA Talent Management 
System.        
 
tember, 2011 The author changed and simplified the Capstone Project after the (IRB) pre-
review at the Denver Veteran Affair Medical Center (VAMV) on September 14, 
2011.  
 
September, 
2011 
The author changed the PICO to: the population of interest are PCPs at the 
Denver VAMC; the intervention is providing a Detailed (Appendix A) and Basic 
(Appendix B) prostate cancer screening educational pamphlet  to primary care 
providers (PCPs) in two Denver Veteran Affair Medical Clinics (VAMC);  the 
comparison is the incidence of prostate cancer screening informed decision 
making in Denver VA Firm B Primary Care Clinics without the guidance of the 
pamphlet ; the outcomes of interest are  to be quantified are the provider’s 
pamphlet preference (Basic or Detailed) and their opinion ( yes or no) about 
whether the prostate cancer screening educational pamphlets offered guidance 
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for informed decision making.  
 
September, 
2011  
The author met with Ita Leitner, the COMIRB exempt/expedited coordinator at 
University of Colorado Health Sciences Center (UCHSC).     
 
October, 2011  The author upgraded the Detailed pamphlet to include graphics, including a “can 
of worms”, to represent the dilemma caused by screening.  
 
October, 2011  The author worked with Shawn Fury, the ECHCS Medical Media Program 
Manager, to create the Detailed pamphlet for COMIRB review.  
 
October, 2011  The author received VA clearance letter on 10/5/2011 and Regis IRB approval 
as an exempt study on   10/18/2011.   
 
October,2011   The author submitted the IRB Application, VA Clearance Letter, and pamphlets 
to   COMIRB on 10/11/2011(running 5-7 weeks out for review). 
 
November,2011  The author received a COMIRB Minor Modification Request on 11/02/2011. 
  
November, 
2011 
The author received COMIRB approval for the Project, protocol 11-1514, on 
11/9/2011 as Not Human Subject Research—Quality Assurance.  
 
November-
December, 
2011 
The author waited for approval by the VA Research and Development 
Committee scheduled to meet on 12/14/2011.   The Protocol went for review as 
scheduled because there were no Conflict of Interest issues.    
 
December, 
2011 
The author received VA Eastern Colorado Health Care System Authorization 
to Recruit & Conduct a Not Human Subjects Research Study  (12/15/ 2011) 
signed by Dr. Keith, the Associate Chief of Staff , Research and Development 
Service on 12/20/2011.    
 
December , 
2011  
The author sent a message via Office Outlook to Denver VAMC PCPS about the 
October, 2011 United States Preventative Services Task Force (USPSTF) 
guidelines not to screen healthy men for prostate cancer; major medical 
organizations recommendations for informed decision making; a copy of the 
Detailed prostate cancer screening pamphlet, and; a request for four volunteer 
PCPS in Firm A and four PCPS in Saturday Clinic to test the pamphlet on 
12/22/2011.  
    
December, 
2011  
The author received a word of caution from her former mentor, “I just want to be 
sure that you have followed the proper channels and rules to keep you and VA 
out of trouble…” (D. Weinshenker, personal communication, December 23, 
2011).  Received responses from three nurse practitioners (NPs) and one MD 
from the Aurora Clinic interested in testing the pamphlet. 
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December, 
2011 
The author received a response from former mentor after he saw the VA R&D 
approval letter, “Sounds like everything is in order. Good luck with the project! 
Don” (D. Weinshenker, personal communication, December 26, 2011).   
January, 2012  The author sent out a second Email message requesting four volunteers in Firm 
A and one more volunteer in Saturday Clinic. A message was sent to 
participating PCPs to document that informed prostate cancer screening took 
place.  Hoffman’s (2011) article about prostate cancer screening in the NEJM 
was sent to participating providers.  
January 2012   The author personally recruited two NPs and one physician from Firm A to 
participate on January 4, although the physician ignored the request. The project 
started in Saturday Clinic on January 7 when four NP PCPs used the pamphlet 
for the first time. A request was placed for 1000 more pamphlets because 
providers were giving the pamphlets to patients to take home.  
January 2012 The author met with her mentor and was advised not to distribute the pamphlets 
yet. Further pamphlet production was halted and the participants were advised of 
the change. A third Email request was sent to providers in Firm A to participate 
in the project.  One physician personally volunteered and two physicians 
personally declined.     
January 2012 The author sent a message to PCPs about how fear of litigation is a valid concern 
because the structure of the U.S. legal system supports local screening and not 
ordering a PSA can be considered a malpractice error of omission (Guerra et al., 
2007).  Lewis, Gohagan, and Merenstein’s (2007) article on the locality rule and 
Adami’s (2010) article on the prostate cancer pseudo-epidemic was sent to all 
PCPs  .     
February, 2012  The author sent a message to all providers about the prostate cancer screening 
project and requested four PCPs in Firm B to discuss their prostate cancer 
screening practices without the use of the pamphlet.  This led to a rebuttal by 
two physicians and subsequently became a topic of discussion at the physicians 
monthly Journal Club, leading to the comparison data needed.  
February, 2012  The author distributed the survey to the eight participating participants resulting 
in collection of the quantitative data.   
February, 2012  The author was contacted by the Health Promotion Disease Prevention Program 
Manager; a meeting took place to discuss a QI project currently in progress to 
reducing PSA screenings in men over 75 years.   
February, 2012 The author sent a message to all providers about how Dr. Lithium Lin’s poster 
on the Principles of Shared Decision Making can be used for patients that 
request PSA screening. This message resulted in four providers from Colorado 
Springs and Pueblo requesting copies of the poster and Detailed prostate cancer 
screening pamphlet.    
February, 2012  The author contacted Shawn Fury for help in sending posters to the southern 
CBOCs.  A message was sent to the CBOC providers to contact Shawn with the 
measurements they needed and further discussions followed.   
February, 2012   The author sent providers an Executive Summary of the project and asked for 
comments about the Detailed pamphlet before it was sent to Public Affairs for 
approval for public use.  One provider highlighted a few typos, grammatical 
errors.   
March, 2012   The author sent the Detailed brochure to Public Affairs and received approval 
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for public distribution the following day. “Patricia-This looks fine and I approve, 
but with one question: In the first paragraph of the “‘Looking for Cancer” 
section, the second sentence said “screening leads to…substantial morbidity 
(illness).”  It reads as if screening leads to illness.  If the sentence is correct, 
you’re good to go” (G. Clark, personal communication, March 6, 2012).  
March, 2012   The author responded to Mr. Clark that the sentence is correct and messages 
were sent to all providers about the Detailed pamphlet approval for public use. 
Shawn Fury was contact to produce 1000 pamphlets who responded, “We are 
temporarily of hospital printing funds. I will process your request as soon as 
funds become available (S. Fury, personal communication, March,, 8, 2012).  
March, 2012 The author received the following email: “Yes, Funds are now available and 
your order for 1000 Prostate brochures was placed earlier this week. It should 
take 2 or more weeks for delivery” (S. Fury, personal communication, March 16, 
2012).     
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Appendix M  
Budget and Resources 
Resources needed for project  
Category of Resource                    Type of Resource  
Staff time                                        Clinical staff time to assist with project  
                                                        Librarian time to assist with literature search 
                                                        Information technology time to assist with Microsoft                        
Consultants                                     Research design consultants (VA research office and  
                                                       two PhD- prepared nurse mentors) 
                                                       ECHCS Medical Media Program Manager  
                                                      Primary care Provider’s input  
 Information technology               ECHCS computers with Microsoft Word  
                                                      Computers with internet access                                                                                                                                             
Supplies and materials                  Detailed pamphlet production       
 
Resource Sheet is adapted from Houser, J.H. (2011). Evidence-based practice in health care. In 
J.H. Houser and K.S. Oman (Eds) Evidence-Based Practice: An Implementation Guide for 
Healthcare Organizations.  (Table 2-2, p. 27). Sudbury, MA: Jones and Bartlett Learning.   
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Budget Estimates for Prostate Cancer Informed Decision Making Project 
 Costs Billed per project Projected variable Costs 
• Labor $50/hour $50 x 80 hours = $4000 
• Office supplies $50/project $50 
• Commute/gas $.65/mile $.65 x 350 miles = $ 227 
• Phones/communications $150/month $150 x 3 months = $450 
• Internet access $30/month $30 x 3 months =$90 
• IT support $50/hour $50 x 10=$500 
• Library support $0/hour $0/hourx10=$0 
• Membership $200/professional 
membership 
$200 
• Pamphlet production 1000 pamphlets $900 
• Media Manger $69/hour $69 x 24 hours = $ 1656 
• Consultation fees $75/hour $75 x 5 hours=$375 
Total Costs  $8448.00 
. 
 
Variable Fixed and Direct Costs is adapted from Cleverley, W.O., Song, S.H., & Cleverly, J.O. 
(2011).  Cost Measurement. In W.O., Cleverley, S.H. Song, and J.O. Cleverly (Eds.) Essentials 
of health care finance (pp.324-325). Sudbury MA: Jones and Bartlett Learning. 
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Appendix N 
CITI Collaborative Institutional Training Initiative  
 
Human Research Curriculum Completion Report 
Printed on 6/11/2011  
 Learner: Patricia Hughes (username: hughestish) 
Institution: Regis University 
Contact 
Information  
Department: nursing 
Email: hughes.tish@gmail.com 
 Social Behavioral Research Investigators and Key Personnel:  
 
Stage 1. Basic Course Passed on 06/11/11 (Ref # 6161464)  
Required Modules 
Date 
Completed 
Introduction 06/10/11  no quiz  
History and Ethical Principles - SBR 06/10/11  4/4 (100%)  
The Regulations and The Social and Behavioral Sciences - 
SBR 
06/10/11  5/5 (100%)  
Assessing Risk in Social and Behavioral Sciences - SBR 06/11/11  5/5 (100%)  
Informed Consent - SBR 06/11/11  5/5 (100%)  
Privacy and Confidentiality - SBR 06/11/11  5/5 (100%)  
Regis University 06/11/11  no quiz  
For this Completion Report to be valid, the learner listed above must be affiliated 
with a CITI participating institution. Falsified information and unauthorized use of 
the CITI course site is unethical, and may be considered scientific misconduct by 
your institution.  
Paul Braunschweiger Ph.D. 
Professor, University of Miami 
Director Office of Research Education 
CITI Course Coordinator 
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Appendix O 
Human Research CITI Training 
 
........ ' .. Y'"'''''' .~ .. Y'" • 
CITI Collaborative Institulional Training Initiative 
Human Research Curriculum Completion Report 
Printed on 9/29/2011 
Institution: Denver, CO-554 
Contact Department: emergency 
iIriormiItion r'hone: ;;u~o ext 2425 
Email: hughes.tish@gmail.com 
VA Human Subjects Protection and Good ClinIcal Practices: 
Behavioral Research for Biomedical 
Module 3: Clinical Practice and VA 
FOt' thIS compietlon Report to be valid, the learner listed above must be 
affiliated with a ern participating Institution. Falsified information and 
• "roo;; • u, .. 
https:Jlwww.citiprogram.orglmembersllearnerslIlcrbystage.asp?strKeyID=-72B38530-A80... 912912011 
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¥V'UP";;'''''' '''''1''''' ,~" ,u, ' 
CITI Collaborative Institutional Training Initiative 
.:" , ;.;=-.:::,:.;: '''''.:::::.;:'' • .::: -:. : __ ;~~ ~!..~·~H!PS)·!:':!.Irriculum Completion 
Report 
Printed on 101312011 
Leamer: Patricia Hughes (usemame: EOGHANI 
Institution: University of Colorado at Colorado Health Sciences Center - COMIRB 
Contact Department: Emergency 
intonnatJon pnone: jUj.-jli\H$OlU extl41~ 
Email: hughes.tish@gmail.oom 
cm Health Infonnation Privacy and Security (HIPS) for Students and 
Instructors: I hiS course 101" :stuaents ana Instruct0f'8 wm satrsfy. me marKIate 
for basic training in the HIPAA. In addition other modules on keeping your 
computers, passwords and electronic media safe and secure are included. 
Federal and 
,:: ~!:IiII Com;:Hetion RaDOn to De valid. the learner Usted above must be 
affiliated with a cm participating Institution. Falsified infonnation and 
unauthorized use of tha CIT! course site Is unetflieal, and may be 
cons1d8Nd sclentltk misconduct by your Institution. 
Paul Braunschweiger Ph.D. 
P~ssor, University of Miami 
Director Office of Research Education 
CITI Course Coordinator 
hnps:llwww.citiprogram.org!memberslleamersIllctbystage.asp?strKeylD='D6F2A63O-903... 1012/201 J 
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CITI Collaborative Institutional Training Initiative 
Human R .... rch Curriculum Completion Report 
Printed on 10/0U2011 
i:dNN'ner.f·,;or...::.J. U; ...... i;<'"_ .... -'l.:,.r.i'T.:;",,, rf~'-i.~ ... -.: •. 
' ~" ' V" 
Inatitution: UniversitY of Colorado at Colorado Health Sciences Center - COMIRB 
Contact Department: Emergency 
,iR:iPJ.mlliian- r.nCIOe: 3Oj-JW~O ext 24'1~ 
Email: hughes.tish@gmail.com 
Group 2 Social and BehavJoral R ... arch: 
.. or aua ~omoMtOOn KeDOn 10 De vallO. me teamer I_tad aboY1J mv:ai 0;;:; 
afflliamd with a em JNlrticipating institution. Fafslfieci Information and 
unauthorized u •• of the cm cou .... aita is unethical, and may be 
conslO8l'8d 8clenUftc mlSConauct by your ln8tttut1on. 
Paul Braunsehweiger Ph.D. 
PmfAAAnt IlnlvAJ'!II.iN of Mi::lmi 
Director Office of Research Education 
CITI Course Coordinator 
bttps:llwww.citiprogram.orgImem~auner-sllfabystage .asp?str~ey lD-9FE9890S-S2A... 101312011 
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Appendix P  
VA Clearance Letter 
0...: DetiDbef S, 201 1 
VA Claarance LaHar 
(Pwp .. ..........,.) 
To: Pftnci!* IlWMdpIDrtPrImUy contact 
Frvm: VA R_rdI orne. 
--
I!utem CoIcftdo HNIth CaNlIyst.m (ECHCS) 
ThII form Mn'M to notify the Colorado Multfple IMtHutionel Review Board (COIIIIRB) that 1he 
abow-enUtllld ~ .... been PN.......ww.cI by the VA RMMrch otnoe for VA 
Nquit........ ""'- aAeo Includw a ,..... for edentlflc quality & mertt and VA 
~ by • member of tM R&D CommltlH. 1M ReO mamber'a N\iiew add,...... 
.. foIowdi ..... : 
• The ~h us. procedw. con.iatltnt .... 1Iound rMMrch ...... 
• The,...rch ~ .. sound enough 110 yIekI tIM! exptCtiId ~. 
AttaoMc; II the Prtvacy and Securtty I'eYtw v.rtfIcatIon report. 
ThenfoN, COIIIRB II authorlzitd to Pf'OCMCI wtth the ...,.., and approv.l proeMS per 
COIIIRB ponc," &nd procedurw. 
""Is\" i i 
RF'SI>ER; ntIS IS f!ilI 1lE R6D cO .... alEE APPROVAL lETTER. YOU MUST RECEIVE 
co.RB APPROVAL LET1ER, VA sueco.rnB! ON RESEARCH SAfnY (8RS) 
APPROVAL, AND THE R&OCO.P, , i& APPROVAL LETTER (PLUS R&D STAMPS> VA 
CONSENT FORM, 1,- APPUCABLE) PRIOR TO INITlAllNG YOUR STUDY. 
co.EHT8 (if appIlcMla): VA."..rev_ ~ the protocol be aummIIrtud UncMr 
ProIocoIlnfomNItioni full protocol wu lnc~ within Apptlcatton. 
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Appendix  Q 
Regis IRB Approval Letter
 
U N V E R S I 
October 18, 2011 
Patricia Hughes 
279 Cottonwood Drive 
Evergreen, CO 80439 
RE: lRB N: 11 ·298 
Dear Patricia: 
Academic Altai .. 
~cG •• ntl 
IRB - REGIS UNIVERSITY 
Your applicatiooto the Regis IRB for your project "Informed Decision Making with the 
Guidancc: of Two Prostate Cancer Screening Educational Pamphlets" was approved as exempt on 
October 18,2011. 
Supporting reference information from the: chair: ..... approved as an excmpt study under 
45CFR46.1 01(bXl Xii) (health education curricula). 
The designation of "exempt," means no further IRB review of this project, as it is currently 
designed, is needed. 
If changes are lJlllde in the research plan that significantly alter the involvement of human 
subjects from that which was approved in the named application, the new research plan must be 
resubmitted to the Regis IRB for approval. 
Si~ / ~~"7-~~=-'--=--------
rl'iIniel Roysden, ~ 
Chair, Institutional Review Board 
cc: Patricia Mullen, Ph.D. 
A JESUIT UNIVERSITY 
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Appendix R 
COMIRB Modification Letter 
 
zz~----~'~ -",~-...-,,-MIRB , ....... ,,",--,,,",--,' ---
_ .. c-_ _ 
---"""'" 
___ 0:-
---,," --~-
02-Nov-2011 
Inv •• lIgstor: 
Sponaor(a): 
Sub)ecl: 
Rav",w Data: 
Minor Modifitations Required 
Patricia Hughes 
COMIRB ProtocoI,,-1514Inilial Application 
01 · Nov-2011 
300."'.'= II'h<-J 
300.72<1._ IFO<) 
---~..... ~ FW~[fWAI 
TltIs: Informed DecIsIon Making Woth The Guidance or Two Prostate Cancer Sorooning Educational 
" ....... 
eommOltoo sees no problem or unaecep\3b1e risks in the protocol and consent. but stipulated changes to certBin documents 
are needed. These are <UI&eribed In \he reviewer oommenls below. The propOsal will not be approved unlil these stipulated 
changes lIre """'" and~. 
If Ihe modifications am not rooeivad in COMIRe within 30 days, your proIocoI will be WITHDRAWN. 
No research actMtie8 may begin on this protoooI until fi",,1 approval is received. 
Comments: j)~ 
1. Your sample will not allow you to do the stalisticat analysis you are proposing. 
2. Do you want this reviewed as a 01 proje<:I? Your proIocoI and documents mention both research and Qllhroughoul. II 
you want this ~ 8 5 01 , \Ile<1 you can not pul)4;sh the results under re8(illrch. only as a QI project. 
3. MOffl 'eWow ""'Y be required if this ia a research p<ejecI. 
PAPER SUBMISSION· HOW TO RESPOND TO A DETERMINATION OF MINOR MOOIFICATIONS: 
1. Plttaae enSure all documents a,(I 'ingl9-$idlKl aod ~ the PIM;"'s name and COMIRe protoooI number on them. 
2. Submit one COllY 01 an ~emIz&d cove. letter desaibing yQ<.I' response 10 each ism;e raised by the .ev>ewe. aod the 
Changes you mada. 
3. Exempt Re'liew' If changes are made 10 the Requesl kit Exemption Ioml, rellUbm~ one copy and enter revision dale on 
", 
4. Expedrted Rew.w: 
a. If changes are requested 10 any pari of the Application for Protocol Review. or anyone of 1M applicalion atlachfTl9fll$ {A, 
F. H. etc.), msubmlt one copy of the revised Application Ioml and All the application attachments. enl'" revision date on 
PII. 1. &&Ction A, and the same vtI ... ion date on all application attachments. 
1:>. If changes are requested to the Protocol. subm~ one highlighted copy of the revilHld protocol. 
5. Exempt and Expedited Review: H changes a" • • equested 10 &ubject materials (consent. assent. questionnaire, survey. 
advertiMmant, ote.l. subm~ one highlighted copy showing changes made and 000 doan copy of each revised document. 
For consent revisions. onl9. new version dala and v8fSion II in the header. 
164 
 
 
 
Appendix S 
COMIRB Approval Letter 
-
t.In iVO/'$H~ 01 CoiOOlIOO Mot.pltal 
0."". HealIh "'&<Ileal Cen t..-
V.LerM'. Al!mInlstrdOf1 "'~ Cent ... 
Tt.o ChJOjr ....... ~
U.,;_.~J of Col"....cIc Dell ..... ' 
CoIcndo P ...... /lUon Cent ... 
09-Nov·2011 
Inv(latl~tor. 
SponsOl'(s): 
Not Human Subject Research 
Patricia Hughes 
Subject: 
Effective Date: 
COM1RB Protocol 11-1514 Initial Application 
08-Nov-2011 
103.124.1055 {P~onel 
303.n4.0990 [Fax) 
COt-1! BE! HOme p AAe (Web] 
m mlrb@vedeover.cdu IEoMa lt] 
FWAOOOO 5010 IFWA) 
TItle: Informed Decision Making With The Guidance Of Two ~rO$tate Cancer Screening Educational Pamphlets 
Not Human Research 
Your research project submitted to COMIRB under protocol number "·1514 has been reviewed and our determination Is thalli is not human 
research as deflneo by our policies and current regulations and In accordance with OHRP and FDA guidelines . 
• Therefore , you may proceed wflh the projecl strictly ronewing the protocol as submitted and reviewed by COMIRS. No continuing review of the 
project will be required, however, you must resubmil ihe protocol to COMIRS for approval If any substantive changes are made to the protocol!n 
question. 
Reylew Cornments· 
COMlRB dc:tennined project to be Not Hwnan Subject Research Quality Assurance. 
Please note that any publications cannOt use the tenn'research' under DHHS regulations but l)1USt clearly indicate that this is a 
Quality Assurance project only and that its results are not generalizable. . 
These docwnents were reviewed for detennination of Not Human Subject Research: 
Application 
Application FOl" Review! Approval (Word Vcrsion, Fonn A) 
Appendix B - Prostate Detailed Educational Pamphlet 
Appendix C - Basic Prostate Cancer Screening Pamphlet 
V A Prostate Cancer Brochure - for Providers 
VA Prostate Educational Pamphlet - for Providers 
VA - Be Informed before opening the prostate cancer screening can ofworrns 
Sincerely, 
UCO Panel A 
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Appendix T 
VA Eastern Colorado Health Care System Authorization Letter
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ElFI'.\ ~T:'Ill:"T 01' \'E-:TER -\ .' " _\"FAIRS 
[.\STER;'>i CULOIt,\I)() IIE,\LTII C\IU: ,,\ 'STF:~I 
1055 Ckrltlun! S!r,'t·' 
Oclt\'n, Clllnrndn 1111210 
30;t<W9-XIJ20 
Date: December 15, 2011 
To: Patricia Hughes 
From: Associate Chief of Staff. Research and Development Service (151) 
Protocol Title: 11 -1514 Informed Decision Making with the Guidance 
of Two Prostate Cancer Screening Educational Pamphlets 
COMIRB Determined Not Human Subjects Researcl'l: November 8, 2011 
SRS # and Approval Date: 5-113251E October 6, 2011 
R&D Approval Date: December 14, 201 1 
VA Eastern Colorado Health Care System 
AuthorIZation to Recruit & Conduct a 
Not Human Subjects Research Study 
This notice authorizes the above-referenced investigator to conduct 
Ul9 above referenced not human research protocol as approved by 
!he Subcommittee 00 Research Safety and R&D Committee, 
This authorization remains in effect until such time lhat anyone of the 
folklwing occur: 
• SRS or R&D Gommitte& withdraws approval for any reason 
• The research project is closed by the Investigator or sponsor 
• The invesllgator fails to maintain a current approved 
continuing review by R&D Committee, 
• The VA ECHCS determines that the research ]XC/ect can no 
longer be conducted atlhe VA ECHCS for failure to comply with any 
applicable regulation or local policy or deviation from the approved 
protocol. 
If multiple sites are involved with this study the VA R&D Committee has 
only approved the VA C{)mponenl of this protocol. 
~v£! Robe Keit M.D. Associate lei of Staff, R&D 
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GIll<li l- Proje!;t Closure Pagclofl 
Tl l5h Hughes <hughes.tll5h@gmall .eom> 
Project Closure 
2 messages 
Tish Hughes <hughes.llsh@gmail.com> 
To: "Leitner. Ita" <ita,leitn-er@ucdenver,edu> 
Dear Ms. Leilner, 
The project, p(otocol number 11-1514, was completed March, 2012. The 
prostale cancer screening educalional pamphlet was approved for pu~lc 
use. Can you close the project with COMIRB. 
Thank-you for your courtesy and cooperation, 
Patricia Hughes 
l eitner, Ita <lla.Leilner@ucdenver,edu;. 
To: Tish Hughes chughes.tish@gmail.com> 
Good Morning Tish, 
Tue, Mar 13, 2012 at 9:05 AM 
Tue, Mar 13, 2012 at 9:47 AM 
As it was determined to be Not Human Subject Resear!;h no need to do any additional paper work for II. As 
we review ~ once and II you are don-e, thai is r,ne. 
Thanks for the not ice arid Congratulation on oompletlog this project! 
'10 
Ita Leitner 
ita leilner@u_C(l_~ 
ExempVExpediled Coordinator 
303-724-1068, fax 303-724-0990 
Mailing Address:-
COMIRB. Mall Stop F490 
13001 E. 17th Place, Room N3214 
Aurora, CO 80045 
IOw' ... 'e",....,. .... ) 
https:llmail.googlc.com/muil/hl lwbz53wOwh7chl? &va=pt&th'" I 360cbe85c48eb84 3/1512012 
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